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CHAPTER 1
GENERAL
INTRODUCTION


E. Oussoren, M.M.M.G. Brands, G.J.G. Ruijter, A.T. van der Ploeg, A.J.J. Reuser 
Biochim Biophys Acta 2011, 1812(11):1542-1556
CHAPTER 2
BONES, JOINTS AND
TEETH DEVELOPMENT IN
MUCOPOLYSACCHARIDOSES;
RELEVANCE TO
THERAPEUTIC OPTIONS
ABSTRACT
The mucopolysaccharidoses (MPS) are prominent among the lysosomal storage dis-
eases. The intra-lysosomal accumulation of glycosaminoglycans (GAGs) in this group 
of diseases, which are caused by several different enzyme deficiencies, induce a cas-
cade of responses that affect cellular functions and maintenance of the extra-cellular 
matrix. Against the background of normal tissue-specific processes, this review sum-
marizes and discusses the histological and biochemical abnormalities reported in the 
bones, joints, teeth and extracellular matrix of MPS patients and animal models. With 
an eye to the possibilities and limitations of reversing the pathological changes in the 
various tissues, we address therapeutic challenges and present a model in which the 
cascade of pathologic events is depicted in terms of primary and secondary events.
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INTRODUCTION
Mucopolysaccharidosis and glycosaminoglycans 
The word Mucopolysaccharidosis (MPS) literally means “a disease in which viscous poly-
saccharides are being stored”. There are eleven such diseases, each caused by genetic 
deficiency of a different lysosomal enzyme involved in the degradation of these poly-
saccharides. The diseases are numbered from MPS I to MPS IX and named after the 
physicians who first described the syndromes or discovered the underlying enzyme 
deficiency (table 1) [1-9]. Chemically, the viscous polysaccharides are glycosaminoglycans 
(GAGs) that consist of long, un-branched chains of negatively charged amino sugars and 
uronic acids and have a very high capacity to bind water. Most are linked to a protein core 
(proteoglycan), form large complexes with hyaluronic acid and are the ground substance 
of connective tissues. Depending on the precise composition of the polysaccharide chain, 
the glycosaminoglycans have names such as dermatan sulfate, heparan sulfate, keratan 
sulfate, chondroitin sulfate and hyaluronic acid (table 1).
Table 1 Enzyme deficiencies and storage products in MPS
Number Eponym Enzyme deficiency Storage product
I Hurler/
Scheie
α-L-iduronidase Heparan sulfate
Dermatan sulfate
II Hunter Iduronate 2-sulfatase Heparan sulfate
Dermatan sulfate
III-A Sanfilippo type A Sulfamidase Heparan sulfate
III-B Sanfilippo type B α-N-acetylglucosaminidase Heparan sulfate
III-C Sanfilippo type C Acetyl-CoA; α glucosaminide 
N-acetyltransferase
Heparan sulfate
III-D Sanfilippo type D N-acetylglucosamine6-sulfatase Heparan sulfate
IV-A Morquio type A Galactose 6-sulfatase Keratan sulfate
Chondroitin 6-sulfate
IV-B Morquio type B β-galactosidase Keratan sulfate
Chondroitin 6-sulfate
VI Maroteaux–
Lamy
N-acetylgalactosamine
4-sulfatase
Dermatan sulfate
Chondroitin 4-sulfate
VII Sly β-glucuronidase Heparan sulfate
Dermatan sulfate
Chondroitin 4-sulfate
Chondroitin 6-sulfate
IX Hyaluronidase Hyaluronic acid
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Connective tissue is composed of cells and extracellular matrix (ECM). The matrix is 
produced by the cells and consists of protein fibers (mainly collagen) and proteoglycans. 
It provides volume and function which is specified largely by its chemical composition. 
For instance, the connective tissue located directly under the epithelium of the skin 
and under the endothelium of the large blood vessels is loosely organized to provide a 
soft cushion that can absorb subtle transformation by pressure. In non-structural organs 
such as the liver, the connective tissue literally holds the hepatocytes together in a func-
tional network of cell strains and blood sinuses. Articular cartilage ( joints) is very rich in 
GAGs and can contain up to 80% water. This jelly-like substance is optimally structured 
to absorb pressure, but breaks up when traction is applied. It is thus unlike tendons, 
whose glycosaminoglycan content and cell density are low, but whose collagen content 
is high, with the collagen fibers also being laid in a single direction to transduce force. 
The connective tissue matrix of bone and teeth is mineralized. GAGs also serve as key 
biological response modifiers [10-12]. Like any other biological substance in the body, GAGs 
are continuously renewed. They are degraded by enzymes produced by the connective 
tissue cells, in part extracellularly and in part intracellularly in the lysosomes after uptake 
through endocytosis. Lack of degradation due to a lysosomal enzyme deficiency leads 
to intralysosomal GAG storage, followed by loss of cellular functions, tissue damage and 
organ dysfunction. This process determines the clinical symptoms observed in patients 
with mucopolysaccharidoses.
This review describes the processes underlying normal development of bone, joints and 
teeth in relation to abnormalities seen in MPS patients and MPS animal models and the 
therapeutic challenges these abnormalities present.
Bones, joints and teeth in MPS patients
As well as joint and dental problems, most patients with mucopolysaccharidoses have 
bone problems that cause skeletal deformities. Some of these clinical features are illus-
trated in figure 1. The bone and joint abnormalities were summarized recently [13].
Due mainly to lysosomal deposition of GAGs in the chondrocytes [14], the extracellular 
matrix (ECM) of the articular cartilage, the synovia and the surrounding tissues, MPS 
patients have stiff joints, contractures and poor mobility. Hyperlaxity of the joints can 
also occur. Together, these processes ultimately manifest as degenerative joint disease. 
Since the abnormalities develop early in life, they also interfere with normal growth 
which explains the typical short stature of most MPS patients (fig. 2).
Before we introduce the pathophysiology of MPSs, the following paragraphs describe the 
normal development of bones, joints and teeth first.
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Figure 1 Radiographs of the skull, pelvis and images of teeth in MPS
A
C
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Fig.1. A and B) Lateral and anterior-posterior radiograph of the skull of a two-year-old patient with MPS 
VI.
Note the atypical shape of the skull, (dolichocephalic) with partial craniosynostosis involving mainly the 
sagittal and the lambdoid sutures (not visible) and the thickened skull (rectangle).
C) Shows an X -ray of an eight-year-old patient with MPS VI. Note the irregularities of the epiphyses in 
the femoral heads. The growth plates of both femur heads are too small and lateralized (arrows). The neck 
of the caput femoris is broad and plump (two headed arrow) and in a valgus position. There is dysplasia 
of the acetabula (arrow heads); the right acetabulum is steep and shallow. The asterisk shows flaring of 
the wing of the os ileum.
D) Shows an X-ray of a ten-year-old patient with MPS VI. Note the deformed and flattened epiphyses of 
the femur (arrows) and the dysplastic acetabula (arrow heads).
E and F) Abnormal teeth in an eight-year-old and a six-year-old patient with MPS I. Both patients have 
hypoplastic peg-shaped teeth (arrows) and dysplastic teeth (arrow heads). The asterisks indicate gingival 
hyperplasia.
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Figure 2 Growth chart MPS VI patient
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Fig. 2. The growth chart of a patient with MPS VI (open circles). Enzyme-replacement therapy was 
started at 7 years of age (arrow).
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NORMAL DEVELOPMENT OF BONES,
JOINTS AND TEETH
Bones
The human skeleton consists of bones that meet at joints and are held together by lig-
aments. To enable movement, tendons connect bones with muscles. Cartilage is part of 
the skeleton. It is found in joints and in the growth plate of immature long bones. The 
skeleton also serves as a scaffold and cage that supports and protects vital organs.
Bone tissue is a reservoir for calcium, phosphate and other ions and harbors the marrow, 
which is essential for blood-cell formation. Bone is maintained by osteocytes, each of which 
is directly connected to the circulatory system by thin cytoplasmic extensions running to 
the blood vessels through canaliculi (small tunnels in the calcified bone matrix). Together 
with osteoclasts, osteoblasts are instrumental in bone synthesis and bone remodeling. 
In a process called endochondral ossification, long bones grow due to the proliferation 
and differentiation of chondroblasts in the growth plate of immature long bones; newly 
formed cartilage is replaced by bone as fast as it is formed. Flat bones are formed by the 
differentiation of mesenchymal cells to bone-forming osteoblasts in a process known 
as intramembranous ossification. Three types of cell are important for the formation, 
growth, renewal and maintenance of bone: osteoblasts, osteocytes and osteoclasts. Their 
roles and functions are detailed below.
Osteoblasts, the bone-forming cells, are of mesodermal origin. Originating from multipo-
tent mesenchymal cells, they differentiate into osteocytes while synthesizing the organic 
components of the bone matrix (type I collagen, proteoglycans and glycoproteins). The 
young bone is deposited along the remnants of the cartilage of the growth plate and 
along pre-existing bone as an osteoid layer that turns into bone after calcification. The 
lifespan of an osteoblast ranges from one to two hundred days. Sixty to eighty percent 
die by apoptosis [15].
Osteocytes, the cells surrounded by calcified bone, have a very long lifespan of one to fifty 
years. Maintaining the bones throughout the skeleton, they are about ten times more 
numerous than the osteoblasts and a thousand times more numerous than the osteoclasts 
[15,16]. Housed in lacunae between lamellae of matrix, they maintain contact with each 
other and with cells at the bone surface through long, very thin dendritic processes that 
traverse the bone matrix [15]. A gel-like matrix surrounds the osteocytes and the dendritic 
processes. Oxygen, nutrients and waste products are transported through the canaliculi 
to and from the osteocytes by hydraulic vascular pressure, partly by diffusion and partly 
by the convection induced by mechanical forces.
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Osteoclasts are created by the fusion and differentiation of cells from the monocyte mac-
rophage cell lineage. They contain between five and fifty nuclei [17]. The lifespan of an 
osteoclast is approximately one to twenty-five days and they die by apoptosis [15].
Osteoclasts are bone-resorptive cells that play a crucial role in normal bone turnover. 
They adhere tightly to the bone surface where they create an extracellular lysosomal 
space [18] in which protons are secreted by the vacuolar H+-ATPase pump [19, 20]. The 
apical membrane of the polarized osteoclast opposing the bone is ruffled. It is into this 
membrane that lysosomal vesicles are inserted [21]. The bone minerals dissolve in the 
acidic environment of the extracellular space, paving the way for lysosomal proteases to 
degrade the organic components of the bone matrix [20, 21]. The degradation products 
are endocytosed at the ruffled border membrane and delivered to the basal membrane 
by transcytosis [22, 23].
Bone formation and remodeling
As stated briefly in the introduction, there are two ways in which bones are formed. Both 
processes involve the transformation of pre-existing mesenchymal tissue into bone tissue. 
In the process of intramembranous or desmal ossification, mesenchymal cells directly 
differentiate into osteoblasts that produce the bone matrix, which subsequently acquires 
its strength through mineralization. By contrast, endochondral ossification involves the 
primary deposit of a cartilage template which originates through mesenchymal cell dif-
ferentiation and is gradually replaced by bone.
The growth of short bones and flat bones is achieved by intramembranous ossification. 
Compacted mesenchymal cells define an ossification center, which is surrounded by 
the periosteum, a thin layer of connective tissue with osteoprogenitor cells at the bone 
surface side and fibrogenic cells adjacent to the mesenchyme. The osteogenic cells dif-
ferentiate into osteoblasts and continuously deposit new layers of lamellar bone against 
the preexisting bone [16, 24]. The formation of the skull is a typical example of intram-
embranous ossification (fig. 3).
The curved plates of young bone are surrounded by a single layer of osteoblasts and are 
deposited amid very loose mesenchymal tissue. During the process of embryonic devel-
opment, the plates of bone are continuously reshaped as they grow. Osteoblasts and 
osteoclasts work in concert to obtain the proper curvature. Old bone is carved away from 
the inside and new bone is deposited on the outside. Defects in this process can lead to 
an abnormal shape of the skull, such as that seen in pycnodysostosis, which is caused by 
cathepsin K deficiency. The different plates of the skull fuse shortly after birth, forming 
an inflexible bony joint called synostosis.
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Figure 3 Intramembranous ossification
Fig. 3. Intramembranous ossification: 1 and 6) mesenchyme; 2 and 4) osteoblasts; 3) bone with osteocytes; 
5) compacted mesenchyme with a blood vessel.
A role in intramembranous ossification is played by bone-morphogenetic proteins such 
as BMP2, BMP4 and BMP7. These are thought to activate transcription factor Cbfa1 in the 
mesenchymal cells, which are thus transformed into osteoblasts [25].
Rapid growth of long bones is achieved by endochondral ossification and requires the 
presence of a growth plate. The growth plates disappear towards adulthood, when length-
wise bone growth stops, though bone widening may still occur. Skeletal long bones are 
initially deposited in the mesenchymal tissue as a cartilage template whose shape resem-
bles a miniature version of the bone to be formed. When the cartilage template reaches 
a certain size, a collar of bone is deposited around the mid portion and blood vessels 
penetrate the cartilage structure.
Chondrocytes in the center enlarge and die through apoptosis. Osteoprogenitor cells, 
which are transported to this region by the blood vessel, differentiate into osteoblasts 
and form a primary ossification center which later becomes the diaphysis. Secondary 
ossification centers appear later at the thicker endings of the cartilage template. These 
become the epiphyses.
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Until adolescence, the growth plate remains cartilage and separates the diaphysis from 
the epiphysis. Cartilage is also maintained at the endings of the bones where joints are 
formed. In this area, the mesenchymal cells that have formed the cartilage templates of 
opposing long bones migrate and differentiate, leaving either a cavity and forming a diar-
throsis with free bone movement, or leaving a synarthrosis with little or no movement, 
such as syndesmosis, synchondrosis, or synostosis. The cavity of a diarthrosis is filled 
with synovial fluid produced by the synovial membrane protruding into the joint from 
the periphery. The fluid provides lubrication to the joint and nutrients to the avascular 
articular cartilage [16, 24].
The growth plate is divided into five zones: a resting zone, a proliferative zone, a hyper-
trophic zone, a calcified zone and an ossification zone. These start at the mid portion of 
the growth-plate and extend in two directions, with major growth taking place towards 
the diaphysis and minor growth towards the epiphysis (fig. 4) [16, 24].
The hypertrophic chondrocytes are degraded by osteoclasts. The osteoblasts, arising from 
osteoprogenitor cells, deposit uncalcified young bone (osteoid) against the remnants 
of the cartilage matrix. The mineralized bone trabeculae that are formed support the 
growth plate.
Many different factors are involved in endochondral ossification. GAGs have an important 
regulatory function. They interact in the FGFs, BMPs (as described below), TGF-β and the 
wingless-type (Wnt) signaling pathways [26].
The extracellular matrix (ECM) of bone and cartilage; the role of GAGs
Fifty percent of the extracellular bone matrix consists of inorganic material: calcium, 
phosphorus, bicarbonate, citrate, magnesium, potassium and sodium. Calcium and phos-
phorus form hydroxyapatite crystals. The organic material in the matrix of bone consists 
of collagen type I fibers; in the cartilage, it consists of collagen type II fibers.
Large water-retaining proteoglycan aggregates (PG) fill the intervening spaces, interact-
ing with the network of collagen fibers. The entire structure of cells and extracellular 
matrix is completed by various glycoproteins, such as chondronectin [16]. Homeostasis 
of the extracellular matrix depends on the balance between de novo synthesis and deg-
radation of the matrix components, which is the primary responsibility of osteocytes 
and chondrocytes [27].
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Figure 4 The epiphyseal growth plate
Fig. 4. The epiphyseal growth plate. 1) The resting zone: hyaline cartilage with chondrocyte progenitor 
cells. 2) The proliferative zone: chondrocytes undergo rapid mitosis and align into vertical columns. The 
columns are separated by septa of extracellular matrix consisting primarily of collagen (collagen type 
II) and proteoglycans. 3) The hypertrophic zone: chondrocytes mature and become hypertrophic. They 
contain large amounts of glycogen and start to secrete alkaline phosphates and collagen type X. The 
matrix is reduced to thin septa between the chondrocytes. 4) The calcified cartilage zone: concurrent 
with the death of chondrocytes, the thin septa of cartilage matrix are calcified by the deposition of 
hydroxyapatite. 5) The ossification zone: blood capillaries and osteoprogenitor cells invade the cavities 
left by the chondrocytes. The osteogenitor cells form osteoblasts, which are distributed in a layer over 
the calcified septa. The osteoblasts deposit young bone (osteoid) on top of the three-dimensional cal-
cified cartilage matrix (Mescher AL ‘Junqueira’s Basic Histology’, Brighton et al. [24]). The bone matrix 
consists of collagen type I, GAGs and inorganic material (Ortega et al. [37]).
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In cartilage, the collagen fibers are organized in a lacy network that provides tensile 
strength [28, 29]. Aggrecan is the most common PG in articular cartilage. Chondroitin 
and keratan sulfate are the side chains of aggrecan [30]. Other smaller proteoglycans are 
less abundant and have one or two GAG side chains, such as dermatan sulfate or heparan 
sulfate [31].
Proteoglycans, glycosaminoglycans and hyaluronic acid as matrix components
Proteoglycans typically consist of a protein core to which long sugar chains (glycosamino-
glycans) are covalently attached. The attachment sites are formed by serine residues in the 
core protein that occur at an interval of 12 amino acids. Proteoglycans have a feather-like 
structure (fig. 5). The glycosaminoglycans linked to the serine residues consist of repeat-
ing disaccharide units of sulfated and unsulfated uronic acids and N-acetyl hexosamines. 
The composition of the repeating disaccharide units determines the name of the glycos-
aminoglycans (e.g., heparan sulfate (HS), dermatan sulfate (DS), chondroitin sulfate and 
keratin sulfate (KS)). KS does not contain uronic acid moieties, but galactose instead. 
One and the same core protein can contain different glycosaminoglycan side chains. The 
large proteoglycan structures are linked to a polysaccharide backbone, hyaluronic acid 
and together, they form an even more voluminous complex. In the extracellular matrix 
of articular cartilage, the long chain of hyaluronic acid is oriented in parallel with the 
collagen type II fibers. The featherlike structure of proteoglycans overlays the collagen 
fibers, forming a tight molecular network. Because the negatively charged glycosami-
noglycans have a capacity to bind and retain water, they form a jelly-like structure. The 
tightly packed negatively charged glycosaminoglycans move apart as far as possible. They 
are brought together by pressure; the more pressure is put on the cartilage, the higher the 
repelling force will be. This enables the cartilage of the joints to absorb shocks.
An intact proteoglycan network is essential for the integrity and assembly of the 
functional cartilage matrix. This was demonstrated in an artificial system of cultured 
chondrocytes [31] which showed that inhibition of GAG incorporation in newly formed 
cartilage matrix not only causes the newly synthesized GAGs to diffuse further away from 
the chondrocytes, but also reduces the cross-linking of the collagen.
Proteoglycans, mainly those inserted into the plasma membrane and containing few gly-
cosaminoglycan side chains, also serve as key biological response modifiers. Some of these 
roles are addressed below. Summarized briefly, they act as 1) stabilizers, cofactors and/
or co-receptors for growth factors, cytokines and chemokines, 2) regulators of cathepsin 
activity, 3) signaling molecules during embryogenesis and in response to cellular damage 
such as wounds, infection and tumorigenesis and 4) targets for bacterial, viral and para-
sitic virulence factors (attachment, invasion and immune system evasion) [10-12].
Bones, joints and teeth development in Mucopolysaccharidoses; Relevance to therapeutic options   |   45
CH
A
PTER 2
Figure 5 Basic structure of aggrecan
Fig. 5. Aggrecan is the complex of proteoglycans that all are connected to a central long chain of hyal-
uronic acid via link proteins (red dots). The proteoglycans in the large aggrecan complex are feather-like 
structures composed of a number of regularly spaced glycosaminoglycan chains, such as keratin sulfate 
and chondroitin sulfate (in light blue), which are covalently linked to a protein core (yellow).
Bone remodeling and the extracellular matrix (ECM)
Bone remodeling is a continuous process of bone resorption (osteoclasts) and bone for-
mation (osteoblasts). The average turnover (volume replacement) of bone is 10% per year, 
but there are large differences dependent on age and bone regions [15].
Bone tissue is able to adapt its structure and function in response to mechanical forces 
and metabolic demands [32]. A change in the balance between bone resorption (osteo-
clast) and bone formation (osteoblast) results in a corresponding loss or gain of bone 
tissue. As cathepsins and matrix metalloproteinases (MMPs) are key enzymes in the 
turnover of the ECM, they are essential to the process of bone remodeling [27].
46   |   Chapter 2
Cathepsin K is highly expressed by osteoclasts. It is a lysosomal enzyme that cleaves the 
triple helical region of type I and II collagen at multiple sites [27, 33]. During endochondral 
ossification, cathepsin K degrades type II collagen (cartilage) in the hypertrophic zone 
to create space for the deposition of young bone by osteoblasts [34]. Some evidence has 
been presented that certain types of GAGs modulate the cathepsin K activity depending 
on their concentrations [35]. According to this model, GAG storage in MPS might affect 
the bone remodeling [36]. Because MMPs fragment the protein core of the proteoglycans, 
the ECM disintegrates, resulting in a cascade of events. The release of biologically active 
components activates other proteases and affects processes such as cell attachment, 
migration, proliferation, differentiation and apoptosis [37].
MMP activity is controlled by various mechanisms. For instance, MMP transcription is 
upregulated via growth factors and cytokines and MMP translation and proenzyme acti-
vation are regulated by tissue inhibitors (TIMPs; tissue inhibitors of metalloproteinases), 
which inhibit the translation of MMPs and form complexes with MMPs that influence 
proenzyme activation [38-40]. Precise regulation of MMP activity is crucial for main-
taining the balance between tissue remodeling and destruction. During endochondral 
ossification, at least three MMPs are highly expressed. When neovascularization of the 
cartilage anlage begins, MT1-MMP and MMP9 are expressed in the pre-osteoclasts and 
other chondroclastic cells of unknown origin. MMP13 is expressed in the terminal hyper-
trophic chondrocytes and the newly recruited osteoblasts [37].
Interaction of GAGs with bone morphogenetic proteins (BMPs) and fibroblast 
growth factor (FGF)
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong 
to the transforming growth factor β (TGF-β) superfamily [41]. They interact with several 
regulatory pathways [42] and promote the differentiation of osteoclasts and chondrocytes 
from mesenchymal progenitor cells. In the growth plate they also promote chondrocyte 
hypertrophy and apoptosis. Strict regulation of the BMP activity is required to secure 
normal bone formation during postnatal life [41]. BMPs play an integral role in the devel-
opment of the skeletal system, as well as in the heart and  nervous system [43]. In humans, 
mutations in the BMP pathway are associated with skeletal disorders. For instance, a 
mutation in the Ib BMP receptor has been identified in a patient with brachydactyly 
and mutations in the BMP antagonist noggin have been found in patients with sympha-
langism and synostoses [42]. BMPs are secretory proteins with the ability to promote bone 
formation, but can also induce formation of ectopic cartilage. Although the activities 
of BMPs and their antagonists are modulated by heparan sulfate containing proteogly-
cans (HSPG), it is not fully understood how their activity in the MPS storage diseases is 
influenced by these GAGs [43]. The sulfated residues on these GAGs are thought to bind 
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to BMPs and their antagonists, thereby modulating receptor-mediated signaling. The 
growth factor regulatory role of some of the GAGs is also shown by a chondroitin-sul-
fate-synthesis-deficient mouse model. Mice deficient for chondroitin 4-sulfotransferase 
have growth plate abnormalities resembling those in MPS VI mice, in which the TGF-β 
signaling is upregulated and the BMP signaling down-regulated. This indicates that the 
chondroitin sulfate balances the activity and localization of these two growth factors 
[44, 45].
Fibroblast growth factor and BMP signaling have opposing functions in the growth plate. 
They interact through mutual antagonism. FGF ligands and FGF receptors (FGFR) are 
both expressed in developing skeletal and cartilage anlage. Several human craniosynos-
tosis disorders have been linked to activating mutations in FGF receptors. Disruption of 
FGFR2 signaling in skeletal tissues results in skeletal dwarfism and lower bone-mineral 
density (BMD). Lower proliferation of osteoprogenitor cells is combined with reduced 
anabolic function of mature osteoblasts and diminished osteoblast differentiation [46, 47].
FGF-2, a prototypical member of the FGF family that is involved in tissue morphogenesis 
and neurogenesis, binds to two kinds of cell-surface receptors: high affinity FGF receptors 
(FGFRs) and low-affinity receptors (composed of HS proteoglycans) that act as extracel-
lular FGF2 reservoirs and co-receptors. Formation of the FGF-2-FGFR-HSPG complex is 
necessary for mitogenesis and optimal biologic response to FGF-2 [48]. Dermatan sulfate 
(DS) also binds and activates FGF-2. The interaction between DS and FGF-2 has been 
studied only with respect to cellular proliferation: in its capacity to stimulate cell growth 
in vitro, DS exceeded HS [49].
Three studies have suggested that high concentrations of small, abnormally sulfated 
HS chains (such as those present in Hurler syndrome) can have a detrimental effect on 
orderly hematopoietic stem-cell growth and differentiation [50-52].
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TEETH
Teeth, too, are bony structures. Their shaft consists of dentin and the crown protruding 
in the oral cavity is covered with enamel. The inner part of teeth, the dental pulp, is com-
posed of loose connective tissue. Odontoblasts are the cells that form the organic matrix 
of the shaft (dentin) (fig. 6), which consists of collagen type I, phosphoproteins, phospho-
lipids and proteoglycans. Newly formed, not yet calcified dentin is called pre-dentin and 
has its equivalent in osteoid, uncalcified young bone [16]. During tooth development, ame-
loblasts are aligned across the cap of the primitive tooth and produce a layer of enamel, 
also a type of bone, which forms the crown. The root is covered with a layer of cementum 
produced by the cementoblasts which is connected to the bony socket of the jaw by the 
periodontal ligament, an array of collagen fibers that also hold the teeth in position [53].
Figure 6 Embryonic tooth formation
Fig. 6. Embryonic tooth formation in rabbit. 1) ameloblast; 2) dentin; 3) odontoblast; 4) mesenchyme
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Development of the teeth
The mandible and maxilla grow to accommodate the developing teeth. The enamel on 
the crown of the teeth is derived from ectoderm; all other parts differentiate from the 
surrounding mesenchyme. Tooth buds of the primary dentition appear around the tenth 
week of embryonic development; the buds for the second dentition start to develop four 
years after birth [53].
BMPs and FGFs and their role in tooth development
GAGs can affect BMP activity as described above. BMP4 plays an important role in tooth 
development from the moment the initial epithelial lamina is formed until the late bell 
stage [54]. During postnatal tooth development, it is highly expressed in both the odon-
toblasts and in ameloblasts. Initial tooth development appears to require a BMP signal. 
Deletion of the BMP4 gene in odontoblasts and surrounding osteoblasts leads to perma-
nent defects in tooth cytodifferentiation and also in the supporting periodontal tissue 
(decreasing the rate of formation from pre-dentin, decreasing odontoblast maturation, 
affecting proper dentinal tubule formation and reducing the expression of collagen type I 
and osteocalcin). In mice, dysmorphogenic odontoblasts were seen that failed to properly 
elongate and differentiate, thereby producing permanently thinner dentin, enlarged pulp 
chambers in the molars and less bone tissue to support the teeth. Indirectly, deletion 
of the BMP4 gene also disturbed the process of enamel formation. Postnatally, odonto-
blast-derived BMP4 plays a key paracrine or endocrine role in amelogenesis [54]. 
The BMP2 gene appears to be involved in BMP4 activation. Its deletion in odontoblasts 
leads to disorganization of morphologically altered odontoblasts at the dentinal tubule 
stage and failure to mature in later stages of tooth development [54].
Fibroblast growth factors (FGFs) are involved in epithelial-mesenchymal tissue inter-
action. FGF signaling via FGFR2 in the epithelium is crucial for cell proliferation during 
tooth and palate development [55]. Interference of abnormal HS and DS (as seen in MPS) 
with the FGF pathway may cause abnormal growth and differentiation of teeth in MPS 
[48, 52].
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BONE, JOINT AND TEETH PROBLEMS
IN MUCOPOLYSACCHARIDOSES
Although the severity of bone disease varies by the type of MPS, most of the skeletal 
anomalies in MPS patients are likely to originate from aberrant cartilage and bone devel-
opment. For instance, the complex skeletal pathology observed in six-week-old MPS I 
mice suggests that very early changes predispose for the dysostosis that becomes appar-
ent later in life [56]. Growth in length relies on the perfectly orchestrated proliferation 
and differentiation of chondrocytes in the growth plate, a process which is irreversibly 
disturbed in MPS by the lack of GAG turnover.
Various bone problems in MPS patients can be explained by abnormal endochondral 
ossification. These include thoracolumbar kyphosis/scoliosis, odontoid hypoplasia, wide 
oar-shaped ribs, shortened long bones, coxa valga, dysplastic femoral heads, genu valgum 
and bullet-shaped phalanges. Additionally, histological abnormalities have been reported 
in each of the 5 zones of the growth plate as described below. The main causes of osteo-
penia in MPS patients are probably abnormal bone remodeling (osteoblast/osteoclast 
dysfunction) and abnormalities in the growth plate, exacerbated by immobility in an 
advanced stage of the disease. Developmental deformities of the vertebral bodies and the 
femoral heads accelerate the normal degeneration of the joints caused by weight-bearing 
forces and also induce inflammation.
Macrocephaly with thickened skull and short wide clavicles can be explained by abnormal 
intramembranous ossification and abnormal bone remodeling. Reports of MPS cases with 
craniosynostosis in the literature have speculated that GAGs may interact with the FGF 
receptor [46, 47].
Dental complications in Mucopolysaccharidoses (MPS I, IV and VI) can be severe. They 
include hypoplastic peg-shaped teeth with retarded eruption or unerupted dentition; 
thin enamel (often ‘greyish’); a pitted surface; dentigerous, cyst like follicles, malocclu-
sions; short mandibular rami with abnormal condyles (condylar defects); and gingival 
hyperplasia [57-59]. Affected MPS patients easily develop dental caries and need regular, 
conservative dental therapy [60]. Secondary cellular responses involving interactions of 
GAGs with BMP and FGF may play a role in all bone, joint and tooth problems seen in 
MPS patients.
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Endochondral ossification and the epiphyseal growth plate in MPS patients 
and animals
Resting zone
Chondrocytes in the resting zone of the growth plates of patients with MPS I, II and IV 
are unusually large and contain granular material. They are named “foam” cells because 
they contain numerous, large cytoplasmic vacuoles filled with undegraded GAGs. Foci 
of loose connective tissue interrupt the architecture of the growth plate, creating irreg-
ularly shaped metaphyses. The remaining parts of the growth plate are fairly regular, 
with well-organized endochondral ossification [61]. In a MPS VI feline model, the resting 
zone of the tibia occupies a larger than usual space in which the chondrocytes are rather 
tightly packed (hyperplasticity) [62].
Clonal expansion of the chondrocytes in the resting zone, which is seen in MPS VI felines, 
can be explained by a response to GAG accumulation. GAGs are negatively charged and 
able to mobilize and bind mitotic growth factors. Compared with the proliferative and 
hypertrophic chondrocytes, the articular chondrocytes and the chondrocytes in the rest-
ing zone have a long half-life. Pathology is therefore more likely to develop in the slowly 
dividing cells in the resting zone.
Proliferative and hypertrophic zones
In the MPS VII mice, the number of chondrocytes in the proliferative zone is markedly 
decreased (60%); the proliferative capacity is only 55%. The ECM directly surrounding the 
chondrocytes is very rich in chondroitin-4-sulfate (C4S). On the basis of these findings 
it has been hypothesized that C4S might interact with a cell membrane receptor and 
thereby reduce chondrocyte proliferation and bone growth [63]. In six-week-old MPS 
I mice the growth plate is abnormally broad with distended resting, proliferative and 
hypertrophic zones and the chondrocytes are hypertrophic. In contrast to the decreased 
proliferation in the MPS VII mice, the proliferative zone in six-week-old MPS I mice 
occupies a relatively high number of chondrocytes and the columnar organization is 
relatively well preserved. In older mice, the columnar organization of the growth plate is 
disrupted and the bone trabeculae begin to thin [56].
Similar defects in the process of endochondral ossification have been observed in MPS 
I patients, in felines with MPS I and MPS VI and in mice with MPS VI [64]. For instance, 
chondrocyte maturation in distinct regions of the hypertrophic zone was disorganized 
in the iliac crest growth plate of MPS I patients and in the growth plates in the femoral 
head and tibia of MPS VI felines [64]. The lower rate of bone growth in MPS patients and 
animal models may be attributable to delayed turnover of hypertrophic cells [62]. The 
lower number of hypertrophic cells in MPS VI rats has been ascribed to enhanced expres-
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sion of TGF-β that inhibits the terminal differentiation of immature chondrocytes [38]. 
A decrease in the number of hypertrophic chondrocytes that are subsequently replaced 
by bone can explain the osteopenia in MPS VI rats.
The ossification zone
The accumulation of GAGs in MPS VII mice and dogs has been demonstrated in osteoclasts 
and osteoblasts located in the ossification zone [65]. In the iliac growth plate of humans 
with MPS I there were fewer longitudinal septa upon which cartilage mineralization and 
metaphyseal osteoblastic activity could occur. The primary spongiosum was irregular with 
poor speculation [64]. In the femoral growth plate of MPS VI felines, calcifying cartilage was 
disorganized by irregularities in the chondro-osseous junction and there were osteoclast 
deficits [66]. Abnormalities in the cortical bone structure supporting the growth plate have 
been reported in a murine MPS I model [56]: at six weeks of age, the zone of provisional cal-
cification and primary spongiosa was abnormally wide, indicating either that more matrix 
was produced or that it was less degraded than normal. Islands of un-ossified cartilage 
persisted amidst the newly formed bone, resulting in the loss of well-defined narrow tra-
beculae. Some of these findings could be explained by the lack of osteoclast activity, which 
normally degrade GAGs from the cartilage matrix, leaving a well ordered scaffold consisting 
mainly of type II collagen fibers to which the osteoblasts can adhere.
The GAG storage in MPS I appears to compromise this process. Ossification starts before 
the GAGs have been removed from the matrix and remnants of the cartilage anlage are 
retained within the newly formed bone. This leads to abnormalities in the composition 
and architecture of the growth plate and thus to growth retardation. The abnormalities 
persist, which suggests that the lack of GAG degradation also affects the process of bone 
remodeling [56].
In a MPS VI cat model the abnormalities are not restricted to the cartilage of the growth 
plate but also pertain to osteoblast function, suggesting that bone formation is deficient 
[62]. Osteonectin, a glycoprotein secreted by osteoblasts, with affinity for collagen and 
promoting bone mineralization, has been mentioned in this context. It is a substrate for 
MMP-2 and 9 that are both elevated in MPS bones and joints [38]. Like the osteoblasts, but 
to an even greater extent, the osteoclasts in MPS VII mice contain large foamy vacuoles 
[20]. The osteoclasts fail to form ruffled border membranes and seem to detach easily 
from the bone surface. These defects are intrinsic to the MPS VII osteoclasts and not the 
result of an abnormal bone matrix. They are corrected during bone marrow transplan-
tation, when the osteoclasts are replaced. Osteoclast function may also be impaired by 
an excess of GAGs in the extracellular matrix, which inhibits cathepsin K activity and 
thereby cartilage resorption [35].
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The role of signal transducers and activator of transcription (STAT)
Several studies have indicated the role of STAT in the process of endochondral ossifi-
cation and MPS-related change. STAT stands for a family of transcription factors. The 
phosphorylation and activation of STAT1 by activated FGFR3 increases the expression of 
the cell-cycle inhibitor p21, reducing chondrocyte proliferation [46]. Metcalf et al. have 
shown that mRNAs that encode several of the STAT transcription factors known to be 
selectively altered by inflammation were abnormally expressed in the growth plates of 
MPS VII mice [63].
Osteopenia and osteoporosis in MPS
The abnormal cartilaginous structures in the epiphyseal growth plate are an important 
cause of osteopenia in most MPS patients, but not in MPS III patients. Heparan sulfate 
accumulation causes neurological complications (psychomotor retardation) and only 
minor skeletal abnormalities including coarse facies and joint stiffness [67].
The psychomotor retardation in MPS I, II and III might also contribute to osteopenia or 
osteoporosis. The secondary inducers include immobilization, too little exposure to the 
sun, poor nutritional status, vitamin D deficiencies and treatment with anti-epileptics 
[68]. In MPS IV and VI patients, severe bone deformities (immobilization) and vitamin D 
deficiencies are also described [69].
The role of weight-bearing forces on abnormally shaped bones and joints
In MPS patients, abnormal bone structures (dysostosis multiplex) are seen very early in 
life. The acetabula of the hips in MPS I, II, IV and VI patients are short and steep and 
form an abnormal acetabular cup. The morphology of the femoral head and neck can be 
changed not only by accumulation of GAGs in the growth plate and bone cells, but also 
by abnormal weight-bearing forces. The latter is shown in figure 7, which demonstrates 
hallux valgus in a patient with MPS II. Hallux valgus is an abnormal angulation of the 
big toe involving the joint between the metatarsal bone and the proximal phalanx. It 
also occurs in the unaffected population (fig. 8). Mis-directed pressure on the bones can 
cause joint inflammation, affect the GAG content of the articular cartilage and induce 
secondary alterations in the underlying bone. It also has a long-range effect on the carti-
lage structure of the joint between the proximal and distal phalanges. The proximal site 
of the joint between the metatarsal bone and the proximal phalanx has fully disappeared 
due to the inflammation. The distal site of this joint has a very low GAG content, although 
the gross structure is still preserved. In response to the primary pathologic changes, new 
bone is formed at the periphery of the joint (osteophyte) and immature cartilage and bone 
are formed just under the zone of articular cartilage. BMPs and other growth factors are 
likely involved in these processes. Although not directly involved, the cartilage of the joint 
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between the proximal and distal phalange of this toe also has a very low GAG content; 
therefore, in this pathology, mixed aspects of osteoarthritis and rheumatoid arthritis (OA 
and RA) are seen, which also occur in MPS. Recently, Baldo et al. described this phenom-
enon in a knee joint of an MPS I murine model [70] showing inflammatory infiltration 
and pannus formation with hypertrophy of synovial cells. Although the primary causes 
of hallux valgus in the general population and in MPS patients are totally different, the 
cascade of pathologic events and the consequences are partly similar.
Figure 7 Hallux valgus MPS II patient
Fig. 7. Hallux valgus of the left foot of a 12 years old MPS II patient. Notice the redness of the skin over the 
joint between the metatarsal bone and the proximal phalanx, which is caused by inflammation (arrow).
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Figure 8 Amputated great toe 
Fig. 8. Microscopic image of an amputated great toe of a 52 year old women not affected by MPS 
(hallux valgus).
A) Overview. B) and C) show details of the joint between the metatarsal bone and the proximal pha-
lanx and D) shows a detail of the joint between the proximal phalanx and the distal phalanx. The joint 
between the metatarsal bone and the proximal phalanx has been destroyed by inflammation due to 
the abnormal pressure and the GAG content in the cartilage has diminished (asterisk) (B). Secondary 
alterations in the underlying bone are also visible in this joint specifically, abnormal cartilage formation 
(arrows) (C). Although the gross architecture is still preserved, the cartilage of the joint between the 
proximal phalanx and the distal phalanx has a very low GAG content (asterisks) (D). Image E shows 
healthy cartilage with normal GAG content (asterisk).
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Joints and inflammation
Simonaro et al. hypothesized that lysosomal and/or extracellular GAG storage in MPS 
disorders induce inflammation and affect the growth of connective tissue cells and other 
cell types by activating the toll-like receptor 4 (TLR4) signaling pathway [71]. Activation 
of this pathway can be induced either by 1) GAG fragments interacting with CD44, a 
hyaluronan-binding cell surface glycoprotein receptor (55 kDa) and myeloid differenti-
ation factor-88 (MyD88), or 2) through lipopolysaccharide (LPS), which requires MyD88, 
lipopolysaccharide binding protein LBP and CD14 [72-76]. Simonaro et al. have shown that 
the expression of MyD88, LBP and CD14 is up-regulated in MPS connective tissue cells 
[71]. Large fragments of hyaluronic acid and oligosaccharides released by the breakdown 
of the extracellular matrix also signal through TLR4 via MyD88 and CD44, providing fur-
ther support for the concept that this pathway is activated by GAG storage in the MPS 
disorders [73]. TLR4 activation in MPS animals resulted in the production of ceramide, a 
proapoptotic lipid and the release of numerous inflammatory cytokines and proteases [77]. 
Among the cytokines, TNF-α was markedly elevated both in the circulation and within 
the joint tissue of MPS animals [71].
There is great similarity in the secretion of pro-inflammatory cytokines like TNF-α, IL-1β 
and nitric oxide in the extracellular matrix of cartilage and bone of animals and humans 
with primary MPS syndromes, compared with primary degenerative and inflammatory 
process like osteo- or rheumatoid arthritis. The cytokines are produced by MPS chondro-
cytes, synoviocytes and macrophages [38].
Stimulation of MPS connective tissue cells by the inflammatory cytokines cause 
enhanced secretion of several of the matrix metalloproteinases (MMPs). Dramatically 
elevated expression of MMP-2 and MMP-9 and abnormally high expression of TIMP-1 
accompany joint disease in MPS [38]. The imbalance of MMPs over tissue inhibitors of 
metalloproteinase, the TIMPs, precipitate features of both osteoarthritis as well as rheu-
matoid arthritis in joints of MPS patients. Patients without MPS but with osteoarthritis 
(OA) and cartilage degeneration have changes in the structure and composition of the 
extracellular matrix, characterized by lower proteoglycan content and enhanced collagen 
degradation [78]. To compensate for the loss of matrix substance, the rate of synthesis of 
both matrix components is increased [79, 80].
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Dental problems
Guven et al. have investigated the ultrastructural and chemical properties of MPS I 
(Hurler) teeth. The dentin of the primary teeth was characterized by extremely narrow 
dentinal tubules with an irregular wave-like pattern. The enamel-dentin junction was 
poorly shaped, micro gaps occurred and the enamel displayed an irregular arrangement 
of prisms. Both the enamel and the dentin had an abnormal protein structure and the 
dentin protein content was low [57].
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SECONDARY CELLULAR EFFECTS
AND RESPONSES IN MPS
Interaction of GAGs with BMPs and FGFs
Impaired BMP-4 signaling by GAGs in multipotent adult progenitor cells (MAPCs) in 
human Hurler syndrome identifies a mechanism that might contribute to the progres-
sive skeletal abnormalities. The same mechanisms may be involved in the development 
of neurological problems [43]. It has been demonstrated that cell and matrix associated 
GAGs promote proliferation and block BMP-4-mediated differentiation of several types 
of human malignant cells. The storage of GAGs in Hurler cells may have the same effect. 
GAGs impair the BMP-4 activity but do not change the expression of various BMPs or 
their receptors. The activity of BMP-4 can be restored by clearing the lysosomal GAG 
storage with exogenously supplied enzyme as demonstrated in cultured cells. Both hep-
aran sulfate (HS) and dermatan sulfate (DS) accumulate in Hurler syndrome and are 
cleared by treatment with α-L-iduronidase. The role of DS cannot be ruled out as a con-
tributor to impaired BMP-4 signaling [43] as observed in Hurler MAPCs. HS in Hurler 
syndrome is structurally and functionally abnormal and has impaired ability to bind to 
and mediate the effects of fibroblast growth factor-2 (FGF-2) signaling [48]. This results 
in FGF-2-induced proliferation and survival of Hurler multipotent progenitor cells. Both 
the mitogenic and survival-promoting activities of FGF-2 were restored by substitution 
of Hurler HS with normal HS. Chondroitin 4-sulfate (C4S), one of the GAGs that store in 
MPS VII, can activate FGF signaling, as well through some of the FGFRs [81].
Autophagy, polyubiquitination and mitochondrial function
The molecular pathways underlying pathology in lysosomal storage diseases (LSDs) are 
largely unknown [82]. Recycling of the building blocks of cells, organelles, (glycol)proteins, 
(glycol)lipids, carbohydrates and other kind of macromolecular compounds is required 
for cellular homeostasis [83]. The ubiquitin-proteasome proteolytic system and the auto-
phagosome to lysosome pathways are both used for large scale degradation of cellular 
components. The ubiquitin-proteasome system degrades short lived regulatory proteins 
that are for instance important for processes like cell-cycle progression, regulation of 
gene transcription and signal transduction [84]. The long-lived structures are mainly 
targeted to the lysosomes by autophagosomes [85]. Lysosomal storage leads to reduced 
functionality of the lysosomal compartment and consequently leads to build-up in the 
autophagocytic and endocytic pathways [86-88]. Dysfunction of autophagy as second-
ary event seems to play an important role in the pathophysiology of LSDs. It has been 
shown that lysosomal storage induces impaired autophagy. A recent study also showed 
mitochondrial dysfunction and inflammation to occur as secondary event in MPS VI 
[83]. Similar anomalies in association with DS storage have been observed in the visceral 
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organs but not in the central nervous system of MPS VI rats accompanied by inflamma-
tion and cell death. Prevention of dermatan sulfate storage in these rats by gene therapy 
resulted in restoration of autophagy, as well as regression of inflammation and apoptosis.
Compromised lysosome membrane integrity
Compromised lysosomal membrane integrity is another problem resulting from the accu-
mulation of undegraded or partially degraded substrates in the lysosomes of LSD patients 
[89, 90]. By leading to leakage of ions and metabolites from the lysosomes to the cytosol, it 
causes alterations in cellular homeostasis. Pereira et al. have shown that secondary alter-
ations, such as changes in the Ca2+and H+ homeostasis caused by lysosomal membrane 
permeability, can contribute to cell death and to the pathophysiology of MPS I mice [90]. 
For example, too high a calcium concentration in the cytosol compromises the fusion 
between endosomes and lysosomes. Similary, endosomal and lysosomal pH that is too 
high also has a detrimental effect [91] as has  been demonstrated in mucolipidosis type IV 
[92]. Large changes in lysosomal membrane integrity causes leakage of lysosomal enzymes 
and other macro-molecules from the lysosomes in the cytosol, where the presence of 
lysosomal proteases, such as cathepsins, may contribute to apoptotic cell death [89, 93-96].
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RELEVANCE TO THERAPEUTIC OPTIONS
The following section describes the existing and potential therapeutic options for pre-
venting or correcting short stature, osteopenia, joint stiffness and contractures in MPS 
patients.
Enzyme replacement therapy
Enzyme replacement therapy (ERT) is currently available for MPS I, II and VI [97]. So far, 
although ERT ameliorates bone and/or joint problems in MPS animal models if started 
very early, it has achieved little improvement of bone disease in humans [77]. In a cat with 
MPS VI, Auclair et al. injected the enzyme directly into the joint rather than administer it 
intravenously [98] to improve the therapeutic efficacy in joints. This significantly reduced 
storage material in the articular chondrocytes and the synovial membrane; however, 
within two months of treatment, GAG accumulation recurred [98]. Monthly injections 
produced more positive effects than injections every three months and this  method of 
intra-articular therapy is currently being tested in two MPS VI patients [99].
It should be noted that the correction of MPS storage in the articular cartilage and 
the growth plate remains challenging because the accessibility of the chondrocytes is 
mechanically restricted by slow diffusion of the relatively large therapeutic enzymes 
through the molecular structure of the matrix.
With regard to age-related effects, McGill et al. reported a sibling study in which one 
sibling with MPS VI started ERT in the eighth week after birth and the other at 3.6 years. 
Therapeutic efficacy was assessed by comparing the two siblings’ bone and joint problems. 
Although the child who had been treated very young preserved joint movement, did not 
develop scoliosis and had no facial dysmorphia [100], the growth rate of both siblings 
was similarly decreased and macrocephaly was not prevented in the period between 
birth and 3.6 years. In both siblings, radiological changes of the skeleton progressed and 
degenerative changes took place in the joints [100]. Likewise, in the MPS VI cat model, 
the best response occurred when therapy was started directly after birth and if antibody 
development was prevented [101]. It appears that bones and joints respond better to ERT 
when the treatment is started early, therefore, neonatal screening for MPS enzyme defi-
ciencies might be an option for diagnosing MPS in children as early as possible [102].
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Bone marrow and hematopoietic stem cell transplantation
Although bone marrow transplantation (BMT) or hematopoietic stem cell transplantation 
(HSCT) in MPS I (ideally before 18 months of age) leads to several positive changes, it does 
not greatly reduce the skeletal abnormalities [103]. If no matched donor is available, cord 
blood from unrelated individuals can be used for transplantation [104]. However, despite 
early transplantation, transplant recipients often require major orthopedic surgery for 
genu valgum, acetabular hip dysplasia and kyphoscoliosis later in life [103, 105, 106]. In 
MPS animal models, osteoblast and osteoclast function was restored by bone marrow 
transplantation [20].
Gene therapy in MPS animals
Mango et al. examined the effect of liver-targeted retroviral gene therapy in β-glucuro-
nidase (GUSB) deficient MPS VII mice and dogs. In mice, full correction of femur length 
was not attained despite high level enzyme expression from the liver. This was even not 
achieved when gene therapy was used in very young animals and was explained by the 
poor accessibility of the growth plate [65]. As an alternative to ERT and BMT/HSCT, Byers 
et al. examined the effect of direct transduction of the synovial membrane of rats with 
a GUSB containing lentiviral vector [107]. The transduction was only partially successful. 
Enzyme expression was obtained in the synovia for 8 weeks, but the chondrocytes and 
the fibroblasts of the ligament were not transduced. This was probably due to steric 
exclusion of viral particles by cartilage ECM. In theory, the treatment can only work if 
enough enzyme is produced by the synovial cells, which can then leak into the synovial 
fluid and reach the chondrocytes by diffusion through the ECM.
Short stature and growth hormone (GH)
Even though they did not have a growth-hormone deficiency, a number of MPS IV 
patients have been given growth hormone. There was no evidence that this improved 
their growth [60]. Eight children with MPS I Hurler syndrome who had previously under-
gone HSCT also received GH treatment [108,109]. Some of them had HSCT induced GH 
deficiency, others did not, but all had growth failure. After one year of treatment with 
GH their growth failure was partially corrected. Potential complications of GH are Legg-
Calvé-Perthes disease, scoliosis and carpal tunnel syndrome [110, 111]. Although none of 
the transplanted patients had to discontinue GH treatment due to progressive scoliosis, 
one had a slipped capital femoral epiphysis, which can be caused by the GH therapy. The 
orthopedic complications characteristic of MPS I (Hurler) can be exacerbated by GH treat-
ment, though opinions differ with regard to the prevalence and progression of scoliosis 
or kyphosis during GH treatment. Some studies have indicated that the percentage and 
rate of progression of the scoliosis curve is generally higher than expected during GH 
therapy, while others have reported little to no progression [112-115].
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Hip abnormalities with a Perthes-like disease aspect (femoral head dysplasia, see fig. 1A) 
are common in untreated MPS patients and in patients treated with ERT [116]. It is not 
known whether GH aggravates this problem, but it can be envisaged that the growth plate 
becomes disorganized when chondroblast proliferation is randomly stimulated by GH.
The occurrence of pubertal delay in MPS VI patients and precocious puberty in MPS III 
patients may both be related to primary abnormalities of the hypothalamic-pituitary 
gonadal/thyroid hormone axes and may potentially affect growth. However, gonadal 
and thyroid hormonal dysfunctions have seldom been demonstrated in MPS patients 
and argue against the existence of any substantial abnormalities of the hypothalamic 
pituitary-gonadal/thyroid hormone axes [117, 118].
Osteopenia and the use of growth hormone
Throughout human life, GH and Insulin-like growth factor-I (IGF-I) play important roles 
in the homeostasis of bone. GH acts directly on the target tissues, e.g., bone, skeletal 
muscle and many others tissues. Many of the effects of GH are indirectly mediated by 
circulating (liver-derived) or locally produced IGF-I. Although GH treatment improves 
osteopenia in pediatric patients with growth hormone deficiency [119], the question is 
whether it also improves the osteopenia in MPS patients [120]. In a GH deficient rat model, 
it was demonstrated that GH administration increases periosteal and endocortical bone 
formation. GH also mitigates trabecular bone loss by increasing bone formation [119]. 
Since trabecular bone loss has been demonstrated in most MPS animal models, there 
is good reason to investigate the effect of GH dosing in MPS patients, particularly in 
younger ones whose bone abnormalities and growth retardation are still limited.
Osteopenia and the use of parathyroid hormone
Parathyroid hormone (PTH) is best known for releasing calcium from bone; primary 
hyperparathyroidism causes bone resorption. Parathyroid hormone also has anabolic 
activity [121]. The anabolic properties of PTH manifest at a low, intermittent dose. Under 
this regimen, PTH positively affects bone volume and microarchitecture by stimulat-
ing bone formation. This effect was seen in postmenopausal women with osteoporosis 
as well as in young women with growth disturbances [121, 122]. In the GH-deficient rat 
model (created by hypophysectomy), PTH increases bone formation mainly by reducing 
the osteoclast density per bone area, but has almost no effect on growth in length [119]. 
Given that PTH lowers osteoclast density, it would be unlikely to have a positive effect 
on osteopenia in MPS patients since the number of osteoclasts can be low (MPS VI cats) 
and their function defective (MPS VII mice) [66].
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Osteopenia and the use of bisphosphonates
Patients with Gaucher disease (GD), a lysosomal glycolipidosis, may have severe osteope-
nia even when treated with ERT. In Gaucher disease this has been attributed to “chronic 
macrophage activation”, inflammation and induction of accelerated bone turnover [103]. 
Bone-mineral density was improved by the administration of bisphosphonates, whose 
effect is attributed to the inhibition of osteoclast function [123]. Another lysosomal stor-
age disorder characterized by substantial bone abnormalities is Mucolipidosis. Patients 
with Mucolipidosis type III (ML III, pseudo-Hurler polydystrophy), have skeletal manifes-
tations resembling those of MPS patients. They have a distinctively high turnover of bone 
[124] caused by vigorous, osteoclast driven, subperiosteal bone resorption pertaining to 
virtually the entire periosteal surface. ML III patients treated with bisphosphonates have 
a clinical response, with a decrease in pain and improved mobility. Their bone density 
also increased, particularly in the metaphyseal regions.
Due to immobilization, children with psychomotor retardation related to causes other 
than MPS may have severe osteoporosis. In our clinic, such patients are treated success-
fully with bisphosphonates. If we take these facts into consideration, it could be that MPS 
patients will also benefit from bisphosphonates. On the other hand, bisphosphonates 
inhibit osteoclast function, which seems to be already compromised in MPS [66].
Osteopenia and the use of BMPs
It has been demonstrated that BMP-2 can be used to treat osteoporosis [41]. BMP-2 can 
accelerate bone healing in animal models [125] and in humans it promotes intervertebral 
and lumbar posterolateral fusions [126]. It has also been shown to induce new dentine 
formation, have a potential application in root canal surgery and to be an effective bone 
inducer around dental implants for periodontal reconstruction [127]. Because of the stim-
ulating effect of BMPs on osteoblast differentiation, their potential application in MPS 
deserves attention (this review).
Osteopenia and exercise
The bone and joint problems in hips and knees causes pain and restricted mobility, which 
indirectly leads to osteopenia. Physical exercise improves bone mass in growing children. 
Although the precise mechanism whereby it influences bone metabolism is not known, 
a response to greater mechanical stress and to changes in endocrine parameters are both 
likely contributors [32]. Physiotherapy and exercise might therefore improve osteopenia 
in MPS patients.
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Intervention at the level of secondary cellular events
As stated above, various secondary effects occur in the pathophysiology of MPS, including 
disturbed autophagy and polyubiquitination, mitochondrial dysfunction, inflammation, 
apoptosis and loss of lysosomal membrane integrity. These secondary events can be pre-
vented or resolved by reducing the lysosomal storage of GAGs. While this can be achieved 
by ERT or gene therapy [20, 35, 83, 128], the lysosomal GAG load can also be limited by 
reducing GAG synthesis. Such substrate reduction is used in Gaucher disease and Nie-
mann Pick disease type C [97]. Used as a substrate inhibitor in MPS III animal models, 
Rhodamine B has had a beneficial affect on CNS function [97]. However, the effect of sub-
strate inhibition on bone problems in this and other MPSs has not yet been demonstrated.
Inflammation
Research has been done on preventing the damage of bones and cartilage caused by 
inflammation. Simonaro et al showed the important role of TLR4 signaling in MPS bone 
and joint disease and suggested that targeting TNF-α may have positive therapeutic 
effects [77].
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CONCLUDING REMARKS
Growth retardation, dysostosis multiplex, osteopenia/osteoporosis, stiff joints and 
abnormal teeth in MPS patients are the final result of lysosomal GAG accumulation in 
connective-tissue-forming cells such as mesenchymal cells, fibroblasts, chondrocytes, 
osteoblasts and osteocytes, osteoclasts, odontoblasts, ameloblasts and cementoblasts. 
The primary cause of cellular dysfunction is intralysosomal GAG storage, which directly 
affects the composition and metabolism of the extra-cellular matrix. These primary 
events evoke a cascade of pathological processes that have local effects on tissue and 
organ function and distant effects on systemic functions. As the MPS degrading enzyme 
deficiencies are determined genetically, the GAG storage starts in utero, eliciting a long-
term effect on body structure and function. Skeletal malformations, dental dysplasia and 
hypoplasia are all pre-eminent examples of this process. To conclude this review, figure 9 
summarizes the cascade of pathologic events, starting with primary GAG storage.
Primary and secondary cellular events
GAGs, one of the major components of the ECM, are synthesized and recycled by connec-
tive tissue cells. They enter the cell by endocytosis and are degraded in the lysosomes. If 
one of the lysosomal enzymes involved in their degradation is missing or malfunctioning 
because of a genetic defect, GAGs accumulate in lysosomes. Intralysosomal GAG storage 
not only expands the volume of the lysosomal system, but also the functioning of the 
lysosomes as end-stations of the endocytic and autophagocytic transport pathways. The 
lysosomal membrane integrity is compromised, which has several consequences such as 
dysfunction of the lysosomal membrane ATPase proton pump and leakage of proteases 
(cathepsins) into the cytosol. The high intralysosomal pH prohibits optimal functioning 
of lysosomal hydrolases, thereby contributing to secondary lysosomal storage. The release 
of lysosomal cathepsins and other lysosomal proteases into the cytoplasm has been asso-
ciated with apoptosis. Dysfunction of autophagy leads to a series of cellular disturbances, 
including mitochondrial dysfunction. Abnormal vesicular traffic also affects endocytosis 
and thereby remodeling of the extra-cellular matrix. Such remodeling is also affected by 
the excess of proteoglycan, which can inhibit or stimulate cathepsin K activity. Most of 
the secondary cellular events are not unique for MPS, but occur in several of the lysosomal 
storage disorders. A review of the pathological cascade in neuropathic lysosomal storage 
disorders has recently been published and it shows several similarities with the model 
presented here for the MPS [129].
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Figure 9 Pathologic cascade in Mucopolysaccharidoses  
Fig.9. 1) Lysosomal GAG storage due to deficiencies of MPS-degrading enzyme. 2) Impairment of auto-
phagosome-lysosome fusion. 3) Impairment of endosome-lysosome fusion, affecting remodeling of the 
extra-cellular matrix. 4) Compromised lysosomal membrane integrity and disturbances of ion homeo-
stasis. 5) Leakage of lysosomal hydrolases and H+ out of the lysosome elevates the lysosomal pH and 
diminishes lysosomal function. 6) Leakage of cathepsins and other proteases into the cytosol may 
contribute to apoptosis. 7) Elevated Ca2+ levels in the cytosol, compromises the fusion of endosomes 
and lysosomes. 8) Activation of the TLR4 pathway by GAGs leads to the production of ceramide, which 
in turn leads to the release of cytokines and proteases, further elevating the TNFα level. 9) GAG-induced 
imbalance of MMP-2/9 and TIMP-1 causes degradation of the ECM. 10) Certain GAG’s can modulate the 
cathepsin K activity, which might affect ECM remodeling.
Cell-type-specific and tissue-specific events
Lysosomal GAG storage in chondrocytes directly affects the growth and maintenance of 
cartilage. In early life, long bones grow by endochondral ossification. A disturbance of 
this process by chondrocyte malfunction leads to poor growth, skeletal malformations 
and also osteopenia, whereby fewer trabeculae are formed and less calcification takes 
place. Articular cartilage of the joints persists throughout life. The GAG storage in this 
tissue culminates in a pathology resembling osteoarthritis, as well as rheumatoid arthritis. 
GAG storage in osteoblasts, osteocytes and osteoclasts hampers adequate bone formation 
and bone remodeling. Early anatomical abnormalities of bones can induce and enhance 
osteoarthritis and inflammation such as that caused by abnormal weight-bearing forces. 
Inflammation itself is detrimental to chondrocyte function as it leads to loss of ECM 
components (as in hallux valgus).
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Lysosomal storage of GAGs in teeth-forming cells such as the odontoblasts, ameloblasts 
and cementoblasts seems to be the greatest cause of abnormally shaped and irregularly 
positioned dental elements. The formation of teeth also requires interplay between teeth 
and bony elements of the mandibula and maxilla and it is likely that GAG storage in the 
osteocytes contributes to the problem.
Secondary responses
Partially degraded and undegraded GAGs interact with several growth factors, such as 
BMPs, FGFs and the FGF receptor. Activation of the TLR4 signaling pathway has been 
demonstrated in osteoblasts, osteocytes, osteoclasts, chondrocytes and odontoblasts and 
in the ECM in association with inflammation. Elevated expression of metalloproteinases 
and unbalanced elevation of metalloproteinase inhibitors cause osteoarthritis and rheu-
matoid arthritis, leading to articular cartilage degeneration. The proteoglycan content of 
the ECM is low and collagen is degraded abnormally fast.
Primary and secondary intervention
Therapeutic interventions reducing the lysosomal GAG storage are also expected to 
resolve some of the secondary pathophysiologic events. While enzyme-replacement 
therapy seems the first logical option, its effect on bone, joint and teeth pathology is 
limited by the texture of these tissues. Cartilage is avascular and large molecules can 
barely diffuse through the matrix. Bone cells are nourished by short connections with 
the blood vessels, but bone has a very slow turnover. In addition, the bone, joint and teeth 
problems are the result of long-term aberrant formation and maintenance of these tissues, 
which makes the abnormalities largely irreversible. Therefore, very early intervention is 
mandatory. Surgical intervention can correct or minimize some of the joint, bone and 
dental problems at a later age. Standard approaches can help to resolve inflammation 
related morbidity. Growing insight in the cascade of pathophysiologic events is slowly 
but steadily opening the doors that will enable us to improve the lives of MPS patients 
by manipulating the disease process at the primary or secondary levels.
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CHAPTER 3
A SIMPLE PROCEDURE
TO DIFFERENTIATE RESIDUAL
α-L-IDURONIDASE ACTIVITY
IN MILD AND SEVERE
MPS I PATIENTS 
ABSTRACT
Introduction: Three major clinical subgroups are usually distinguished for Muco-
polysaccharidosis type I, Hurler (MPS IH, severe presentation), Hurler/Scheie (MPS 
IH/S, intermediate) and Scheie (MPS IS, mild). For MPS IH patients, early diagnosis is 
important to facilitate treatment with hematopoietic stem cell transplantation. New-
born screening of MPS I would enable detection at a young age; however, prediction of 
the phenotype on the basis of the genotype in these young children may be difficult. 
Methods: We developed a relatively easy method to measure residual α-L-iduroni-
dase (IDUA) activity in MPS I fibroblasts using the commonly employed substrate 
4-methylumbelliferyl-α-L-iduronide. Enzyme incubation was performed with high 
protein concentrations at different time points up to 8 h. IDUA activity was analyzed 
in fibroblasts from 5 MPS IH, 3 MPS I H/S and 5 MPS IS patients. 
Results: Mean residual IDUA activity was 0.18% (range 0-0.6) of the control value in 
MPS IH fibroblasts, 0.27% (range 0.2-0.3) in MPS IH/S cells and 0.79% (range 0.3-1.8) 
in MPS IS fibroblasts. These results suggest a correlation of residual IDUA activity 
to severity of the MPS I phenotype. Two MPS IS patients with rare (E276K/E276K) or 
indefinite (A327P/unknown) IDUA genotypes had residual IDUA activity in the MPS 
IS range demonstrating the potential of our method to predict phenotypes. IDUAE276K 
was very unstable at 37 °C, but more stable at 23 °C suggestive for thermal instability. 
Conclusion: We report a procedure to determine residual IDUA activity in fibroblasts 
of MPS I patients which may be useful to predict MPS I phenotype.
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INTRODUCTION
Mucopolysaccharidosis type I (MPS I, OMIM #252800) is an autosomal recessively 
inherited lysosomal storage disorder caused by deficiency of α-L-iduronidase (IDUA, 
E.C. 3.2.1.76), a glycosidase involved in the degradation of the glycosaminoglycans (GAG) 
dermatan- and heparan sulfate [1, 2]. The partially degraded GAG, which accumulate in 
the lysosomes, cause a wide range of clinical manifestations in MPS I patients. Three 
major clinical subgroups are commonly distinguished, Hurler syndrome (MPS IH, OMIM 
#607014; severe presentation), Hurler-Scheie syndrome (MPS IH/S, OMIM #607015; inter-
mediate) and Scheie syndrome (MPS IS, OMIM #607016; mild). This classification in 
subgroups is, however, not precisely delineated clinically or biochemically [1]. MPS IH 
is characterised by early onset of clinical signs and symptoms including organomegaly, 
dysmorphic cardiac valves, restrictive pulmonary and obstructive airway disease, skeletal 
deformities, growth retardation, neurological complications and severe mental retarda-
tion. Their life expectancy is short, with death usually occurring in childhood. In MPS IS 
clinical problems develop later in life and are relatively mild (compared to MPS IH) and 
patients have normal intelligence. The phenotype of the MPS IH/S patients is interme-
diate [1] with variable neurological involvement. Later in life (early to mid-teens), these 
patients develop the clinical symptoms described for MPS IH patients. It may be difficult 
to distinguish MPS IH/S patients from the severe or the mild forms of MPS I.
The clinical diagnosis MPS I is confirmed by elevated levels of dermatan and heparan 
sulfate in urine and a deficiency of IDUA enzyme activity in leukocytes or fibroblasts 
[1]. The gene encoding IDUA is located on chromosome 4 (locus 4p16.3) and spans 19 kb 
including 14 exons [3]. More than 100 different mutations in the IDUA gene have been 
reported (Human Gene Mutation Database, http://www.hgmd.org). Prediction of the 
clinical phenotype of MPS I patients by analysis of the IDUA gene is not straightforward 
due to the large number of disease causing mutations, attenuating polymorphisms, rare 
sequence variants present in the IDUA gene and variation in genetic backgrounds [4].
Nowadays the two main therapies for MPS I patients are hematopoietic stem cell trans-
plantation (HSCT) for MPS IH patients and enzyme replacement therapy (ERT) for the 
less severely affected MPS I patients (MPS I H/S and S). HSCT is ideally performed before 
18 months of age (maximum age of 2 ½ years) and may prevent disease progression in the 
central nervous system to a large extent if performed in time [5, 6]. ERT cannot access 
sites of brain pathology due to protection of the brain by the blood-brain barrier there-
fore, ERT does not affect or prevent mental retardation although it effectively reduces 
the storage in other tissues such as liver and spleen [7, 8]. Early recognition/prediction of 
the phenotype of MPS I patients is essential in order to ensure that the most appropri-
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ate, therapeutic strategy is initiated in a timely manner [9]. Newborn screening for MPS 
I might be an option to detect patients at a very young age before clinical features have 
become evident [10]. In such an event, determination of IDUA activity in leukocytes and 
mutation analysis of the IDUA gene would be the next steps to confirm the diagnosis. 
However, if novel mutations are found with unknown effects on IDUA function, the 
phenotype cannot be predicted precluding selection of the right therapy.
In this article an attempt is made to correlate residual IDUA activity in MPS I patients 
with phenotype and genotype. To this end, we have adapted the commonly used IDUA 
assay described by Stirling et al. in such a way that it allows discrimination between MPS 
IH and MPS IS [11]. Residual activity was measured in fibroblasts of MPS I patients with 
different mutations in the IDUA gene. Such enzymatic investigations in cells of young 
patients with previously undetected mutations can be helpful to predict clinical outcome, 
therefore aiding decision making with respect to the most optimal therapeutic strategy 
for individual patients.
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MATERIALS AND METHODS
Sample preparation
Fibroblast cultures of MPS I patients, along with cultures from healthy controls, were 
provided by the European Cell Bank, Rotterdam, the Netherlands. Fibroblasts were cul-
tured under standard conditions in Ham’s F10 medium supplemented with 10% fetal calf 
serum, harvested by trypsinisation and stored as cell pellets at -80 °C. One cell pellet was 
prepared from one 75 cm2 flask. This study was approved by the Erasmus MC Institutional 
Review Board.
Enzyme assays
Fibroblast homogenates were prepared by resuspending one cell pellet in 100 µL water 
followed by sonication for 10 sec at 130 W. Ten µL of homogenate was taken to deter-
mine protein concentration using the Pierce BCA Protein Assay kit (Thermo Scientific) 
in accordance with manufacturer’s instructions. Protein concentration in homogenates 
from MPS I cells was adjusted to 2 mg/mL, while homogenates from control cells were 
diluted with 0.2 % BSA to 0.02 mg/mL homogenate protein. α-L-Iduronidase activity was 
measured essentially as described by Stirling et al. [11] using 10 µL fibroblast homogenate 
with 20 µL substrate solution containing 2 mmol/L 4MU-α-L-iduronide (Glycosynth), 0.1 
mol/L sodiumformate (pH 3.5) and 37.5 mmol/L NaCl. In some experiments, the protease 
inhibitor Pefabloc (Sigma) was added to the homogenate (final concentration 0.45 mg/
mL). The reaction was terminated after different incubation times (0 to 8 h) by adding 200 
µL 0.5 mol/L sodium carbonate (pH 10.7) containing 0.25 % (w/v) Triton-X-100. Substrate 
blanks were prepared at each time point and contained 10 µL water instead of fibroblast 
homogenate. The fluorescence intensity was measured with a fluorimeter (Varioskan, 
Thermo Electron Corporation / Thermo Fisher Scientific Inc, Waltham, MA, US) using an 
excitation wavelength of 365 nm and an emission wavelength of 448 nm. A standard was 
prepared containing 750 nmol/L 4-methylumbelliferone (4MU). α-L-Iduronidase activi-
ties were calculated by subtraction of corresponding substrate blanks and conversion of 
fluorescence readings to nmol product released per mg protein. The limit of detection 
(signal-to-noise ratio 3) was 3.5 pmol 4MU, which is equivalent to an activity of 0.2 nmol/
mg protein for MPS I cell homogenates. Typical fluorescence readings after 8 h of incu-
bation corresponded to 20-30 pmol for substrate blanks, 30-40 pmol for MPS IH cell lines, 
100-200 pmol for MPS IS cell lines and 400 pmol for controls. Half-life of IDUA activity 
was defined as the incubation time resulting in a 50% decrease of activity compared to the 
value at the start of the incubation. Total ß-hexosaminidase was used as a control enzyme 
and was measured according to O’Brien et al. using 4MU-2-acetamido-2-deoxy-ß-D-glu-
copyranoside (Melford) [12].
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Statistical analysis
Statistical analysis was performed with SPSS, software version 17. A Mann-Whitney U test 
was used to test differences in IDUA activity between MPS IH and MPS IS for significance. 
Statistical significance was defined as P <0.05 (two-tailed).
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RESULTS
The residual activity of IDUA was measured in fibroblast cell lines of 5 MPS IH patients, 
three MPS IH/S patients and seven MPS IS patients (table 1, fig. 1). For three of the MPS 
IH patients, homozygous for Q70X, W402X and 134del12, barely detectable activities of 
maximal 0.2 nmol/mg protein/h at 37 °C were found. The very low activities (0.1 to 0.2% 
of the controls) were in accordance with the fact that the aforementioned mutations are 
essentially null alleles. The MPS IH fibroblast cell line homozygous for A327P consistently 
showed a residual activity of about 0.5 nmol/mg protein/h in the first 30 min of the incu-
bation, but then decreased to an activity comparable to Q70X and W402X (fig. 1B). In the 
MPS IH cell line homozygous for L218P the residual IDUA activity was initially higher, 
with a maximal activity of 1.6 nmol/mg protein/h (0.6% of the controls) after one hour of 
incubation. However, the enzyme appeared to be unstable during longer incubation, with 
half-life activity of 2-4 h (fig. 1B). MPS IH cell lines carrying L218P in combination with 
other MPS IH alleles, W402X/L218P and A327P/L218P, had intermediate IDUA activities 
of 1.0 and 0.6 nmol/mg protein/h respectively (0.2 - 0.4% of the controls).
Two MPS IH/S cell lines analyzed were homozygous for P533R and L490P (table 1, fig. 1C). 
The activity of IDUA in these cell lines was 0.8 and 0.9 nmol/mg protein/h respectively, 
corresponding to 0.3% of the controls. In a third MPS IH/S cell line, genotype Q70X/
R383H, IDUA activity was 0.5 nmol/mg protein/h (0.2% of the controls). IDUA activities 
in these three MPS IH/S cell lines were slightly higher than observed for the Q70X and 
W402X MPS IH cell lines.
Seven MPS IS cell lines with five different genotypes were analyzed. A cell line homo-
zygous for R383H had a residual IDUA activity of 1.9 nmol/mg protein/h (0.7% of the 
controls; table 1, fig. 1C). The activity of IDUA of an MPS IS cell lines with genotype A327P/
R383H was lower than the activity observed in the cell line homozygous for R383H as was 
expected on the basis of the combination of a milder Scheie mutation (R383H) with a 
severe Hurler mutation (A327P). An MPS IS cell line with genotype R621X/974ins12 had a 
residual activity of 2.5 nmol/mg protein/h (0.9% relative to the controls) with maximal 
activity up to 2 hours of incubation at 37 °C (fig. 1C). In this cell line the IDUA half-life 
was approximately 4-6 h. The fourth MPS IS cell line carried A327P on one allele, while the 
second mutation was not found. This cell line had an activity of 1.6 nmol/mg protein/h 
(0.6% residual activity).
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Table 1 Residual IDUA activity in control and MPS I fibroblast cell lines at 37 °C
Phenotype Genotype Activity IDUA at 37 °C
(nmol/mg/h)a
Residual activity at 
37 °C (%)b
Control 1 Wt/Wt 197 ± 4 73
Control 2 Wt/Wt 313 ± 24 116
Control 3 Wt/Wt 247 92
Control 4 Wt/Wt 318 118
Hurler Q70X/Q70X 0.2 ± 0.1 0.1
Hurler W402X/W402X 0.2 ± 0.1 0.1
Hurler A327P/A327P 0.5 ± 0.1 0.2
Hurler L218P/L218P 1.6 ± 0.2 0.6
Hurler 134del12/134del12 <0.1   0.1
Hurler/Scheie P533R/P533R 0.8 ± 0.3 0.3
Hurler/Scheie L490P/L490P 0.9 ± 0.1 0.3
Hurler/Scheie Q70X/R383H 0.5 ± 0.1 0.2
Scheie R383H/R383H 1.9 ± 0.7 0.7
Scheie A327P/R383H 0.8 ± 0.1 0.3
Scheie A327P/unknown 1.6 ± 0.1 0.6
Scheie R621X/974ins12 2.5 ± 0.2 0.9
Scheie E276K/E276Kc 3.0 ± 0.4 1.1
Scheie E276K/E276Kc 3.3 ± 1.1 1.2
Scheie E276K/E276Kc 4.9 ± 1.5 1.8
a Activity was determined in the initial linear part of the trace (see also Fig. 1). Average values with stan-
dard deviation of at least two independent determinations are given. For controls 3 and 4 no duplicate 
values were available.
b IDUA activity relative to the mean value of 4 different controls (269 nmol/mg/h). c Sibship.
Three siblings in one Turkish family with MPS IS were homozygous for a recently 
described, novel IDUA mutation, E276K [13]. IDUA activity in these fibroblasts was very 
unstable; almost all activity was lost after 30 minutes of incubation at 37 °C (fig. 1C), 
while IDUA activity was 3-4.9 nmol/mg protein/h (1.1 to 1.8% compared to controls) 
during the first 30 minutes of incubation. The IDUA activity did not stabilize with 
the addition of the protease inhibitor Pefabloc (data not shown). The next step was to 
investigate thermal stability by measuring IDUA activity of the E276K fibroblasts at 23 
and 30 °C in addition to 37 °C (the incubation temperature normally used). By lowering 
the incubation temperature, the activity of IDUA in control fibroblast decreased to 57% 
at 30 °C and 26% at 23 °C of the activity measured at 37 °C (fig. 2A). 
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Figure 1 Residual IDUA activity in control and MPS I fibroblast cell lines at 37 °C
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Fig. 1. IDUA activity in normal control and MPS I fibroblast cell lines. Activity was determined at 37 °C 
as described in the Materials and methods. 
A, normal control; B, MPS IH cell lines (homozygous for Q70X, W402X, A327P, L218P and 134del12); C, MPS 
IH/S cell lines (homozygous for P533R and L490P) and MPS IS cell lines (R383H/R383H, E276K/ E276K, 
R621X/974ins12 and A327P/unknown).
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The IDUA activity in the E276K fibroblasts showed comparable results at 30 °C and 37 
°C during the first 30 minutes of incubation (fig. 2B), while a longer incubation time 
suggested a slightly more stable activity at 30 °C compared to 37 °C. At 23 °C the activity 
was approximately 50% of the value measured at 37 °C after 30 minutes, but at this lower 
temperature, activity levels were maintained much longer. These results suggest that 
the mutant E276K enzyme is thermo labile.
Mean residual IDUA activity was 0.18% (range 0-0.6) of the control value in MPS IH 
fibroblasts, 0.27% (range 0.2-0.3) in MPS IH/S cells and 0.79% (range 0.3-1.8) in MPS IS 
fibroblasts. IDUA activity was significantly different (p = 0.02) between MPS IH and MPS 
IS fibroblasts. The IDUA activity in MPS IH/S cells did not differ significantly from MPS 
IH and MPS IS cells (p = 0.39 and 0.1 respectively). 
Figure 2 IDUA activity of the homozygous E276K fibroblast cell line
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Fig. 2. IDUA activity in a normal control (A) and in an MPS IS fibroblast cell line homozygous for E276K 
(B) at 23, 30 and 37 °C.
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DISCUSSION
The two main therapeutic options for MPS I are hematopoietic stem cell transplantation 
(HSCT) for MPS IH patients and enzyme replacement therapy (ERT) for the less severe 
MPS I phenotypes (MPS I H/S and S). Currently, the determination of the clinical phe-
notype is mainly based on clinical judgement which then determines the therapeutic 
strategy to be implemented. Since the age of symptom onset and the severity of symp-
toms clearly differ between the MPS IH and MPS IS patients, this may not pose a problem 
in most cases. However, with the growing awareness that particularly the mental develop-
ment in MPS IH patients is much better when HSCT is performed at young age, interest 
in newborn screening programs increase. Newborn screening may enable detection of 
MPS IH patients at an early and potentially pre-symptomatic age. However, while the 
choice of therapy is relatively straightforward after a clinical diagnosis, it may not be as 
easy to determine with pre-symptomatic diagnosis through newborn screening. Predic-
tion of the phenotype in these very young MPS I patients based on IDUA deficiency in 
bloodspots/leukocytes and genotype may be difficult and only reliably performed when 
patients have two known truncating IDUA mutations; therefore, additional diagnostic 
tools are required. Assuming that different MPS I phenotypes result from differences in 
residual IDUA activity, one such tool could be accurate determination of residual enzyme 
activity as presented in our study. 
We showed that fibroblasts of MPS IH patients generally have very low or no residual 
IDUA activity, with an average of 0.18% of the control. Fibroblasts of the severely affected 
MPS IH patient homozygous for L218P  had an unexpected, relatively high activity cor-
responding to 0.6% of the control. The highest residual activity, on average 0.79% of the 
control value, was found in fibroblasts of MPS IS patients, while MPS IH/S fibroblasts 
had an intermediate residual activity of 0.27%. Previously, Bunge et al. and Yogalingam et 
al. have measured residual IDUA activity in fibroblasts of patients with different MPS I 
phenotypes [14, 15]. Using the substrates K-L-iduronosyl anhydro-[1-3H]mannitol 6-sulfate 
(IMS) and tritiated α-L-iduronosyl(1-4)anhydromannitol-6-sulfate, they showed that there 
were differences in residual IDUA activity in fibroblasts of MPS IH and MPS IS patients. 
Our results are in line with those reported in the study of Bunge et al [14]. They measured 
less than 0.13% residual IDUA activity in cells of severely affected Hurler patients, whereas 
the residual activity in cells from Scheie patients ranged from 0.4-7% [14]. In MPS IH/S 
patients, residual IDUA activity has been reported in several studies to range from 0.03-
1.8% [14, 16-18]. The potential advantage of the method used in our study is that we have 
used the widely employed substrate 4-methylumbelliferyl-α-L-iduronide, an assay that 
is easy to perform, with reliable results. The differences compared to the routine IDUA 
assay are a higher protein concentration, being 2 mg/mL instead of 1 mg/mL and longer 
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incubation times. Instead of 1 hour of incubation at 37 °C, we prolonged the incubation 
time up to 8 hours and measured the activity at different time points during this period. 
These modifications enabled a better determination of residual IDUA activity and pro-
vided information on IDUA stability.
The mean residual IDUA activity in MPS IH cells (0.18% of the control value) was sig-
nificantly lower (p = 0.02) than the value measured in MPS IS cells (0.79%), suggesting 
a correlation between IDUA activity and the severity of the phenotype. The utility of 
our method is demonstrated for several patients with MPS IS phenotype: a sibship with 
the rare E276K mutation and a patient carrying A327P in combination with an unknown 
mutation. Both had clear residual IDUA activity (0.6-1.8% of the control) consistent with 
their MPS IS phenotype.
For 12 out of 13 cell lines (92%) with different MPS I genotypes (4 MPS IH, 3 MPS IH/S and 
5 MPS IS), residual IDUA activity correlated to MPS I phenotype. An exception was the 
severely affected MPS IH patient homozygous for mutation L218P, which had a higher 
residual IDUA activity compared to the other homozygous Hurler mutations. IDUAL218P 
activity resembled residual activity observed in MPS IS patients. On the basis of the 
observed residual IDUAL218P activity, our method did not predict the severe MPS IH phe-
notype documented for this mutation [9, 17, 19]; however, IDUAL218P activity was unstable 
(fig. 1B). In a structural study of mutant IDUA, Sugawara et al. suggested that L218P (as 
well as A327P) probably causes serious conformation changes in the IDUA enzyme, leading 
to decreased stability of the enzyme [9]. Alternately, the higher than expected activity of 
IDUAL218P could perhaps be explained by a relatively high activity with the artificial 4MU 
substrate compared to the natural substrate. This has been described by Harzer et al. in 
Niemann–Pick A/B patients who exhibited pseudo-normal sphingomyelinase activity 
with the artificial substrate HMU-phosphorylcholine [20].
An interesting finding was the detection of the novel E276K mutation in a sibship of 
Scheie patients from Turkish ancestry. This mutation was recently reported in one Thai 
patient [13]. The E276K, mutation resulted in a very unstable IDUA enzyme leading to an 
almost complete loss of enzyme activity within 30 minutes after start of incubation at 
37 °C. Subsequent determination of IDUA activity at incubation temperatures of 23 °C 
and 30 °C showed a much better stability, particularly at 23 °C, suggesting that the rapid 
decrease in IDUAE276K activity at 37 °C was due to thermal instability. 
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CONCLUSION
We report a simple procedure to determine residual IDUA activity in cultured fibroblasts 
of MPS I patients. This method may offer a potential tool for early prediction of the MPS 
I phenotype of patients. This may be particularly informative when the genotype is unin-
formative (e.g., when a novel mutation with unknown effect is detected), which becomes 
highly important in the event that neonatal screening would be introduced for MPS I 
(see proposed diagnostic algorithm; fig. 3). In such an event, our new method may be 
helpful as was shown for a sibship with the recently reported novel E276K mutation and 
for a patient carrying A327P in combination with an unknown mutation. Both had clear 
residual IDUA activity which correlated to their MPS IS phenotype. Additionally, incu-
bation during longer periods and at different temperatures appeared helpful in detecting 
(thermal) instable IDUA species.
Figure 3 Flowchart MPS I newbornscreening
MPS I positive newborn screening
result
IDUA activity in leucocytes Investigate discrepancy
Normal
Deficient
1. IDUA mutation analysis
2. Skin biopsy for fibroblast culture
Genotype with documented 
MPS I phenotype
Genotype uninformative
Determine residual IDUA activity 
in fibroblasts
IDUA activity < 0.2% of controls
Most likely MPS IH
IDUA activity ≥ 0.3% of controls
Most likely not MPS IH
Fig.3. Proposed flowchart for diagnostic follow-up after a positive MPS I newborn screening result.
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CHAPTER 4
A LONG TERM
FOLLOW-UPSTUDY OF
THE DEVELOPMENT OF HIP DISEASE
IN MUCOPOLYSACCHARIDOSIS
TYPE VI
ABSTRACT
Introduction: Hip problems in Mucopolysaccharidosis type VI (MPS VI) lead to severe 
disability. Lack of data on the course of hip disease in MPS VI make decisions regard-
ing the necessity, timing and type of surgical intervention difficult. Therefore, we 
studied the development of hip pathology in MPS VI patients over time. 
Methods: Data was collected as part of a prospective follow-up study. Standardized 
supine AP pelvis and frog leg lateral radiographs of both hips were performed yearly or 
every 2 years. Image assessment was performed quantitatively (angle measurements) 
as well as qualitatively (hip morphology). Clinical burden of hip disease was evalu-
ated by physical examination, a six-minute walking test (6MWT) and a questionnaire 
assessing pain, wheelchair dependency and walking distance.
Results: A total of 157 pelvic radiographs of 14 ERT treated MPS VI patients were 
evaluated. Age at first image ranged from 2.0 to 21.1 years. Median follow up duration 
was 6.8 years. In all patients, even in the youngest, the acetabulum and os ilium were 
dysplastic. Coverage of the femoral head by the acetabulum improved over time, but 
remained insufficient. While the femoral head appeared normal in the radiographs 
at a young age, over time, the ossification pattern became abnormal in all patients. 
A decrease in the distance covered in the 6MWT was also observed in all patients, 
as well as in the BRUCE treadmill test (median Z scores -3.3). Twelve patients had a 
waddling gait, four patients were partially wheelchairdependent and ten patients had 
limitations in their maximum walking distance.  
Conclusion: Clinically significant hip abnormalities develop in all MPS VI patients 
very early in life, starting with deformities of the os ilium and acetabulum. Femoral 
head abnormalities occur later, most likely due to altered mechanical forces in com-
bination with epiphyseal abnormalities due to glycosaminoglycan storage. The final 
shape and angle of the femoral head differs significantly between individual MPS VI 
patients and is difficult to predict.
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INTRODUCTION
The lysosomal enzyme N-acetyl galactosamine 4-sulfatase (arylsulfatase B, coding gene 
ARSB, EC 3.1.6.12) is deficient in patients with Mucopolysaccharidosis type VI (MPS VI) 
or Maroteaux–Lamy syndrome (OMIM#253200). This deficiency causes intra-lysosomal 
accumulation of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin 4-sul-
fate in various connective tissues and organs, including cartilage and bone [1]. The birth 
prevalence of this autosomal recessive disorder in the Netherlands is 1 in 667,000 [2], 
whereas estimations worldwide range from 1:238,095 to 1:1,505,160 [3].
Patients in whom the disease progresses rapidly have high levels of GAG excretion in 
urine (above 22.7 mg/mmol creatinine) [4], early onset of symptoms and a shorter life 
expectancy compared to those in whom the disease progresses more slowly. However, 
even in patients with slow disease progression, invalidating manifestations of the disease 
develop [5]. Until enzyme replacement therapy (ERT) became available in 2007, allogeneic 
or hematopoietic stem-cell transplantation (HSCT) was the only treatment option for 
MPS VI patients. ERT has positive effects on visceral manifestations of the disease, range 
of motion of the shoulders, endurance capacity and some aspects of quality of life [6-8]. 
However, both HSCT and ERT seem ineffective in preventing the progression of skeletal 
complications such as kyphosis, scoliosis and hip disease [9-12]. Hip problems have a great 
impact on quality of life in all MPS VI patients, including those with milder forms of the 
disease [13-19]. Symptoms include pain in hips and legs, decreased movement and diffi-
culty in walking caused by joint contractures. Some patients become partly or completely 
wheelchair dependent at a young age and orthopedic surgery is often deemed necessary 
[20]. In this prospective follow-up study, we focused in particular on the developmental 
pattern of hip disease in MPS VI in order to better understand clinical needs and direct 
future research. 
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MATERIAL AND METHODS
Patients
We included all patients with a diagnosis of Mucopolysaccharidosis type VI followed at 
the Center for Lysosomal and Metabolic diseases at the Erasmus MC University Medical 
Center in Rotterdam, the Netherlands, who had available hip radiographs. The protocol 
was approved by the Medical Ethical Committee at Erasmus University Medical Center 
in 2007. The diagnosis was established by measuring deficient arylsulfatase B activity 
in leucocytes and fibroblasts, as well as performing DNA analysis of the ARSB gene. All 
patients were treated with 1mg/kg of recombinant human arylsulfatase B (galsulfase, 
Naglazyme®, BioMarin Corporation) weekly. 
Assessment of the AP pelvis and frog leg lateral radiographs 
Yearly supine hip radiographs (Anteroposterior (AP) and frog leg lateral (Lauenstein)) 
radiographs were obtained as part of the standardized clinical follow-up protocol from 
2007 onwards. We also included a small number of radiographs available before this date. 
One patient underwent hip reconstruction and two patients underwent guided growth 
of the knees, postoperative images were excluded from the analysis. 
Quantitative assessment 
To evaluate hip morphology in a standardized manner, we evaluated the following param-
eters (appendix fig. 1A). Acetabular index: The acetabular index (AI) (the inclination angle 
of the acetabulum) [21] was used to evaluate acetabular dysplasia. The AI values were 
compared with normal values  as described by Schmid [22]. Sharp’s angle: After closure of 
the triradiate epiphysis (around twelve years of age in girls and fourteen years in boys), 
the Sharp’s angle (i.e., the angle between the inter-teardrop-line and the line connecting 
the inferior tip of the teardrop to the lateral acetabular rim) was measured [23]. A Sharp’s 
angle value greater than 42.5 degrees is indicative of a dysplastic acetabulum [24]. Ace-
tabular head index: The acetabular head index was used to quantify the femoral head 
coverage [25]. 
Shenton’s line: The continuity of Shenton’s line (drawn along the inferior border of the 
superior pubic ramus and along the inferomedial border of the neck of the femur) was 
assessed. This line is normally continuous and smooth, so interruption of this line is an 
indication of loss of containment. Neck shaft angle (NSA): The neck shaft angle of the 
femoral neck was measured to determine abnormalities of the position of the proximal 
femur. Coxa vara refers to a decreased neck-shaft angle and an increased neck-shaft 
angle is named coxa valga [26]. The NSA values were compared with normal values  as 
described by Schmid [22].
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Appendix figure 1A Measurements of different angles of the pelvis
Appendix fig. 1A. AI=acetabular index, SA=Sharp’s angle, AHI=acetabular head index. 
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Statistical analysis
At group level, the change in the estimated mean of the left and right acetabular index 
(both as degrees and standard deviations) from birth up to age 12 were reported. The 
framework of linear mixed effects models was used to account for the correlations 
between the repeated measurements in individual patients. To account for potential 
non-linear profiles we used natural cubic splines in the fixed-effects and random-effects 
parts of the model with a maximum of 3 degrees of freedom. For the random-effects 
part of the model, an unstructured covariance matrix was used. The nlme package of R 
(version 3.2.1) was used to generate these models [27]. Trajectories of the NSA of individual 
patients were plotted over age for each patient.
Qualitative assessment 
In all patients, the morphology and development of the hip joint over time were assessed 
and compared to normal hip development. The following aspects were assessed: Pelvis: 
Pelvic shape and congruency of the hip joint. Epiphyseal ossification: Shape and irregu-
larities of the femoral head and femur epiphyseal. Metaphyseal ossification: The shape 
of the femoral metaphysis and angularity of the femoral neck.
Clinical assessment
Cardiac and pulmonary functions were assessed to evaluate the potential influence of 
heart or lung disease on mobility. For this assessment, shortening fraction and left-ven-
tricular posterior wall thickness in diastole (LVPWd) were measured by echocardiography 
and forced vital capacity (FVC) by spirometry using a Lilly-type pneumograph (Viasys 
Healthcare, Wurzburg, Germany). The maximum value of three reproducible tests was 
used. Overnight polysomnography was conducted as described previously [7].
The six minute walking test (6MWT) was executed according to guidelines of the Ameri-
can Thoracic Society [28], reported as meters walked in 6 minutes. Z scores were calculated 
using age specific reference values [29]. Extension of the knees and hips were assessed 
using standardized goniometry measurements. During the 6MWT, two experienced phy-
sicians (a metabolic pediatrician and a physiotherapist) observed whether a waddling gait 
was present. Neurological examination was performed by a pediatric neurologist to detect 
neurological causes of limited mobility (e.g., spinal cord compression). On indication, an 
MRI of the craniocervical junction or complete spinal cord was made. When abnormal, 
spinal cord and spinal root function was assessed via somatosensory evoked potentials 
(SSEP). Clinical burden of hip disease in daily life was evaluated by a questionnaire assess-
ing pain, wheelchair dependency and walking distance. These questionnaires were filled 
out once, at the time of the last outpatient clinic visit or by telephone interview, most 
often by the parent or caretaker of the patient.
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RESULTS
Patient characteristics 
Patient characteristics of the 14 included MPS VI patients are shown in table 1. Among 
them were three pairs of siblings. Seven of the fourteen patients had a rapidly progressive 
phenotype defined by disease presentation before the age of 5 years and urinary GAG 
levels above 22.7 mg/mmol creatinine [4]. The remaining seven patients had a slowly 
progressive phenotype. In our study urinary GAG levels of the rapidly progressive patients 
ranged from 59 to 88 mg/mmol creatinine (median 77 µg/mg creatinine). The age of the 
patients at diagnosis ranged from 0.7 to 10.3 years (median 2.2 years in the rapidly progres-
sive and 6.4 years in the slowly progressive patients).
The mutations of patients 1 to 11 have been described in an earlier study [7]. The muta-
tions of patient 13 are not yet known. The sibs 12 and 14 are homozygous for the c.937C>G, 
p.Pro313Ala (ARSB, exon 05) mutation, which has been described in a heterozygous state 
previously [30]. All patients received enzyme replacement therapy. The duration of treat-
ment at the last outpatient visit ranged from 1.9 to 9.8 years, median of 8.1 years. Age at 
the time of the first radiographs ranged from 2 to 16.6 years and for the last radiographs 
from 3.6 to 21.1 years. Time between first and last radiograph ranged from 0.5 to 11.9 years 
(median 6.8 years) (Table 1). 
Assessment of the AP pelvis and frog leg lateral radiographs 
A total of 88 AP pelvis and 69 frog leg lateral radiographs were available for analysis. 
Quantitative assessment 
Acetabular index: fig. 1A shows the average trend of the acetabular index (AI) of 13 MPS VI 
patients over time. On an individual level, 4 patients had an increase of the AI, 5 remained 
stable and 4 decreased over time. All patients AIs were above +2 SD during their entire 
follow-up. On a group level, the AI remained stable high over time in contrast to fast 
(normal) decline in healthy children. At the age of 12 years, the AI value is +6SD on group 
level (fig. 1B). This indicates severe acetabular dysplasia. Sharp’s angle: all but two hips 
were dysplastic as defined by Sharp’s angle of >42.5 degrees.
Acetabular head index: over time, the acetabular head index increased (9 patients) or 
remained unchanged (2 patients), indicating an improvement in coverage of the femoral 
head due to ossification of cartilage at the lateral side of the acetabulum and the for-
mation of a neoacetabulum (examples fig.3 B-F). In two patients (patient 9 and 13), the 
acetabular index decreased, but both patients were still young.  
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Shenton’s line: in eight patients, Shenton’s line was continuous at all ages (patients 1, 2, 
4, 5, 8, 10, 12 and 14). In patients 3 and 6, Shenton’s line was interrupted up to ages 12 and 
14, after which it became continuous again. In patient 7, the line was discontinuous in 
both hips up to age 7, after which the right side was continuous, but the left remained 
discontinuous. In patient 9, the left hip showed interruption of Shenton’s line in all 
radiographs evaluated. In patients 11 and 13, the line was discontinuous at all ages. 
Neck shaft angle (NSA): individual trends of the mean of the right and left NSA until 
age 21 are shown in fig. 1C. There is great variance between the individual patients. The 
oldest (slowly progressive) patient had serious varus position of the neck shaft angle. He 
received an intertrochanteric valgus osteotomy of his left hip. 
Qualitative assessments 
Pelvis
The os ilium was abnormally shaped in all patients at all ages. Characteristic features 
were flaring of the iliac wings and hypoplasia of the basilar portions of the ilium (fig. 2). 
The acetabulum was abnormally shaped, being steep, shallow and small (current study) 
Table 1 Patients characteristics
Pt nr. Age at 
diagnosis 
(years)
First GAG
(mg/mmol 
creatinine)
Type of 
disease 
(progression)
ARSB gene Allele 1 Allele 2 Ethnicity Age at start ERT
(years)
Duration ERT
(years)
Age first 
radiograph of 
pelvis/hips
Age last 
radiograph of 
pelvis/hips
1* 7 12 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 18.3 3.5 16.6 21.1
2 7.5 21.4 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 8.2 8.8 7.6 16.8
3 2.9 67.5 Rapidly 1142+2T>C, exon 5 1142+2T>C, exon 5 Indian 6.8 9.8 3.9 15.8
4 10.3 22 Slowly 629A>G, (p.Y210C), exon 3 937C>G, (p.P313A), exon 5 Dutch 10.6 5.8 10 15.6
5* 0.7 26.3 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 7.6 8.6 7.6 15.1
6# 6.4 22.6 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 7.8 8.2 7.3 13.4
7 5 17.2 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 5.9 9.5 5.3 13.4
8# 5.9 21.7 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 6.1 8.2 5.8 14.2
9 2.7 86 Rapidly 995 T>G, (p V332G), exon 2 995 T>G, (p V332G), exon 2 Morocco 3.0 8.7 2.9 10.5
10 1.9 88 Rapidly 903C>G, (p.N301K), exon 5 
1151G>A, (p.S384N), exon 6 
(neutral)
903C>G, (p.N301K), exon 5 
1151G>A, (p.S384N), exon 6 
(neutral)
Turkish 2.0 7.9 2 9.8
11 1.4 84 Rapidly 971G>T, (p. G324V), exon 5 971G>T, (p. G324V), exon 5 Guinea 2.3 7.1 2.2 8.2
12+ 4.6 59 Rapidly 937C>G, (p.P313A), exon 5 937C>G, (p.P313A), exon 5 Dutch 5.1 1.9 4.6 6.6
13 3.1 86.4 Rapidly Unknown Unknown Dutch/
Zimbabwe
3.2 1.9 3.1 3.6
14+ 2.2 71 Rapidly 937C>G, (p.P313A), exon 5 937C>G, (p.P313A), exon 5 Dutch 2.7 1.9 2.4 4.4
Pt patient; *, #, + siblings; GAG glycosaminoglycans; ERT enzyme replacement therapy. Patient 1 underwent hip surgery 
at age 21, after which his radiographs were excluded from analysis.
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Table 1 Patients characteristics
Pt nr. Age at 
diagnosis 
(years)
First GAG
(mg/mmol 
creatinine)
Type of 
disease 
(progression)
ARSB gene Allele 1 Allele 2 Ethnicity Age at start ERT
(years)
Duration ERT
(years)
Age first 
radiograph of 
pelvis/hips
Age last 
radiograph of 
pelvis/hips
1* 7 12 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 18.3 3.5 16.6 21.1
2 7.5 21.4 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 8.2 8.8 7.6 16.8
3 2.9 67.5 Rapidly 1142+2T>C, exon 5 1142+2T>C, exon 5 Indian 6.8 9.8 3.9 15.8
4 10.3 22 Slowly 629A>G, (p.Y210C), exon 3 937C>G, (p.P313A), exon 5 Dutch 10.6 5.8 10 15.6
5* 0.7 26.3 Slowly 454C>T, (p.R152W), exon 2 454C>T, (p.R152W), exon 2 Turkish 7.6 8.6 7.6 15.1
6# 6.4 22.6 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 7.8 8.2 7.3 13.4
7 5 17.2 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 5.9 9.5 5.3 13.4
8# 5.9 21.7 Slowly 629A>G, (p.Y210C), exon 3 979C>T, (p.R327X), exon 5 Dutch 6.1 8.2 5.8 14.2
9 2.7 86 Rapidly 995 T>G, (p V332G), exon 2 995 T>G, (p V332G), exon 2 Morocco 3.0 8.7 2.9 10.5
10 1.9 88 Rapidly 903C>G, (p.N301K), exon 5 
1151G>A, (p.S384N), exon 6 
(neutral)
903C>G, (p.N301K), exon 5 
1151G>A, (p.S384N), exon 6 
(neutral)
Turkish 2.0 7.9 2 9.8
11 1.4 84 Rapidly 971G>T, (p. G324V), exon 5 971G>T, (p. G324V), exon 5 Guinea 2.3 7.1 2.2 8.2
12+ 4.6 59 Rapidly 937C>G, (p.P313A), exon 5 937C>G, (p.P313A), exon 5 Dutch 5.1 1.9 4.6 6.6
13 3.1 86.4 Rapidly Unknown Unknown Dutch/
Zimbabwe
3.2 1.9 3.1 3.6
14+ 2.2 71 Rapidly 937C>G, (p.P313A), exon 5 937C>G, (p.P313A), exon 5 Dutch 2.7 1.9 2.4 4.4
Pt patient; *, #, + siblings; GAG glycosaminoglycans; ERT enzyme replacement therapy. Patient 1 underwent hip surgery 
at age 21, after which his radiographs were excluded from analysis.
[13-19]. The dysplasia of the acetabulum increases over time without loss of congruency 
as the shape of the acetabulum adjusts to the enlargement of the femoral head over time 
(formation of a neoacetabulum) (fig. 3B-F).
Epiphyseal ossification
Since patients with slowly progressive MPS VI are diagnosed at an older age compared 
to those with rapidly progressive disease, radiographs of the hips under the age of five 
were only available for patients with the rapidly progressive phenotype. Epiphyseal ossi-
fication appeared normal in the radiographs taken, up to the age of 3 years (patients 9, 
10, 11, 13, 14 at age 3, 2, 2, 3.6 and 2 years old) (examples fig. 2 and 3E and F). In radiographs 
of all patients with both phenotypes, from age 3 onwards, ossification shows progressive 
abnormalities, altering the shape of the femoral head over time. The abnormal ossification 
was specifically noted in the central and medial part of the femoral head epiphysis. Only 
in one patient (patient 3) the medial part was altered. The final shape of the femoral head 
(at last available radiograph) differed between patients. 
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Figure 1 Quantitative assessment of pelvic radiographs 
Fig.1. 1A: Modeled trend of the mean of the left and right acetabular index (AI) (solid line) and 95% 
prediction interval (PI) (grey area) based on radiographs of 13 MPS VI patients 0-12 years of age (delta 
1.58, p= 0.57). The reference mean (male and female) is indicated by the dotted black line, while the area 
between the grey dotted lines represents +/- 95% confidence interval.
1B: AI Z-score of the modeled trend shown in fig. 1A (solid line) with +/- 95% prediction interval (PI) 
(grey area) (delta 6.1, p= <0.0001).
C:  Individual trends of the mean of the left and right neck shaft angle of 14 MPS VI patients aged up 
to 21 y (solid lines). Dotted line indicates the reference values (mean of female and male) with +/- 95% 
confidence interval (grey area).
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Figure 2 Hips of young MPS type VI patients
Fig. 2. Examples of two left hips of young, rapidly progressive MPS type VI patients compared to normal 
left hip aged 2 years. I: AP=anteroposterior radiograph, II: Frog leg lateral radiograph. Left part of the 
pelvis and femoral head of a normal control at the age of 2 years (A); abnormal shaped pelvis, with 
dysplasia of the os ilium and steep, shallow, small acetabulum and normal femoral head in patient 14 at 
the age of 2 years (B); and in patient 13 at the age of 3.6 y (C).
A number of patients (1, 2 and 5) had a broad and flat femoral head (also named coxa 
magna) (example fig. 3B and appendix fig. B 1,2 and 3). In others (patients 4, 6, 7, 8, 9, 11 and 
13) the femoral head was extremely flat, while patients 4, 6, 7 and 8 showed irregularities 
of the epiphysis (appendix fig. B4-8) (examples fig. 3C and E). In patients 10, 12 and 14, 
less flattening of the femoral head occurred, but irregularities of the central part of the 
epiphysis were observed (example fig. 3F). Patient 3 was the only patient with an ovoid 
shape of the femoral head (example fig. 3 D).
Metaphyseal ossification (femoral neck)
Development of the femoral metaphysis was abnormal in all patients, resulting in abnor-
mal shape or angularity of the femoral neck. For example, the femoral neck in patient 2 
was broad from the beginning and the neck shaft angle (NSA) was decreased (coxa breva 
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and vara) (fig. 3B). The femoral neck in patients 7, 9 and 10 developed normally over time, 
but the NSA was increased (coxa valga) in patients 7 and 9 and decreased in patient 10 
(coxa vara) (fig. 3C, E and F). In patient 3, the femoral neck narrows centrally over time 
resulting in an hour glass shape deformity (fig. 3D).  
Figure 3 Hip development in MPS VI patients
Fig.3. Examples of developmental patterns of the acetabulum, proximal femoral epiphysis and metaph-
ysis in males aged 2-14 years: A with normal development (radiographs from different individuals) and 
of 5 MPS VI patients: B, patient 2; C, patient 7; D, patient 3; E, patient 9; F, patient 10.
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Appendix figure B Examples of developmental patterns of the acetabulum, proximal femoral epiph-
ysis and metaphysis according to mutation
Appendix fig. B. In patients homozygous for R152W (1, patient 2; 2, patient 5; 3, patient 1) the final 
shape of the femoral head is broad (coxa magna) and flat (coxa plana), with a decreased neck shaft 
angle (NSA) (coxa vara).
In patients with Y210C/R327X (4, patient 8; 5, patient 7; 6, patient 6) and one patient with Y210C/P313A 
(7, patient 4), the final shape of the femoral head is extremely flat with irregularities of the epiphysis, a 
normally shaped metaphysis with increased neck shaft angle (coxa valga).
I: AP=anteroposterior radiograph, II: Frog leg lateral radiograph
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Table 2 Clinical assessments
Pt
nr
SF%
Z score
age
LVPWd 
cm 
Z score
age
FVC%
Z score
age
Polysomnography
age
Goniometry
Knee degrees
flexion
right/left
age
Goniometry
Hip degrees
flexion
right/left
age
Waddling
gait (y/n)
6MWT  
meters
Z score
age
Neurological 
Examination 
Muscle strength legs 
right/left (MRC)
age
MRI craniocervical junction 
MRI total spinal cord
age
SSEP
age
1 44.8
2.4
21.2 yr.
0.72
-2.1
21.2 yr.
82
-1.3
25 yr.
Mild signs of 
obstructive 
hyperpnea
24.6 yr.
162/160 
21 yr.
165/166
21 yr.
y  425 m
    -3.6
 24.6 yr.
Normal
23.9 yr.
Craniocervical C0-C3 narrowing no spinal cord 
compression, ND
25.3 yr.
Normal
 23.2 yr.
2 38
0.8
15.7
0.92 
0.74
15.7
94
-0.45
15.7
Normal 
14.5 yr.
165/165
16.2 yr.
160/155 
16.2 yr.
y 424 m
   -4.7
13.1 yr.
Normal 
16.2 yr.
Craniocervical narrowing no spinal cord compression, ND 
16 yr.
ND
3 21.5
-5.1
15.4 yr.
0.8
1.9
15.4 yr.
63
-2.96
15.3 yr.
No obstructive 
hypopnea 
15.2 yr.
170/170
15.8 yr.
165/165
15.8 yr.
y 264 m
   -7.8 
14.8 yr.
Normal
15.8 yr.
Craniocervical narrowing no spinal cord compression, ND 
15.4 yr.
Normal
9.9 yr.
4 36.4
0.34
14.6 yr.
0.79
-0.1
14.6 yr.
89
-1.3
15.1 yr.
No obstructive 
hypopnea 
13.7 yr.
175/175 
15.6 yr.
170/175 
15.6 yr.
y 512 m
   -2.5
15.2 yr.
Normal, hip flexors and 
abductors 4/4
15.6 yr.
Craniocervical narrowing no spinal cord compression/
lumbar, thoracic cord normal
14.4 yr.
Normal
11.2 yr.
 5 32.1
-0.96
14.6
1.2 *
2.5
14.6
110
1.17
15.1
Normal
13.4 yr.
175/170 
15.6 yr.
170/170 
15.6 yr.
y 466 m
   -3.1
 12.0 yr.
Normal, hip abductors 4/4,
15.1 yr.
Total spinal cord no narrowing
7.9 yr., 15.2 yr.
ND
6 33
-0.65
14.8
0.77
-0.3
14.8
132.6
2.7
14.8
Normal
12.6 yr.
185/185 
15.3 yr.
160/160 
15.3 yr.
y 482m
   -3.2
11.8 yr.
Normal, hip abductors 4/4
15.3 yr.
Craniocervical (cannel) narrowing no spinal cord 
compression, ND 
14.3 yr.
Normal
10.2 yr.
7 31.6
-1.1
14 yr.
0.87
0.75
14 yr.
98.8
-0.2
14
Normal
12.6 yr.
160/167 
12.9 yr.
170/171 
12.9 yr.
y 409 m
   -4.3
11.1 yr.
Normal, hip abductors 4/4
14.3 yr.
Craniocervical narrowing no spinal cord compression, ND 
12.6 yr.
ND
8 38.1
0.8
12.9 yr.
0.8
-0.2
12.9 yr.
104.9
0.7
13.1 yr.
No obstructive 
hypopnea 
12.9 yr.
170/175 
13.6 yr.
160/160 
13.6 yr.
y 505 m
   -2.7
 10.2 yr.
Normal, hip abductors 4/4
 13.6 yr.
Craniocervical narrowing no compression, ND 
13.1 yr.
Normal
9.7 yr.
9 37.3
0.54
10.5 yr.
0.48
-2
10.5 yr.
65
-4
10.5 yr.
Normal
10.4 yr.
170/170 
11.1 yr.
165/165 
11.1 yr.
y 380 m
   -3.5
7.6yr.
Normal, hip abductors 4/4
11.1. yr.
Craniocervical narrowing, spinal cord compression/Th11/ 
Th12, Th12/ L1 discus herniation no compression
9.7 yr.
Normal
9.5 yr., 9.8 yr.
10 37
0.41
8.1 yr.
0.48
-1.7
8.1 yr.
70
-2.56
8.6 yr.
Mild obstruction 
7.7 yr.
165/167 
9 yr.
160/165 
9 yr.
y 384 m
   -1.3
 5.9 yr.
Normal
9.6 yr.
Craniocervical narrowing, no spinal cord compression, 
thoracic/lumbar spinal cord no narrowing
 8.4 yr.
Normal
4.9 yr.
11 40.4
1.4
7.8 yr.
0.68
0.2
7.8 yr.
65
-4
8.2 yr.
Normal
7.1 yr.
170/170
 8.8 yr.
165/170 
8.8 yr.
y ND** Seems normal**
8.8 yr.
Craniocervical narrowing no spinal cord compression/ 
thoracic, lumbar no narrowing
8.5 yr.
Normal
8.9 yr.
12 36.6
0.13
4.6 yr.
0.49
-0.94
4.6 yr.
106
0.48
5.8 yr.
Normal 
4.7 yr.
170/175
 6.3 yr.
165/170
6.3 yr.
n 355 m
   -1.6
5.6 yr.
Normal
 6.6 yr.
Craniocervical narrowing with spinal cord compression/ 
thoracic, lumbar no narrowing
6.4 yr.
Normal
6.4 yr.
13 41.4
1.5
3.8 yr.
0.6
0.56
3.8 yr.
NA Normal
 3.2 yr.
165/170
 4.8 yr.
170/170 
4.8 yr.
y ND Normal
 4.8 yr.
Craniocervical narrowing, no spinal cord compression, 
ND
4.4 yr.
ND
14 37
0.08
2.3 yr.
0.46
-0.86
2.3 yr.
NA No obstructive 
hypopnea 
2.4 yr.
170/175
 4.2 yr.
175/170 
4.2 yr.
n 318 m
   -2.3
 3.2 yr.
Normal
 4.2 yr.
Craniocervical narrowing (also C3-C5) no spinal cord 
compression/thoracic, lumbar no narrowing
2.4 yr.
ND
SF shortening fraction; LVPWd left-ventricular posterior wall thickness in diastole in cm, *minor left ventricle 
hypertrophy, FVC forced vital capacity, neurological investigation included: clonus, Babinski and muscle tonus; SSEP 
somatosensory potentials yr year; ND not done, **This patient was unable to follow instructions.
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Table 2 Clinical assessments
Pt
nr
SF%
Z score
age
LVPWd 
cm 
Z score
age
FVC%
Z score
age
Polysomnography
age
Goniometry
Knee degrees
flexion
right/left
age
Goniometry
Hip degrees
flexion
right/left
age
Waddling
gait (y/n)
6MWT  
meters
Z score
age
Neurological 
Examination 
Muscle strength legs 
right/left (MRC)
age
MRI craniocervical junction 
MRI total spinal cord
age
SSEP
age
1 44.8
2.4
21.2 yr.
0.72
-2.1
21.2 yr.
82
-1.3
25 yr.
Mild signs of 
obstructive 
hyperpnea
24.6 yr.
162/160 
21 yr.
165/166
21 yr.
y  425 m
    -3.6
 24.6 yr.
Normal
23.9 yr.
Craniocervical C0-C3 narrowing no spinal cord 
compression, ND
25.3 yr.
Normal
 23.2 yr.
2 38
0.8
15.7
0.92 
0.74
15.7
94
-0.45
15.7
Normal 
14.5 yr.
165/165
16.2 yr.
160/155 
16.2 yr.
y 424 m
   -4.7
13.1 yr.
Normal 
16.2 yr.
Craniocervical narrowing no spinal cord compression, ND 
16 yr.
ND
3 21.5
-5.1
15.4 yr.
0.8
1.9
15.4 yr.
63
-2.96
15.3 yr.
No obstructive 
hypopnea 
15.2 yr.
170/170
15.8 yr.
165/165
15.8 yr.
y 264 m
   -7.8 
14.8 yr.
Normal
15.8 yr.
Craniocervical narrowing no spinal cord compression, ND 
15.4 yr.
Normal
9.9 yr.
4 36.4
0.34
14.6 yr.
0.79
-0.1
14.6 yr.
89
-1.3
15.1 yr.
No obstructive 
hypopnea 
13.7 yr.
175/175 
15.6 yr.
170/175 
15.6 yr.
y 512 m
   -2.5
15.2 yr.
Normal, hip flexors and 
abductors 4/4
15.6 yr.
Craniocervical narrowing no spinal cord compression/
lumbar, thoracic cord normal
14.4 yr.
Normal
11.2 yr.
 5 32.1
-0.96
14.6
1.2 *
2.5
14.6
110
1.17
15.1
Normal
13.4 yr.
175/170 
15.6 yr.
170/170 
15.6 yr.
y 466 m
   -3.1
 12.0 yr.
Normal, hip abductors 4/4,
15.1 yr.
Total spinal cord no narrowing
7.9 yr., 15.2 yr.
ND
6 33
-0.65
14.8
0.77
-0.3
14.8
132.6
2.7
14.8
Normal
12.6 yr.
185/185 
15.3 yr.
160/160 
15.3 yr.
y 482m
   -3.2
11.8 yr.
Normal, hip abductors 4/4
15.3 yr.
Craniocervical (cannel) narrowing no spinal cord 
compression, ND 
14.3 yr.
Normal
10.2 yr.
7 31.6
-1.1
14 yr.
0.87
0.75
14 yr.
98.8
-0.2
14
Normal
12.6 yr.
160/167 
12.9 yr.
170/171 
12.9 yr.
y 409 m
   -4.3
11.1 yr.
Normal, hip abductors 4/4
14.3 yr.
Craniocervical narrowing no spinal cord compression, ND 
12.6 yr.
ND
8 38.1
0.8
12.9 yr.
0.8
-0.2
12.9 yr.
104.9
0.7
13.1 yr.
No obstructive 
hypopnea 
12.9 yr.
170/175 
13.6 yr.
160/160 
13.6 yr.
y 505 m
   -2.7
 10.2 yr.
Normal, hip abductors 4/4
 13.6 yr.
Craniocervical narrowing no compression, ND 
13.1 yr.
Normal
9.7 yr.
9 37.3
0.54
10.5 yr.
0.48
-2
10.5 yr.
65
-4
10.5 yr.
Normal
10.4 yr.
170/170 
11.1 yr.
165/165 
11.1 yr.
y 380 m
   -3.5
7.6yr.
Normal, hip abductors 4/4
11.1. yr.
Craniocervical narrowing, spinal cord compression/Th11/ 
Th12, Th12/ L1 discus herniation no compression
9.7 yr.
Normal
9.5 yr., 9.8 yr.
10 37
0.41
8.1 yr.
0.48
-1.7
8.1 yr.
70
-2.56
8.6 yr.
Mild obstruction 
7.7 yr.
165/167 
9 yr.
160/165 
9 yr.
y 384 m
   -1.3
 5.9 yr.
Normal
9.6 yr.
Craniocervical narrowing, no spinal cord compression, 
thoracic/lumbar spinal cord no narrowing
 8.4 yr.
Normal
4.9 yr.
11 40.4
1.4
7.8 yr.
0.68
0.2
7.8 yr.
65
-4
8.2 yr.
Normal
7.1 yr.
170/170
 8.8 yr.
165/170 
8.8 yr.
y ND** Seems normal**
8.8 yr.
Craniocervical narrowing no spinal cord compression/ 
thoracic, lumbar no narrowing
8.5 yr.
Normal
8.9 yr.
12 36.6
0.13
4.6 yr.
0.49
-0.94
4.6 yr.
106
0.48
5.8 yr.
Normal 
4.7 yr.
170/175
 6.3 yr.
165/170
6.3 yr.
n 355 m
   -1.6
5.6 yr.
Normal
 6.6 yr.
Craniocervical narrowing with spinal cord compression/ 
thoracic, lumbar no narrowing
6.4 yr.
Normal
6.4 yr.
13 41.4
1.5
3.8 yr.
0.6
0.56
3.8 yr.
NA Normal
 3.2 yr.
165/170
 4.8 yr.
170/170 
4.8 yr.
y ND Normal
 4.8 yr.
Craniocervical narrowing, no spinal cord compression, 
ND
4.4 yr.
ND
14 37
0.08
2.3 yr.
0.46
-0.86
2.3 yr.
NA No obstructive 
hypopnea 
2.4 yr.
170/175
 4.2 yr.
175/170 
4.2 yr.
n 318 m
   -2.3
 3.2 yr.
Normal
 4.2 yr.
Craniocervical narrowing (also C3-C5) no spinal cord 
compression/thoracic, lumbar no narrowing
2.4 yr.
ND
SF shortening fraction; LVPWd left-ventricular posterior wall thickness in diastole in cm, *minor left ventricle 
hypertrophy, FVC forced vital capacity, neurological investigation included: clonus, Babinski and muscle tonus; SSEP 
somatosensory potentials yr year; ND not done, **This patient was unable to follow instructions.
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Clinical assessment  
In three patients (3, 9 and 10), cardiac or pulmonary dysfunction could potentially explain the 
reduced mobility. Patient 3 underwent mitral and aortic valve replacement at age 8 and 14.5 
years respectively (shortening fraction Z score -5 SD) and suffered from restrictive lung disease 
(FVC% -2.96 SD). Patients 9 and 10 had mild dilatation of the left ventricle with normal short-
ening fraction and restrictive lung disease (FVC% -4 and -2.6 SD). In three patients, a reliable 
measurement of pulmonary function was not possible because of either young age (patients 
13 and 14), or because of inability to follow instructions (patient 11). In the remaining patients, 
systolic function of the heart and FVC% were within the normal range. Polysomnography 
showed mild, obstructive hypopneas in only two patients (patients 1 and 10). 
The median distance covered in the 6MWT was 416.5 meters (range 264 to 512 m), median 
Z-score -3.15 (range -1.3 to -7.8). All patients had mild extension contractures of the knees 
and hips (table 2). Twelve of the fourteen patients had a waddling gate.
Appendix table 1 Hip disease, clinical symptoms and physical limitations
Pt nr Age at time questionnaire 
(years)
Pain in right hip 
(age onset)
Pain in left hip 
(age onset)
Abnormal gait 
(y/n)
Waddling Wheelchair Dependent 
(age onset)
Limited walking distance Cause limited walking 
distance
1 24.8 - -# y y No y, 15-20 min Pain left knee, muscle weakness 
left leg
2 15.7 - - y y No y, 15-20 min Exhausted, pain
3 15.3 - - y y Partial (always) y, 10-15 min Exhausted
4 15.0 - - y y Partial
(10 yr.)
y, 1 km Exhausted,
stiffness legs
5 14.9 + 
(7 yr.)
+
(7 yr.)
y y No y, 2-3 hrs Pain, upper leg or knees
6 14.7 ++
(13 yr.)
+
(13 yr.)
y y No No, very long distance Exhausted
7 14.0 - - y y Partial
(always)
y, 20-30 m Exhausted, pain knees
8 13.0 - - y y No No Exhausted
9 10.4 - - y y Partial
(always)
y, 50 m Exhausted
10 8.6 -## - y y No y, 15-30 min/500 m Exhausted
11 8.1 NA NA y y No y, 30 min Exhausted, stiffness hips
12 5.6 - - y n No No Exhausted
13 3.8 - - y y partial/buggy
(always)
y, 1 km Exhausted
14 3.3 - - n n Buggy No NA
# Operation valgus and endorotation osteotomy proximal femur left at age 21 yr, NA not applicable. ## pain in knees. 
+ mild, ++ moderate,+++ severe, y=yes, n=no, yrs= years, min=minutes, hrs= hours, m=meter, km=kilometer.
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Neurological examination showed a mild degree of muscle weakness of the hip abduc-
tors in 6 patients, further neurological examination was normal (table 2). The MRI of the 
craniocervical junction showed narrowing in almost all patients, but compression of the 
spinal cord in only one patient (patient 12). Neurological examination of this patient and 
the SEPP were normal (table 2). 
Appendix table A summarizes the clinical findings related to hip pathology evaluated 
by a questionnaire (median age at assessment 13.7, range 3.5 to 21.8 years). Four patients 
were partially wheelchair dependent. The two youngest patients used a buggy for longer 
distances, which might also be explained by their young age (3.5 and 4 years old). In 
ten patients, the maximum walking distance was limited by exhaustion. The other four 
patients were able to walk long distances. 
Appendix table 1 Hip disease, clinical symptoms and physical limitations
Pt nr Age at time questionnaire 
(years)
Pain in right hip 
(age onset)
Pain in left hip 
(age onset)
Abnormal gait 
(y/n)
Waddling Wheelchair Dependent 
(age onset)
Limited walking distance Cause limited walking 
distance
1 24.8 - -# y y No y, 15-20 min Pain left knee, muscle weakness 
left leg
2 15.7 - - y y No y, 15-20 min Exhausted, pain
3 15.3 - - y y Partial (always) y, 10-15 min Exhausted
4 15.0 - - y y Partial
(10 yr.)
y, 1 km Exhausted,
stiffness legs
5 14.9 + 
(7 yr.)
+
(7 yr.)
y y No y, 2-3 hrs Pain, upper leg or knees
6 14.7 ++
(13 yr.)
+
(13 yr.)
y y No No, very long distance Exhausted
7 14.0 - - y y Partial
(always)
y, 20-30 m Exhausted, pain knees
8 13.0 - - y y No No Exhausted
9 10.4 - - y y Partial
(always)
y, 50 m Exhausted
10 8.6 -## - y y No y, 15-30 min/500 m Exhausted
11 8.1 NA NA y y No y, 30 min Exhausted, stiffness hips
12 5.6 - - y n No No Exhausted
13 3.8 - - y y partial/buggy
(always)
y, 1 km Exhausted
14 3.3 - - n n Buggy No NA
# Operation valgus and endorotation osteotomy proximal femur left at age 21 yr, NA not applicable. ## pain in knees. 
+ mild, ++ moderate,+++ severe, y=yes, n=no, yrs= years, min=minutes, hrs= hours, m=meter, km=kilometer.
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DISCUSSION
Our study shows that all patients with MPS VI develop progressive and debilitating hip 
disease. In contrast to other disease features (e.g. cardiac and pulmonary involvement 
[20]), no patients were spared and the hip abnormalities had an impact on mobility in 
all patients. In this cohort study, we did not detect differences in hip disease severity 
between patients with rapidly or slowly progressive MPS VI disease type. Even in those 
patients that started ERT very early in life (patients 9-11 and 13, 14, start of treatment 
before the age of 3.5 years), hip development was grossly abnormal and not significantly 
different from those patients that started ERT later in life (patients 3 and 12, started ERT 
at age 6.8 and 5.1 respectively). 
Radiological abnormalities of the hip
The pelvic abnormalities already observed at very young age suggest that altered devel-
opment already takes place early in life. An abnormal shape of the pelvis with a steep, 
shallow and small acetabulum and a dysplastic os ilium were observed in the earliest 
radiographs taken (our study age 2 and 3 years (fig. 2), published patients age 11 months 
and 1.1 years) [20]. The early presence of hip abnormalities in MPS VI suggests that they 
originate from altered fetal hip development [31, 32]. During normal fetal development, 
the ilium shows a defined pattern of internal organization. Specific architectural patterns 
occur in those regions known to be necessary to deal with forces caused by bipedal loco-
motion later in life [33]. GAGs have an important regulatory function in the endochondral 
ossification of growth plates. Studies in MPS animal models have shown that GAG accu-
mulation during fetal life causes disorganization in different zones of the growth plates 
in long bones and the iliac crest [34]. This fetal developmental origin of the hip pathology 
in MPS VI could explain the limited effect of ERT, bone marrow, or hematopoietic stem 
cell transplantation on this disease characteristic [9-12].
The femoral head  in very young MPS type VI patients appears to be normal (fig. 2 and 3B 
[20]). Over time, the femoral head became abnormally shaped in all patients. The abnor-
mal pelvic shape probably induces different biomechanical forces on the femoral head 
once the patient starts walking, which is consistent with the finding that femoral head 
abnormalities occur from age three onwards. The fact that the growth plate of the femoral 
head itself is abnormally developed due to GAG accumulation could make the femoral 
head more vulnerable to these abnormal forces. This results in altered development of 
the femoral head and shape of the proximal femur. 
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It is important to note that the final shape of the femur head and neck differs largely 
between MPS VI patients (fig. 3). This is in contrast to MPS I Hurler, MPS II, III and IV in 
which the shape of the femoral head does not differ greatly between patients [10, 15, 19, 
35-41]. In our study, though small, there seems to be a relation between the genotype and 
the type of femoral head deformity that occurs over time. For example, in teenagers and 
young adult patients homozygous for the 454 C>T (p.R152W) mutation (n=3), we found a 
coxa magna, whereas in patients of the same age with the relatively mild 629A>G (p.Y210C) 
mutation on one allele (n=4), a very flat, irregular femoral head in valgus position was 
found. For other genotypes, specific femoral head deformities were also found (appen-
dix fig. B). To confirm this potential genotype-phenotype relationship, larger studies are 
needed. The differences could also be caused by other factors such as environmental (life 
style) factors or secondary genetic factors.
Clinical Burden and consideration for surgery
In this study we show that the clinical problem for the majority of MPS VI patients in 
the age range 2 to 17 years old is not hip pain. Walking distance in the majority of patients 
was primarily limited by exhaustion, likely caused by the high workload of walking with 
a waddling gait. This waddling gait is caused by the hip bone abnormalities and is not 
caused by primary knee problems or spinal stenosis (table 2 and appendix table A). 
Planning hip surgery in MPS VI patients, both in terms of timing and type of intervention, 
is challenging. One can opt for early surgery, using the development over time to predict 
the most likely outcome of the shape and angulation of the femoral head in an individual 
patient. Changing the shape of the acetabulum (redirection or reshaping osteotomy), can 
be performed to improve coverage of the femoral head. However, in contrast to other 
forms of hip dysplasia, the cartilage of the femoral head is also grossly abnormal in MPS 
patients. This may limit a favorable outcome of improvement from this type of surgery. 
The other option is to wait until the patient develops significant complaints and then 
perform either a femoral or periacetabular osteotomy, or total hip replacement. Additional 
imaging techniques, including 3D and statistical shape modelling of the developing hip, 
may aid outcome prediction and surgery planning in the future [42, 43]. 
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CONCLUSION
In all MPS VI patients, significant hip abnormalities develop very early in life starting with 
deformities of the os ilium and acetabulum. Femoral head abnormalities occur later, most 
likely due to altered mechanical forces in combination with epiphyseal abnormalities 
due to glycosaminoglycan storage. The final shape and angle of the femoral head differs 
significantly between individual MPS VI patients and is difficult to predict.
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CHAPTER 5
MUCOLIPIDOSIS
TYPE III, A SERIES OF
ADULT PATIENTS
ABSTRACT
Introduction: Mucolipidosis type III α/β or γ (ML III) are rare autosomal recessive 
diseases in which reduced activity of the enzyme UDP-N-acetyl glucosamine-1-phos-
photransferase (GLcNAc-PTase) leads to intra-lysosomal accumulation of different 
substrates. Publications on the natural history of ML III, especially the milder forms, 
are scarce. This study provides a detailed description of the disease characteristics 
and its natural course in adult patients with ML III.
Methods: In this retrospective chart study, the clinical, biochemical and molecular 
findings in adult patients with a confirmed diagnosis of ML III from three treatment 
centers were collected. 
Results: Thirteen patients with ML III were included in this study. Four patients (31%) 
were initially misdiagnosed with a type of MPS. Four patients (31%) had mild cognitive 
impairment. Six patients (46%) needed help with activities of daily living (ADL) or 
were wheelchair dependent. All patients had dysostosis multiplex and progressive 
secondary osteoarthritis, characterized by cartilage destruction and bone lesions in 
multiple joints. All patients underwent multiple orthopedic surgical interventions as 
early as the second or third decade of life, of which total hip replacement (THR) was 
the most common procedure (61% of patients). Carpal tunnel syndrome (CTS) was 
found in twelve patients (92%) and in eight patients (61%) CTS release was performed.
Conclusions: Severe skeletal abnormalities, resulting from abnormal bone develop-
ment and severe progressive osteoarthritis, are the hallmark of ML III, necessitating 
surgical orthopedic interventions early in life. Future therapies for this disease should 
focus on improving cartilage and bone quality, preventing skeletal complications and 
improving mobility.
Mucolipidosis type III, a series of adult patients   |   119
CH
A
PTER 5
INTRODUCTION
Mucolipidoses type II/III α/β or γ (ML II OMIM#252500, ML III α/β MIM# 252600, ML III 
γ OMIM#252605) are rare autosomal recessive diseases [1-6]. In these conditions, activity 
of the membrane bound hexameric enzyme UDP-N-acetyl glucosamine-1-phosphotrans-
ferase (GLcNAc-PTase), consisting of three subunits named α2, β2 and γ2, is absent or 
reduced [3, 7-10]. The GNPTAB gene (chromosome 12q23.3; OMIM#607840) encodes for the 
α/β subunits and GNPTG gene (chromosome 16; OMIM#607838) for the γ subunits. GLc-
NAc-PTase is responsible for the first step in the phosphorylation of enzyme-conjugated 
mannose residues to mannose-6-phosphate in the Golgi apparatus. Mannose-6-phosphate 
serves as the recognition marker, targeting newly synthesized lysosomal enzymes to the 
lysosome. In the reduced presence or absence of this marker, lysosomal enzymes are 
secreted in plasma, where they are unable to execute their function [9] which results in 
the accumulation of several substrates such as glycosaminoglycans and (glyco)sphingo-
lipids. 
ML presents as a clinical spectrum. In the most severe form, ML II (OMIM#252500, I-cell 
disease), GlcNac-PTase activity is completely deficient, leading to severe and rapidly pro-
gressive airway, cardiac, skeletal and nervous system disease, resulting in death in early 
childhood [1, 2, 5]. ML III α/β has a broader phenotypic range from severely affected 
patients that die in childhood, to milder affected patients displaying primarily skeletal 
symptoms, who survive into adulthood [2, 6, 11-15]. The patients with ML III γ that have 
been described so far all have milder phenotypes [3, 4, 16-18].
Clinical features that have been described in ML III are mild coarsening of the face, 
corneal clouding, mild retinopathy, cardiac valve abnormalities, restrictive pulmonary 
function, tracheal/ bronchomalacia, skeletal dysplasia, scoliosis, stiffness of the joints, 
short stature, claw hand deformity, carpal/tarsal tunnel syndrome and spinal cord com-
pression [2, 4, 12-14, 18-29]. Reports on intellectual performance and learning abilities vary 
from normal to mild cognitive impairment [2, 4, 10, 15, 26, 27, 30-34]. Publications on the nat-
ural history of adult ML III patients are rare. Some single case studies or small case series 
of ML III patients reaching adulthood have been published, but they lack a systematic 
description of disease onset, progression over time, severity of the disease characteristics 
and surgical interventions [2, 4, 12-15, 34].
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Currently, there are no curative treatments for ML II and III. From experience in other 
extremely rare disorders (e.g., the MPS’s) for which therapy became available, we recognize 
the importance of natural history data collection, especially in milder cases, since the 
focus in medical literature is often on the severe phenotypes. Once treatment becomes 
available, the latter may lead to an overestimation of treatment effect as the course of 
the treated patients that are mildly affected is compared to severely affected patients 
reported in the literature. Natural history studies help to identify future therapeutic goals, 
aid counseling and provide the basis for tailored, standardized follow up of these patients. 
The aim of this study is to provide a detailed description of the disease characteristics of 
ML III and its natural course, by studying data from adult patients.
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METHODS
Patients
In this retrospective medical record review, the clinical, biochemical and molecular 
findings from adult patients with a confirmed diagnosis of ML III from three specialist 
centers were collected (the Academic Medical Center (AMC), Amsterdam, the Nether-
lands; Erasmus MC, Rotterdam, the Netherlands and the National Hospital for Neurology 
and Neurosurgery, London, United Kingdom).
The diagnosis of ML III was established by measurement of plasma and/or fibroblast 
activity of several lysosomal enzymes including β-hexosaminidase A, β-hexosamini-
dase A+B, α-L-fucosidase, β-D-glucuronidase, α-D-mannosidase and β-D-galactosidase. 
In addition, in a subset of patients, GlcNAc-1-PTase activity in fibroblasts was measured, 
or DNA analysis of the GNPTAB or GNPTG gene was performed.
Data on demographic and general characteristics (age of initial/correct diagnosis and 
anthropometry), clinical symptoms, cognitive ability, highest education qualification, 
impairments in activities of daily living (ADL), wheelchair dependency, employment, 
imaging results (radiographs and MRI scans), number and types of orthopedic surgeries 
performed and echocardiography and pulmonary function tests, were collected from 
patient records. 
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RESULTS
Patient characteristics
Characteristics of the thirteen adult patients are outlined in table 1. The median age at 
last follow up was 30 years (range 18 to 68). Most patients were of Caucasian descent and 
both genders were equally represented. Patients 9, 11 and 10, 12 are siblings. Out of the 13 
patients, one was initially misdiagnosed as MPS II and three as MPS IV. In one patient 
who was diagnosed with MPS IV at the age of 30, the correct diagnosis was as established 
as late as age 64. 
Most patients developed clinical symptoms in the first decade of life. The diagnosis of 
ML was made in ten patients through the establishment of elevated levels of lysosomal 
enzymes in plasma, confirmed by a concomitant decreased lysosomal enzyme activity 
in fibroblast in four patients (in one patient, only enzyme measurements in fibroblasts 
were performed) and in one patient by a decreased activity of GlcNAc-1-PTase. In seven 
patients, DNA analysis was performed. Three patients had mutations in the GNPTAB gene 
and four patients in the GNPTG gene. The mutations and clinical features of patient 2 
were published 13 years ago by Raas-Rotschild et al [4]. The GNPTAB gene c.1178A>G; p.(His-
393Arg) mutation (patient 1), the GNPTG gene homozygous variants c.409+11_411+35del 
(patient 3) and c.318-1G>C (patients 6 and 7) and the GNPTG gene heterozygous mutation 
c.122_138del; p.(Pro41fs) with the c.331 T>C variant (patient 5) have not been published 
before.  
Clinical signs and functioning in daily life
Five patients had notably short statures (range 129-158 cm, median of 145 cm) (table 2), in 
patient 13 height could not be measured. Six patients needed help with activities of daily 
life (ADL) and/or were wheelchair dependent. All but one patient suffered from carpal 
tunnel syndrome (supplemental table 2).
Four patients had mild cognitive impairment (patients 4, 5, 10 and 13), while cognitive 
function was normal in the other nine patients (table 2). Ten patients were employed 
at any time during adult life. Pregnancies with healthy offspring were reported in two 
patients (patients 3  and 11).   
Skeletal pathology
The most prominent clinical signs were the skeletal abnormalities. All patients had abnor-
mally shaped bones (dysostosis multiplex) and progressive osteoarthritis, characterised 
by cartilage destruction in joints and areas of radiolucency in bones that may reflect 
erosive bone lesions (supplemental table 1). These abnormalities were found on X-rays 
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of the hand, feet, shoulders, elbows, hips, knees and spine [14, 20-22, 29, 35, 36]. In four 
patients, the carpal and/or tarsal bones were hypoplastic, with secondary osteoarthritic 
changes observed in the older patients (examples fig. 1A and supplemental table 1). In 
eleven patients, the same abnormalities were seen in the humeral/ femoral heads and 
femoral neck (examples fig. 1A and B). In all patients with available hip morphology data 
(n=9), hip dysplasia and altered pelvic shape were present (examples fig. 1B). Abnormali-
ties of the spine were present in all patients. The most common findings were atypically 
shaped vertebrae (hypoplasia), subluxation and scoliosis (examples fig. 1A). The majority 
of patients reported pain of the glenohumeral joints and/or the hands, feet, hips, knees 
and the lumbar spine. In six patients, signs of spinal cord or nerve root compression were 
present (supplemental table 1). 
Figure 1A shows exemplary radiographs of the skull, spine, shoulder, elbow, knee, hand, 
ankle and foot of three ML III patients (patients 4, 5 and 7) at the ages of 18, 28 and 65 
years. The findings in these radiographs are described in the legend of fig. 1A. X-rays of 
the pelvis of four ML III patients (patients 1, 5, 6 and 7) over time are shown separately 
in figure 1B. In all patients, there is severe hip dysplasia, with flaring of iliac wings as 
well as significant ossification disorders of the femoral heads, with arthritic changes of 
the hips. In the most severely affected patient (patient 1), near total destruction of the 
femoral heads occurred by age 11. In contrast, in patient number 5, the femoral heads 
are hardly affected  at the age of eight years old, but by the second decade of life, severe 
osteoarthritis of both hips had developed. 
The oldest patient (patient 7) was completely wheelchair dependent from the age of 
23 years onwards. In this patient, for unknown reasons, no surgical hip interventions 
have been performed. The femoral heads were abnormally shaped with severe secondary 
osteoarthritis. This is also seen on macroscopic and histopathological examination of 
the left hip, which was removed after her death at the age of 69 years (fig. 1B), when she 
succumbed to metastatic bladder cancer.
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Table 1 Patient characteristics
Patient Gender Initial 
Diagnosis
(years)
Age at 
correct 
diagnosis 
(years)
Age at last 
Follow up
(years)
Mutations
GNPTAB gene
Allele 1 Allele 2
Mutations 
GNPTG gene
Allele 1 Allele 2
Multiple lysosomal
enzyme activities
Plasma                     Fibroblasts
1 M MPS IV
8
11 23 NM_024312.4:c.1178A>G 
p.(His393Arg)
NM_024312.4:c.3503_3504del
p.(Leu1168fs)[1]
Elevated N.A.*
2 M 7 27 NM_024312.4:c.196C>T
p.(Gln66*)
NM_024312.4:c.366-1G>C
p.?[2] N.A. Reduced
3 F MPS II
4
7 48 NM_032520.4:c.409+11_411+35del
p.?
NM_032520.4:c.409+11_411+35del
p.?
Elevated Reduced
4 F 9 18 NM_024312.4:c.1090C>T 
p.(Arg364*)
NM_024312.4:c.2715+2T>G 
p.?
Elevated N.A.
5 M 8 30 NM_032520.4:c.122_138del 
p.(Pro41fs)
NM_032520.4:c.331T>C
p.(Trp111Arg)
Elevated N.A.
6 M MPS IV 46 48 NM_032520.4:c.318-1G>C
p.? 
NM_032520.4:c.318-1G>C
p.?
N.A. Reduced
7 F MSP IVB
30
64 68 NM_032520.4:c.318-1G>C
p.?
NM_032520.4:c.318-1G>C
p.?
Elevated N.A.
8 F 7 28 N.A. N.A. N.A. N.A. N.A. Reduced
9^ M 22 28 N.A. N.A. N.A. N.A. Elevated N.A.
10# M 8 39 N.A. N.A. N.A. N.A. Elevated N.A.
11^ F 17 32 N.A. N.A. N.A. N.A. Elevated N.A.
12# F Unknown 35 N.A. N.A. N.A. N.A. Elevated N.A.
13 F 3.5 27 N.A. N.A. N.A. N.A. Elevated Reduced
*: GLCNAC1PT enzyme deficient in fibroblasts, N.A.: not available, #^; siblings
1.Kudo M, Bao M, D’Souza A, Ying F, Pan H, Roe BA, et al. The alpha- and beta-subunits of the human UDP-N-
acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single 
cDNA. J Biol Chem 2005; 280:36141-36149.
2.Raas-Rothschild A, Bargal R, Goldman O, Ben-Asher E, Groener JE, Toutain A, et al. Genomic organisation of the 
UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. 
J Med Genet 2004; 41:e52.
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Table 1 Patient characteristics
Patient Gender Initial 
Diagnosis
(years)
Age at 
correct 
diagnosis 
(years)
Age at last 
Follow up
(years)
Mutations
GNPTAB gene
Allele 1 Allele 2
Mutations 
GNPTG gene
Allele 1 Allele 2
Multiple lysosomal
enzyme activities
Plasma                     Fibroblasts
1 M MPS IV
8
11 23 NM_024312.4:c.1178A>G 
p.(His393Arg)
NM_024312.4:c.3503_3504del
p.(Leu1168fs)[1]
Elevated N.A.*
2 M 7 27 NM_024312.4:c.196C>T
p.(Gln66*)
NM_024312.4:c.366-1G>C
p.?[2] N.A. Reduced
3 F MPS II
4
7 48 NM_032520.4:c.409+11_411+35del
p.?
NM_032520.4:c.409+11_411+35del
p.?
Elevated Reduced
4 F 9 18 NM_024312.4:c.1090C>T 
p.(Arg364*)
NM_024312.4:c.2715+2T>G 
p.?
Elevated N.A.
5 M 8 30 NM_032520.4:c.122_138del 
p.(Pro41fs)
NM_032520.4:c.331T>C
p.(Trp111Arg)
Elevated N.A.
6 M MPS IV 46 48 NM_032520.4:c.318-1G>C
p.? 
NM_032520.4:c.318-1G>C
p.?
N.A. Reduced
7 F MSP IVB
30
64 68 NM_032520.4:c.318-1G>C
p.?
NM_032520.4:c.318-1G>C
p.?
Elevated N.A.
8 F 7 28 N.A. N.A. N.A. N.A. N.A. Reduced
9^ M 22 28 N.A. N.A. N.A. N.A. Elevated N.A.
10# M 8 39 N.A. N.A. N.A. N.A. Elevated N.A.
11^ F 17 32 N.A. N.A. N.A. N.A. Elevated N.A.
12# F Unknown 35 N.A. N.A. N.A. N.A. Elevated N.A.
13 F 3.5 27 N.A. N.A. N.A. N.A. Elevated Reduced
*: GLCNAC1PT enzyme deficient in fibroblasts, N.A.: not available, #^; siblings
1.Kudo M, Bao M, D’Souza A, Ying F, Pan H, Roe BA, et al. The alpha- and beta-subunits of the human UDP-N-
acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single 
cDNA. J Biol Chem 2005; 280:36141-36149.
2.Raas-Rothschild A, Bargal R, Goldman O, Ben-Asher E, Groener JE, Toutain A, et al. Genomic organisation of the 
UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. 
J Med Genet 2004; 41:e52.
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Table 2 Anthropometry, cognitive involvement and functioning in daily life 
Patient Height (cm) BMI (kg/m2) at last follow-up Cognitive impairment (Y/N) Highest Education qualifications Impairment in ADL/ 
Wheelchair user  (Y/N)
In employment (Y/N)
1 129 (16) N. Secondary education N/Y* Y
2 171 (24) N. Academic education N/N Y
3 144 (28) N Secondary education N/N y
4 170 (24) Y, Mild, [IQ 65] Secondary education N/N Y
5 170 (22) Y, Mild. Special need education Y/N N#
6 176 (33) N Professional education Y/N^ Y
7 150 (52) N N.A. Y/Y (from age 23 yrs onwards) Y
8 145 (24) N University Y/Y Y
9 179 (23) N University N/N Y
10 169 (29) Y, Mild, [IQ 70] Secondary school N/N N
11 158 (21) N College N/N Y
12 160(20) N (OCD, depression) Secondary school N/N N
13 + Y, Mild College (assisted) Y/Y N
Y; yes, N; no, IQ: intelligence quotient, ADL: activities of daily living, *can walk 400 meters without a 
wheelchair
#: was previously employed, ^: rollator dependent, + height could not be measured (wheelchair depen-
dent for many years), weight 45 kg.
Supplemental table 1  Skeletal abnormalities
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
1 Severe hip dysplasia. Os 
ilium: neo-acetabulum 
formation and flaring 
wings
(19 yr.)
Dislocation/luxation femur 
to cranial in relation to the 
acetabulum. Absence of femoral 
heads. Shaft: osteopenia
(19 yr.)
Flattened vertebral bodies, hypoplastic dens, cervical 
pannus around dens-atlas area, thoracic, lumbar 
spondylosis
Cranio-cervical compression spinal cord
(20 yr.)
2 Acetabula steep, barely 
covering femoral heads
(24 yr.)
Epiphyseal dysplasia 
(6 yr.)
Femoral heads subluxation to 
cranial  L>R, subchondral areas of 
radiolucency 
(24 yr.)
Secondary osteoarthritis femoral 
heads after femoral osteotomy, L>R
(25 yr.)
Irregular aspect dorsal side patella, slight 
intra-articular effusion 
(24 yr.)
Upper ankle joints early signs of secondary 
osteoarthritis L/R
(27 yr.)
S shape scoliosis
L1 to L5: secondary osteoarthritis degenerative 
changes with multiple Schmorl nodules 
L2-L3, L3-L4, L4-L5: slight bulging disc 
(24 yr.)
3 Flaring os ileum and 
dysplasia
(42 yr.)
Secondary osteoarthritis L knee joint 
abnormal aspect of the bones, tibiofemoral 
joint space slightly narrowed medial, areas of 
radiolucency medial condyle and R tibia
(36 yr.)
Thoracolumbar severe convex left sided scoliosis, 
osteopenia, secondary osteoarthritis, degeneration 
L1-L2 
Flattened vertebral bodies, mainly cervical increased 
anteroposterior diameter 
Sclerosis SI-joint
(42 yr.)
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Table 2 Anthropometry, cognitive involvement and functioning in daily life 
Patient Height (cm) BMI (kg/m2) at last follow-up Cognitive impairment (Y/N) Highest Education qualifications Impairment in ADL/ 
Wheelchair user  (Y/N)
In employment (Y/N)
1 129 (16) N. Secondary education N/Y* Y
2 171 (24) N. Academic education N/N Y
3 144 (28) N Secondary education N/N y
4 170 (24) Y, Mild, [IQ 65] Secondary education N/N Y
5 170 (22) Y, Mild. Special need education Y/N N#
6 176 (33) N Professional education Y/N^ Y
7 150 (52) N N.A. Y/Y (from age 23 yrs onwards) Y
8 145 (24) N University Y/Y Y
9 179 (23) N University N/N Y
10 169 (29) Y, Mild, [IQ 70] Secondary school N/N N
11 158 (21) N College N/N Y
12 160(20) N (OCD, depression) Secondary school N/N N
13 + Y, Mild College (assisted) Y/Y N
Y; yes, N; no, IQ: intelligence quotient, ADL: activities of daily living, *can walk 400 meters without a 
wheelchair
#: was previously employed, ^: rollator dependent, + height could not be measured (wheelchair depen-
dent for many years), weight 45 kg.
Supplemental table 1  Skeletal abnormalities
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
1 Severe hip dysplasia. Os 
ilium: neo-acetabulum 
formation and flaring 
wings
(19 yr.)
Dislocation/luxation femur 
to cranial in relation to the 
acetabulum. Absence of femoral 
heads. Shaft: osteopenia
(19 yr.)
Flattened vertebral bodies, hypoplastic dens, cervical 
pannus around dens-atlas area, thoracic, lumbar 
spondylosis
Cranio-cervical compression spinal cord
(20 yr.)
2 Acetabula steep, barely 
covering femoral heads
(24 yr.)
Epiphyseal dysplasia 
(6 yr.)
Femoral heads subluxation to 
cranial  L>R, subchondral areas of 
radiolucency 
(24 yr.)
Secondary osteoarthritis femoral 
heads after femoral osteotomy, L>R
(25 yr.)
Irregular aspect dorsal side patella, slight 
intra-articular effusion 
(24 yr.)
Upper ankle joints early signs of secondary 
osteoarthritis L/R
(27 yr.)
S shape scoliosis
L1 to L5: secondary osteoarthritis degenerative 
changes with multiple Schmorl nodules 
L2-L3, L3-L4, L4-L5: slight bulging disc 
(24 yr.)
3 Flaring os ileum and 
dysplasia
(42 yr.)
Secondary osteoarthritis L knee joint 
abnormal aspect of the bones, tibiofemoral 
joint space slightly narrowed medial, areas of 
radiolucency medial condyle and R tibia
(36 yr.)
Thoracolumbar severe convex left sided scoliosis, 
osteopenia, secondary osteoarthritis, degeneration 
L1-L2 
Flattened vertebral bodies, mainly cervical increased 
anteroposterior diameter 
Sclerosis SI-joint
(42 yr.)
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Supplemental table 1  Continued
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
4 Mild horizontal 
acetabulum roof R
(18 yr.)
Mild coxa recta L/R
(18 yr.)
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Secondary osteoarthritic changes of the endplates of 
the corpus vertebrae 
(18 yr.)
5 Glenoid deformation L/R 
Madelung’s deformity 
L/R
(28 yr.)
Caput MCP: deformities, 
secondary osteoarthritis 
with collapse and areas of 
radiolucency
Os lunatum L/R: 
hypoplasia proximal pool. 
Os scaphoid L/R: absence 
proximal pool
(30 yr.)
Hip dysplasia L/R
(28 yr.)
Secondary osteoarthritis femoral 
heads L/R 
(28 yr.)
Multiple abnormalities feet R>L (dysostosis 
multiplex)
(17 yr.)
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Secondary osteoarthritis endplates of the corpus 
vertebrae 
(28 yr.)
6 Glenoids hypoplasia and 
secondary osteoarthritis
(38 yr.)
Severe secondary 
osteoarthritis of the wrist 
bones and MCPJ L/R: 
(44 yr.)
Flaring iliac wings, 
acetabulum 
(45 yr.)
Secondary osteoarthritis femoral 
heads L/R
(25 yr.)
Osteopenia, secondary osteoarthritis 
tibiofemoral and patella with femoral joint 
space narrowing
Secondary osteoarthritis knees 
(50 yr.)
Abnormal talus, tibia and caput MT-I 
(sclerosis)
Flat caput metatarsalia with secondary 
osteoarthritis (44 yr.)
Hypoplasia of dens and vertebral bodies C3 to C7
C4-C5 and C5-C6: bilateral narrowing 
intervertebral foramina
Spinal cord compression C3 -C5
Radicular syndrome C6 L
(50 yr.)
7 Severe secondary 
osteoarthritis humeral 
heads (subcortical areas 
of radiolucency, sclerosis) 
(65 yr.)
Distal part ulna, os 
scaphoid, os lunatum, 
MCPJ-III and IPJ: 
deformities, destruction, 
osteoarthritis 
(60 yr.)
Hip dysplasia
(60 yr.)
Dysplasia, flattening and cranial 
subluxations. Severe secondary 
osteoarthritis (subchondral 
sclerosis and areas of radiolucency) 
femoral heads with joint space 
narrowing
Coxa valga L/R
(60 yr.)
Flattening and lateralization 
femoral heads Distal femur shaft 
fracture
(65 yr.)
Knee joint; severe secondary osteoarthritis 
(narrowing of the medial compartment, 
deformation of the tibia plateau with lateral 
hook formation/bone formation) 
Secondary osteoarthritis (hook formation at 
the lateral femur condyles) with deformed 
aspect femur condyles L/R 
(65 yr.)
Altered vertebral shape, flattened (most prominent 
TH9/TH10). L3 and L4: anterior displacement
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Severe secondary osteoarthritis endplates of the 
corpus vertebrae 
L3-L4 and L4-L5: decreased diameter of the spinal 
cannel
(66 yr.)
8 Secondary osteoarthritis 
glenohumeral joint
PIPJ dig II R: secondary 
osteoarthritis
(30 yr.) 
Hip dysplasia Avascular necrosis ankles
(10 yr.)
Secondary osteoarthritis with degenerative 
changes ankles, some collapse talus. Bilateral 
valgus knee deformities
(25 yr.)
Hammer toe R
(30 yr.)
Ankle secondary osteoarthritis R, 
predominant anterior wear and slight 
anterior subluxation
(34 yr.)
Atlantoaxial subluxation os odontoid
Loss of cervical lordosis 
C2, C3: grade 2 Anterolisthesis
C4-C5 and C5-C6: Grade 1 retrolisthesis 
Multiple osteophyte bars 
C4 to C7: several multilevel bilateral neural foraminal 
narrowing with indention of the cervical cord
L5: spinal cord compression resulting in weakness of 
the right side
(30 yr.)
T10/T11: severe stenosis resulting in clonus on leg L/R
(34 yr.)
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Supplemental table 1  Continued
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
4 Mild horizontal 
acetabulum roof R
(18 yr.)
Mild coxa recta L/R
(18 yr.)
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Secondary osteoarthritic changes of the endplates of 
the corpus vertebrae 
(18 yr.)
5 Glenoid deformation L/R 
Madelung’s deformity 
L/R
(28 yr.)
Caput MCP: deformities, 
secondary osteoarthritis 
with collapse and areas of 
radiolucency
Os lunatum L/R: 
hypoplasia proximal pool. 
Os scaphoid L/R: absence 
proximal pool
(30 yr.)
Hip dysplasia L/R
(28 yr.)
Secondary osteoarthritis femoral 
heads L/R 
(28 yr.)
Multiple abnormalities feet R>L (dysostosis 
multiplex)
(17 yr.)
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Secondary osteoarthritis endplates of the corpus 
vertebrae 
(28 yr.)
6 Glenoids hypoplasia and 
secondary osteoarthritis
(38 yr.)
Severe secondary 
osteoarthritis of the wrist 
bones and MCPJ L/R: 
(44 yr.)
Flaring iliac wings, 
acetabulum 
(45 yr.)
Secondary osteoarthritis femoral 
heads L/R
(25 yr.)
Osteopenia, secondary osteoarthritis 
tibiofemoral and patella with femoral joint 
space narrowing
Secondary osteoarthritis knees 
(50 yr.)
Abnormal talus, tibia and caput MT-I 
(sclerosis)
Flat caput metatarsalia with secondary 
osteoarthritis (44 yr.)
Hypoplasia of dens and vertebral bodies C3 to C7
C4-C5 and C5-C6: bilateral narrowing 
intervertebral foramina
Spinal cord compression C3 -C5
Radicular syndrome C6 L
(50 yr.)
7 Severe secondary 
osteoarthritis humeral 
heads (subcortical areas 
of radiolucency, sclerosis) 
(65 yr.)
Distal part ulna, os 
scaphoid, os lunatum, 
MCPJ-III and IPJ: 
deformities, destruction, 
osteoarthritis 
(60 yr.)
Hip dysplasia
(60 yr.)
Dysplasia, flattening and cranial 
subluxations. Severe secondary 
osteoarthritis (subchondral 
sclerosis and areas of radiolucency) 
femoral heads with joint space 
narrowing
Coxa valga L/R
(60 yr.)
Flattening and lateralization 
femoral heads Distal femur shaft 
fracture
(65 yr.)
Knee joint; severe secondary osteoarthritis 
(narrowing of the medial compartment, 
deformation of the tibia plateau with lateral 
hook formation/bone formation) 
Secondary osteoarthritis (hook formation at 
the lateral femur condyles) with deformed 
aspect femur condyles L/R 
(65 yr.)
Altered vertebral shape, flattened (most prominent 
TH9/TH10). L3 and L4: anterior displacement
Mild convex right sided scoliosis, with increased 
kyphosis and increased interpedicular distance 
Severe secondary osteoarthritis endplates of the 
corpus vertebrae 
L3-L4 and L4-L5: decreased diameter of the spinal 
cannel
(66 yr.)
8 Secondary osteoarthritis 
glenohumeral joint
PIPJ dig II R: secondary 
osteoarthritis
(30 yr.) 
Hip dysplasia Avascular necrosis ankles
(10 yr.)
Secondary osteoarthritis with degenerative 
changes ankles, some collapse talus. Bilateral 
valgus knee deformities
(25 yr.)
Hammer toe R
(30 yr.)
Ankle secondary osteoarthritis R, 
predominant anterior wear and slight 
anterior subluxation
(34 yr.)
Atlantoaxial subluxation os odontoid
Loss of cervical lordosis 
C2, C3: grade 2 Anterolisthesis
C4-C5 and C5-C6: Grade 1 retrolisthesis 
Multiple osteophyte bars 
C4 to C7: several multilevel bilateral neural foraminal 
narrowing with indention of the cervical cord
L5: spinal cord compression resulting in weakness of 
the right side
(30 yr.)
T10/T11: severe stenosis resulting in clonus on leg L/R
(34 yr.)
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Supplemental table 1  Continued
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
9 Unknown Cervical spine loss of normal lordosis and secondary 
osteoarthritis; degenerative change of the 
intervertebral discs, cervical, thoracic, lumbar regions 
Some narrowing of the neural exit foramina at C2-3, 
C3-4 bilaterally
At the cranial cervical junction there is a Chiari 
I malformation with the right cerebellar tonsil 
extending inferiorly to the lower edge of the C1 arch
(23 yr.)
10 Unknown Secondary osteoarthritis femoral 
head L 
(35 yr.)
Secondary osteoarthritis whole spinal cord. 
Decreased diameter of the spinal cannel at multiple 
levels
(30 yr.)
Severe marked cervical spondylosis, multiple disc 
bulges 
Some nerve root compression
(34 yr.)
11 IPJ: fixed flexion and 
deformities, secondary 
osteoarthritis
Loose fragments in the articular surfaces 
of patellae (associated with fissuring and 
chondral flaps) L/R
(32 yr.)
Mild convex right site lumbar scoliosis 
C2-C3: grade 1 anterolisthesis
(30 yr.)
C6-7 (and to a lesser degree C7-T1): secondary 
osteoarthritis (degenerative bone and disc changes) 
C5-6: modest degree of foraminal compromise
(32 yr.)
12 Hip joint L/R: Loss 
of height, secondary 
osteoarthritis 
(subchondral sclerosis, 
changes acetabular 
margins)
(24 yr.)
Sclerosis, osteophytes, progressive 
secondary osteoarthritis femoral 
heads L/R
(24 yr.)
Extensive secondary osteoarthritis 
femoral heads L/R 
(26 yr.)
Hallux valgus with deformed hammer toes L
(29 yr.)
Intractable right sided L5 radiculopathy and is stuck 
in forward flexion
Cervical, thoracic and lumbar spine: multilevel 
secondary osteoarthritis (degenerative disc changes)
(30 yr.)
13 Hypoplastic poorly 
formed glenoid fossae
Varus positioning of both 
humeral heads
(22 yr.)
Very shallow acetabula
Incomplete fusion of 
right pubic ramus 
Widening and erosion 
of joints and growth 
plates
(18 yr.)
Flat and deformed femoral heads
(18 yr.)
Loss of vertebral body height ad end-plate changes 
throughout
Severe narrowing of and compression of spinal cord 
at cranio-cervical junction (pre-laminoplasty)
(19 yr.)
MCP: metacarpal, L: left, R: Right, yr.=years, SI-joint: sacroiliac joint, MCPJ: metacarpal joint, IPJ: 
Interphalangeal joint, PIPJ: proximal interphalangeal joint, Dig: digitus, THR: total hip replacement, 
MT: metatarsals. 
For each finding, the age at which this was written down in the medical chart is depicted, this does 
not necesserily correspond with the age of onset of the symptom or sign. If no age is given, the 
symptom or sign was noted in the chart undated.
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Supplemental table 1  Continued
Patient Shoulders and Hands Pelvis Femur Knees and feet Spine, spinal cord compression
9 Unknown Cervical spine loss of normal lordosis and secondary 
osteoarthritis; degenerative change of the 
intervertebral discs, cervical, thoracic, lumbar regions 
Some narrowing of the neural exit foramina at C2-3, 
C3-4 bilaterally
At the cranial cervical junction there is a Chiari 
I malformation with the right cerebellar tonsil 
extending inferiorly to the lower edge of the C1 arch
(23 yr.)
10 Unknown Secondary osteoarthritis femoral 
head L 
(35 yr.)
Secondary osteoarthritis whole spinal cord. 
Decreased diameter of the spinal cannel at multiple 
levels
(30 yr.)
Severe marked cervical spondylosis, multiple disc 
bulges 
Some nerve root compression
(34 yr.)
11 IPJ: fixed flexion and 
deformities, secondary 
osteoarthritis
Loose fragments in the articular surfaces 
of patellae (associated with fissuring and 
chondral flaps) L/R
(32 yr.)
Mild convex right site lumbar scoliosis 
C2-C3: grade 1 anterolisthesis
(30 yr.)
C6-7 (and to a lesser degree C7-T1): secondary 
osteoarthritis (degenerative bone and disc changes) 
C5-6: modest degree of foraminal compromise
(32 yr.)
12 Hip joint L/R: Loss 
of height, secondary 
osteoarthritis 
(subchondral sclerosis, 
changes acetabular 
margins)
(24 yr.)
Sclerosis, osteophytes, progressive 
secondary osteoarthritis femoral 
heads L/R
(24 yr.)
Extensive secondary osteoarthritis 
femoral heads L/R 
(26 yr.)
Hallux valgus with deformed hammer toes L
(29 yr.)
Intractable right sided L5 radiculopathy and is stuck 
in forward flexion
Cervical, thoracic and lumbar spine: multilevel 
secondary osteoarthritis (degenerative disc changes)
(30 yr.)
13 Hypoplastic poorly 
formed glenoid fossae
Varus positioning of both 
humeral heads
(22 yr.)
Very shallow acetabula
Incomplete fusion of 
right pubic ramus 
Widening and erosion 
of joints and growth 
plates
(18 yr.)
Flat and deformed femoral heads
(18 yr.)
Loss of vertebral body height ad end-plate changes 
throughout
Severe narrowing of and compression of spinal cord 
at cranio-cervical junction (pre-laminoplasty)
(19 yr.)
MCP: metacarpal, L: left, R: Right, yr.=years, SI-joint: sacroiliac joint, MCPJ: metacarpal joint, IPJ: 
Interphalangeal joint, PIPJ: proximal interphalangeal joint, Dig: digitus, THR: total hip replacement, 
MT: metatarsals. 
For each finding, the age at which this was written down in the medical chart is depicted, this does 
not necesserily correspond with the age of onset of the symptom or sign. If no age is given, the 
symptom or sign was noted in the chart undated.
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Figure 1A Skeletal radiographs
Fig.1A. Examples of three ML III patients, aged 18, 28 and 65 years (patients 4, 5 and 7). Skeletal radio-
graphs of the skull (anterior posterior and lateral), spine (thoracic/lumbar vertebrae AP and lateral), left 
shoulder (AP), left elbow (lateral), left knee (AP), left hand (AP) and left ankle/foot (AP and or lateral). 
In general, the developmental bone abnormalities were present in all patients, but presence and severity 
of osteoarthritic changes were more prominent in the older patients.
Skull: In all patients thickened cortical bones and a prominent sella turcica were observed. Open skull 
sutures in patients 4 and 5. Dens aspect of the skull vault in patient 7.
Spine: Mild convex right sided scoliosis, with increased kyphosis and increased interpedicular distances 
in all three patients. Flattened corpora vertebrae on several levels (cervical, thoracic and lumbar) in 
all three patients. Osteoarthritic changes of the endplates of the corpus vertebrae, most prominent in 
the oldest patient (patient 7). In patient 7 there is anterior displacement of vertebrae L3 and L4 with a 
decreased diameter of the spinal cannel.  
Shoulder and elbows: In patient 4, no abnormalities of these joints were observed. Osteoarthritic 
changes in the humeral head, glenoid and elbow deformation were seen in patients 5 and 7.  
Knee: No lateral left knee radiograph was available for patient 4. In patient 5 there is a patella baja 
and signs of osteochondral abnormalities of the patella with osteophyte formation. In patient 7 (X ray 
performed at age 60 years) osteoarthritic changes were observed with lateral hook formation/bone 
formation of the tibia plateau and at the lateral femur condyle.
Hand: Abnormal shaped phalanges in all three patients (subtle in patient number 4). Osteoarthritic 
changes of the phalangeal joints (proximal and distal) in patients 5 and 7. Abnormal shaped metacarpal 
bones (hypoplasia and collapse) with secondary osteoarthritis (patients 5 and 7).
Feet/ankle: In patient 4, no abnormalities of the joints were observed. In patient 5, there is osteoarthritis 
of the distal fibula. Suggestion for bifida talus or talus bipartite. Severe osteoarthritis of the ankle is 
seen in patient 7.
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Figure 1B Radiographs, macroscopy and histopathology of the hip bones
Fig. 1B. X-rays of the hips of patients 1, 5, 6 and 7 over different ages. Macro- and microscopic photo-
graphs of the left hip of patient 7 are shown. This patient died at the age of 69 from metastatic bladder 
cancer.
Most prominent findings on radiographs:
Pelvis: in all patients, pelvic bones are abnormally shaped with flared iliac wings with hypoplasia of the 
inferior part of the ilea. The acetabula are severely dysplastic, very steep and shallow. Neoacetabula for-
mation occurred in patients 5, 6 and 7. Impingement of the coxofemoral spaces was also seen in patient 7.
Femoral heads, neck shaft angle: Severe ossification disorders and severe secondary osteoarthritis of 
the femoral heads (with subchondral cysts, sclerosis and flattening in patients 5, 6 and 7) were present in 
all patients. In patient 1, at age 11, there was near total absence of the femoral heads. Femoral shaft angle 
abnormalities: in patient 1, the shaft angle over time develops from coxa valga to coxa vara. In patient 5 
there is a coxa valga and in patient 7, coxa vara. On autopsy in patient 7, part of the left femur, femoral 
head and part of the acetabulum were removed (as shown on the macroscopic photo). The femoral 
head (shown from above): severe osteoarthritis is present, with complete destruction of the cartilage. 
An arrow on the top of the femoral head shows yellow collared bone tissue and not the normal, glossy 
blue-white in appearance, cartilage. Total destruction of cartilage is also illustrated by the histological 
slides of the upper part of the femoral head, coloured with HE, magnification X25 and X100. A square 
on the X25 magnification indicates the place of the X100 magnification. No cartilage is left at the place 
of the asterix on the 100X magnification.
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Orthopedic surgical interventions and medical treatment
For all patients, the type of orthopedic surgeries and the age at which these surgeries were 
performed, are depicted in fig. 2. Details of the specific surgical procedures can be found 
in supplemental table 2. The most frequent intervention was hip surgery, performed in 
eight patients, with the first interventions in the second or third decade of life. In all of 
these patients, total hip replacement (THR) was eventually required. 
Eight patients underwent bilateral CTS release, mostly in the second decade of life. In 
one patient, this intervention was performed more than once. Less frequently, surgi-
cal interventions of the knees, feet and spinal cord were performed. Several patients 
were treated with repeated corticosteroid injections in the glenohumeral or knee joint 
to reduce pain. Two patients were treated with bisphosphonates at their last outpatient 
visit (patients 8 and 10). 
Cardiac and pulmonary examinations 
Echocardiography was performed in 12 patients (supplemental table 3). In patient 4, there 
were limited signs of cardiac hypertrophy, with thickening of the posterior left ventricular 
wall. Systolic ventricular function was normal in all patients. A mildly dilated right ven-
tricle with normal systolic function was seen in patient 10. Five patients (patients 1, 4, 5, 10 
and 13) had mild regurgitation of one or more valves (mitral, aortic, pulmonary, or tricus-
pid) and one patient had moderate stenosis and regurgitation of the aortic valve (patient 
5). None of the patients required valve replacement at the time of their last follow up. 
Pulmonary function tests were performed in 6 patients (supplemental table 3) and two 
patients had mild to moderate restrictive lung disease (patients 1 and 4).  
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Figure 2 Orthopedic surgical interventions
Fig.2. All orthopedic surgical interventions of thirteen ML III patients and the age at which they were 
performed, are shown. In some patients, the same surgical intervention was performed more than once. 
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Supplemental table 2 Orthopedic surgeries
Patient CTS
Age (years)
Pelvis, Femur
Age (years)
Hands, knees and feet
Age (Years)
Spine, spinal cord
Age (Years)
1 20& 21 Custom-made THR L, THR R with distal tenotomy 
hamstring R
2 16 CTS release L/R 15
24& 25
Femoral varus osteotomy and endorotating osteotomy 
proximal femur L/R
THR (sequential) L/R
3 # 24  THR (sequential)  L/R 34 Total knee prosthesis R
4 12&13 CTS release R/L
5 18 CTS release L/R
22& 24
30
Femoral  varus osteotomy (sequential) L/R
THR (sequential)  R/L
17 Bunioectomy metatarsalia, 
PIP resection dig. V L/R feet
6 15
25
31
35
37
45
45
46& 47
47
47
Femoral varus osteotomy R
Arthrodesis L hip
THR L (Charnley)
Removal of bridge plate R
THR trochanter osteotomy R
Osteosynthesis femur R (femur fracture R)
Bridge plate failure, reposition, fixation fracture distal femur 
R with plate osteosynthesis
Re-osteosynthesis femur R, allograft bone grafting
Drainage abscess (R femur)
Removing osteosynthesis material, resection pseudarthrosis 
part R femur, placement angle blade plate R femur condyle
41 Arthrodesis upper ankle joint
7 65&66 CTS release  L/R
8 9-14 Multiple CTS 
releases
20 THR (sequential) L/R
26
27
31
Arthroscopic debridement ankle R
Arthroscopy knee L
Total knee replacement L
18
19
27
29
29
33
36
C1/C2 fusion secondary to cervical fracture
Trans articular screws os odontoid
L4/L5 and sacral fusion
L4-S2 anterior fusion
C4/5, C5/6, C6/7 bilateral foraminoplasties
T10-11 post. decompressive laminectomy, 
extension of the posterior fixation to T10
Occipito-cervico-thoracic spine fusion
9 24 CTS release L/R
10 # 27& 30 Uncemented THR (sequential) R/ L
11 9&10 CTS release L/R 11
27
Surgery for trigger fingers, tendon release 
bilaterally (ring finger)
Knee arthroscopy and washout L/R
12 # 27 Uncemented Ceramic THR (sequential) L/R
13 5 Bilateral CTS release 26 Excision arthroplasty of R hip 22 C3-T1 laminoplasty
CTS; carpal tunnel syndrome, # CTS present bilateral, no surgical intervention, THR; total hip replacement, L: left, R: 
right;  PIP; proximal interphalangeal, dig; digits
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Supplemental table 2 Orthopedic surgeries
Patient CTS
Age (years)
Pelvis, Femur
Age (years)
Hands, knees and feet
Age (Years)
Spine, spinal cord
Age (Years)
1 20& 21 Custom-made THR L, THR R with distal tenotomy 
hamstring R
2 16 CTS release L/R 15
24& 25
Femoral varus osteotomy and endorotating osteotomy 
proximal femur L/R
THR (sequential) L/R
3 # 24  THR (sequential)  L/R 34 Total knee prosthesis R
4 12&13 CTS release R/L
5 18 CTS release L/R
22& 24
30
Femoral  varus osteotomy (sequential) L/R
THR (sequential)  R/L
17 Bunioectomy metatarsalia, 
PIP resection dig. V L/R feet
6 15
25
31
35
37
45
45
46& 47
47
47
Femoral varus osteotomy R
Arthrodesis L hip
THR L (Charnley)
Removal of bridge plate R
THR trochanter osteotomy R
Osteosynthesis femur R (femur fracture R)
Bridge plate failure, reposition, fixation fracture distal femur 
R with plate osteosynthesis
Re-osteosynthesis femur R, allograft bone grafting
Drainage abscess (R femur)
Removing osteosynthesis material, resection pseudarthrosis 
part R femur, placement angle blade plate R femur condyle
41 Arthrodesis upper ankle joint
7 65&66 CTS release  L/R
8 9-14 Multiple CTS 
releases
20 THR (sequential) L/R
26
27
31
Arthroscopic debridement ankle R
Arthroscopy knee L
Total knee replacement L
18
19
27
29
29
33
36
C1/C2 fusion secondary to cervical fracture
Trans articular screws os odontoid
L4/L5 and sacral fusion
L4-S2 anterior fusion
C4/5, C5/6, C6/7 bilateral foraminoplasties
T10-11 post. decompressive laminectomy, 
extension of the posterior fixation to T10
Occipito-cervico-thoracic spine fusion
9 24 CTS release L/R
10 # 27& 30 Uncemented THR (sequential) R/ L
11 9&10 CTS release L/R 11
27
Surgery for trigger fingers, tendon release 
bilaterally (ring finger)
Knee arthroscopy and washout L/R
12 # 27 Uncemented Ceramic THR (sequential) L/R
13 5 Bilateral CTS release 26 Excision arthroplasty of R hip 22 C3-T1 laminoplasty
CTS; carpal tunnel syndrome, # CTS present bilateral, no surgical intervention, THR; total hip replacement, L: left, R: 
right;  PIP; proximal interphalangeal, dig; digits
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Supplemental table 3 Cardiac and pulmonary evaluations
A. Cardiac evaluation
Patient Age cardiac 
evaluation 
(years)
LVH LV function Other 
abnormalities
1 20 No Normal Mild AR and MR
2 21 No Normal No
3 43 No Normal Myxomatous 
mitral valve with 
redundant tissue, 
minor billowing, 
no insufficiency
4 16 No Normal Mild MR. 
Posterior left 
ventricular wall 
slightly thickened
5 29 No Normal Bicuspid aortic 
valve, mild AS, 
moderate AR, 
mild MR and TR
6 N.A. N.A. N.A. N.A.
7 65 No Normal No
8 32 No Normal No
9 28 No Normal No
10 35 No Normal Mild/ moderate 
TR. Mildly dilated 
RV with normal 
systolic function
11 30 No Normal No
12 35 No Normal No
13 26 No Normal Moderate/ severe 
AR, mild MR, PR 
and TR
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Supplemental table 3 Continued
B. Pulmonary evaluation
Patient Age at 
spirometry 
(years)
FVC 
(% predicted)
FEV1 
(% predicted)
FEV1/VC 
(% predicted)
Comments
1 23 60 52 96 Moderate 
restrictive 
spirometry 
without 
obstructive 
characteristics
3 46 116 121 105 No restriction, 
no obstruction
4 17 74 78 78 Mild 
Restriction
5 30 101 85 85
7 66 89 88 72 No airway 
restriction or 
obstruction, 
normal flow-
volume curve
13 24 36 37 105
N.A.: not available, LVH: left ventricle hypertrophy; LV: left ventricle; RV: right ventricle; N.A.: 
not available, AR: aortic regurgitation, MR: mitral regurgitation, AS: aortic stenosis, TR: tricuspid 
regurgitation, PR: pulmonary regurgitation, FVC: forced vital capacity; FEV1: Forced expiratory 
volume in 1 second; VC: vital capacity
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DISCUSSION 
This multi-center retrospective medical record review describes the clinical course of 
adult forms of ML III.  About half of the patients experienced significant physical lim-
itations, being either wheelchair dependent and/or needing help with activities of daily 
living. Pain was reported by all patients.  Approximately one third of the patient group 
had mild cognitive impairment. Three fourths of the patient group had been employed 
at any time during adulthood.  
All patients have extensive skeletal pathology, requiring orthopedic surgical interven-
tions as early as the second or third decade of life. Total hip replacement (THR) was the 
most common intervention, performed in 67% of all patients. In three patients, this was 
preceded by femoral varus osteotomy, but despite this position correction, these patients 
still needed THR some ten years later (fig. 1B, supplemental table 2). 
As is seen in the different forms of MPS, abnormal bone development (dysostosis multi-
plex) [6] is uniformly present in ML III patients. Clinically, the earliest disabling feature is 
hip disease, characterized by pain and limited mobility. Abnormal hip morphology (ace-
tabula, iliac bones and femoral heads) have been observed in very young ML III patients 
(at birth, at age four and six years [2, 14, 20]), suggesting early developmental alterations 
such as seen in MPS VI for example [37].  
In addition to the dysostosis multiplex, the joints in ML III patients are affected through-
out their lifespan by rapidly progressive osteoarthritis, resulting in cartilage destruction 
and bone lesions (areas of radiolucency and sclerosis). Clinically all patients suffer from 
bone and joint pain.
Bone disease in ML III may arise from an imbalance between bone forming osteoblasts 
and bone resorbing osteoclasts caused by the increased presence of osteoclastic enzymes 
in the bone-resorbing zone in osteoclasts [38]. Mannose-6-phosphate is important for 
the trafficking of these enzymes along the exocytic pathway to the apical membrane, 
where they are secreted in the bone-resorbing compartment [39]. The absence of man-
nose-6-phosphate on the osteoclastic enzymes may lead to increased secretion of these 
enzymes, resulting in uncontrolled bone and cartilage degradation [22, 40]. However, this 
hypothesis still needs to be substantiated by pathophysiological studies. 
CTS was highly prevalent in our ML III patient population (present in 11 out of 13 patients) 
and bilateral CTS release was performed in eight patients. Cardiac valve abnormalities 
were found in six patients although there were no signs of cardiac dysfunction. Six 
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patients underwent formal pulmonary function assessment and two patients had mod-
erate to mild restriction, most likely due to thoracic skeletal abnormalities. No remarks 
concerning airway infections or pulmonary complaints were present in the medical 
records. This distinguishes this condition from the different forms of MPS (e.g. type I, 
II, IV and VI) in which cardiac and pulmonary problems are more frequent, often with 
severe clinical implications, also seen in the milder adult forms of these disorders [41-43]. 
Future therapies
Future therapies for ML III should aim to improve bone metabolism in order to reduce 
bone pain, delay the need for surgical intervention and improve mobility. Bisphospho-
nates are given in ML III patients to decrease osteoclastic activity, with variable outcomes 
[22, 26, 27, 44]. Since long term use of these drugs suppresses bone turnover and may have 
a negative effect on length growth, they may be of limited use in ML III. A newer anti-
bone resorption drug, Denosumab (blocking the osteoclast activating cytokine receptor 
activator of NFκB ligand) may hold promise for the treatment of ML and has already 
been used with some success in osteogenesis imperfecta, improving both growth and 
vertebral shape [45-47]. Another option for treatment may be reduction of inflammation 
using drugs such as pentosan polysulfate (PPS), which has been shown to improve range 
of motion and reduce pain in MPS I patients [48]. Future pathophysiological studies on 
the characteristics of bone metabolism in ML III will be needed to establish the most 
promising therapeutic option for this disease. 
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CONCLUSION
Severe skeletal abnormalities resulting from abnormal bone development and severe 
progressive osteoarthritis, are the hallmarks of ML III, necessitating surgical orthopedic 
interventions early in life. Future therapies for this disease should focus on improving 
cartilage and bone quality, preventing skeletal complications and improving mobility.
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CHAPTER 6
CRANIOSYNOSTOSIS 
AFFECTS THE MAJORITY OF 
MUCOPOLYSACCHARIDOSIS 
PATIENTS AND CAN CONTRIBUTE 
TO INCREASED INTRACRANIAL 
PRESSURE
ABSTRACT
Introduction: The mucopolysaccharidoses are multisystem lysosomal storage dis-
eases characterized by extensive skeletal deformities, including skull abnormalities. 
The objective of this study was to determine the incidence of craniosynostosis in the 
different MPS types and its clinical consequences. 
Methods: In a prospective cohort study spanning 10 years, skull imaging and clinical 
evaluations were performed in 47 MPS patients (type I, II, VI and VII). A total of 215 
radiographs of the skull were analyzed. The presence and type of craniosynostosis, the 
sutures involved, progression over time, skull shape, head circumference, fundoscopy 
and ventriculoperitoneal shunt (VPS) placement data were evaluated.  
Results: Craniosynostosis of at least one suture was present in 77% of all 47 MPS 
patients (≤ 6 years in 40% of all patients). In 32% of all MPS patients, premature closure 
of all sutures was seen (≤ 6 years in 13% of all patients). All patients with early closure 
had a more severe MPS phenotype, both in the neuronopathic (MPS I, II) and non-neu-
ronopathic (MPS VI) patient groups. Because of symptomatic increased intracranial 
pressure, a VPS was placed in six patients, with craniosynostosis as a likely or certain 
causative factor for the increased pressure in four patients. One patient underwent 
cranial vault expansion because of severe craniosynostosis.
Conclusion: Craniosynostosis occurs in the majority of the MPS patients. Since the 
clinical consequences can be severe and surgical intervention is possible, skull growth 
and signs and symptoms of increased intracranial pressure should be monitored in 
both neuronopathic and non-neuronopathic patients with MPS. 
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INTRODUCTION
Mucopolysaccharidoses are lysosomal storage diseases caused by deficiencies of glycos-
aminoglycan (GAG) degrading enzymes. The mucopolysaccharidoses are multisystem 
disorders with a broad range of clinical manifestations, including extensive skeletal 
abnormalities (dysostosis multiplex, joint contractures) and hydrocephalus [1, 2]. Neuro-
logical decline due to GAG accumulation in the brain is seen in a subset of patients with 
mucopolysaccharidosis (MPS) type I, II, III and VII [1, 3].
In healthy individuals, the skull expands by growth from the sutures up to the age of six 
years. After the age of six, both sutural and appositional growth takes place [4, 5]. The 
metopic suture closes between the age of 3 and 9 months [6]. The sagittal, coronal and 
lambdoid sutures begin to close much later, around ages 22, 24 and 26 respectively [4].  If 
one or more suture(s) close(s) at an earlier age, this can result in growth stagnation and/
or an abnormal skull shape. This premature fusion (craniosynostosis) can be classified 
as simple (one fused suture), or complex (multiple sutures involved); primary (sutural 
biology abnormality), or secondary (due to external influences) and as part of a syndrome 
or isolated [7].
Early closure of each suture results in a different shape of the skull. For example, early 
closure of the sagittal suture results in an elongated and narrow skull (scaphocephaly) 
and early closure of the lambdoid sutures results in occipital flattening (pachycephaly) 
[8]. Early onset craniosynostosis, defined as closure of sutures before the age of 6 years, 
can restrict skull growth and can cause elevated intracranial pressure (ICP) which can 
result in visual impairment[9]. Therefore, early recognition of craniosynostosis is of great 
importance. Timely surgical intervention can provide space for the brain to grow, thus 
preserving development and vision [10]. 
Up till now, only two small cross-sectional studies investigated the prevalence of cranio-
synostosis in MPS patients. They found secondary craniosynostosis in 19% (7 out of 36) of 
severe MPS II patients and 11% (2 out of 18) of MPS IVA patients. Additionally, three case 
reports describe the presence of craniosynostosis in MPS (type I and type VI) [4, 11-16]. 
The incidence and type of craniosynostosis in MPS, the development over time, severity 
and clinical consequences have not been studied. In our prospective study, this was sys-
tematically evaluated in a relatively large cohort of patients with MPS I, II, VI and VII.
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METHODS 
Patients 
From 2007 onwards all pediatric patients with mucopolysaccharidosis (type I, II, VI and 
VII) treated in the Center for Lysosomal and Metabolic diseases of the Erasmus MC Rot-
terdam, were included in a prospective cohort study. In all patients, the diagnosis of MPS 
had been confirmed by measurement of enzyme deficiency in leucocytes or fibroblasts 
and by DNA analysis. Yearly evaluation was done according to a standardized follow-up 
protocol which included taking the patients’ medical history, physical and neurological 
examination, skull radiographs and ophthalmological examinations. Available data from 
2002 to 2007 was added retrospectively. The study was approved by the Medical Ethical 
Review board at the Erasmus MC.
Radiographic evaluation of sutures and skull shape
Skull radiographs (anterior posterior (AP) and lateral) were obtained yearly up to the 
age of 18 years. Radiographs of patients with a ventriculoperitoneal shunt (VPS) were 
excluded after drain placement, as the drain itself can induce secondary closure of one 
or more sutures in proximity to the drain [17]. Furthermore, the postoperative radiographs 
of a patient who underwent cranial surgery were excluded from the analysis. 
Each radiograph was evaluated by two independent observers (craniosynostosis expert 
and plastic surgeon professor I. M. and lysosomal expert and metabolic pediatrician E.O.). 
In each radiograph, three sutures (coronal, sagittal and lambdoid) were scored as open, 
partially closed, or closed. The metopic suture was not analyzed as it closes physiologically 
between the age of 3 and 9 months and for most patients, radiographs were not available 
at such an early age [6].  
For each MPS type (I, II, VI and VII) the proportion of patients with craniosynostosis 
was determined. Furthermore, the proportion of patients with one closed suture, as well 
as those with two or more closed sutures was determined and the order in which the 
sutures closed was analyzed. For each patient, the shape of the skull was described using 
the last available radiograph. Of three patients with craniosynostosis, three dimensional 
CT scans of the skull were available. 
Head circumferences, ophthalmological and physical examination
Head circumference was measured at least yearly and the measurements closest to the 
evaluated radiographs of the skull were used for analysis. At physical examination, head 
shape and facial features were examined. 
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The presence of raised ICP was evaluated by fundoscopy during yearly ophthalmological 
assessments unless fundoscopy could not be reliably performed due to corneal clouding 
or behavioral problems. 
Ventriculoperitoneal shunt (VPS) placement  
Of the MPS patients who received a VPS, the following parameters at the time of 
placement were determined: age, VPS indication (clinical features, brain imaging and 
cerebrospinal fluid pressure (CSF)), head circumference, head shape, presence or absence 
of craniosynostosis and result of fundoscopy.
Statistics
All data are presented as median and range unless otherwise stated.
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RESULTS
Patients data and characteristics
Forty-seven patients with MPS (type I, II, VI and VII) were included in this study (72% 
were male patients). The median age at diagnosis was 2.8 (range 0-12) years. Table 1 shows 
disease type and severity, mutation(s), gender, age at diagnosis, age at first and last radio-
graph and skull shape for each patient. 
Skull radiographs
A total of 215 skull radiographs were analyzed. The first available radiograph was taken 
at 4.2 (0-12.4) years of age for the entire MPS patient group. The follow-up period was 3.4 
(0.1-9.1) years (table 1).
Prevalence of craniosynostosis in MPS 
Craniosynostosis of at least one suture was present in 77% of all 47 MPS patients and in 
40% of patients this occurred before the age of 6 years (fig. 1 and 2). Table 2 shows the 
prevalence of craniosynostosis, the number of sutures involved and the resulting head 
shape for each MPS type. 
Sutures involved, progression over time and severity
In all MPS patients, 9% had premature (partial) closure of only one suture. In 66% of all 
MPS patients, two or three sutures partially or fully closed prematurely (fig. 1 and table 
2). The longitudinal data on the closure of each suture in each individual MPS patient 
are depicted in figure 2. In most cases, two or three sutures were already (partially) closed 
at the time the first radiograph was made (fig. 2). The coronal suture was never the first 
to close (fig. 1). In 32% of all MPS patients, premature closure of all sutures was seen (≤ 6 
years in 13% of all patients; table 2). All these patients with early closure (≤ 6 year) had a 
more severe MPS phenotype. 
Skull shape 
No specific skull shape abnormality (normocephaly) could be detected in 51% of all MPS 
patients (table 1, 2). Despite a normal skull shape in two patients, all sutures had closed 
before age 6 (MPS VI, patients 1 and 5). This is also referred to as pansynostosis [18].  
Scaphocephaly was seen in 26% of all MPS patients. In 8 of these 12 patients, closure of 
the sagittal suture had occurred around or before age 6. Pachycephaly was detected in 
23% of all MPS patients. Pachycephaly with scaphocephaly was seen in one patient (MPS 
I, patient 2). Plagiocephaly at the right anterior side of the head was seen in one MPS II 
patient (fig. 3A, patient 10).
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Figure 1 Suture closure in the different MPS types
Fig. 1. Kaplan-Meier curves of open suture(s) (coronal: A, lambdoid: B and sagittal: C) by MPS subtype 
(type I, II, VI ). 1.0 means 100% of patients with open or partially closed suture, 0 means suture closed in 
all patients. MPS VII patients were not included in the graph because of the low number (n=2).
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Table 1 Patients characteristics
MPS I
Pt nr.
Hurler (H) / 
Hurler/Scheie (HS) / 
Scheie (S)
IDUA gene
Protein
Gender
Male (M) /
Female (F)
Age
at diagnosis
(years)
Age
first X skull
(years)
Age
last X skull
(years)
Scull shape
last
radiograph
1 H p.Q70X/p.L218P M 2.4 11.8 normal
2 H p.Q70X/p.W402X F 2 6.1 scaphocephaly, pachycephaly
3 H p.Q70X/p.L218P M 1.7 6.2 8.1 pachycephaly
4 H p.Q70X/p.L218P M 0.9 1 scaphocephaly
5 H p.Q70X/p.A327P M 1 0.8 pachycephaly
6# H p.Q70X/p.Q70X F 1 1.2 2.2 scaphocephaly
7 H p.Q70X/p.L218P M 0.9 1.0 3.2 pachycephaly
8 H p.A327P/p.A327P F 1.3 1 scaphocephaly
9 H c.1273dup, p.H425fs/ c.1273dup, p.H425fs F 0.7 2.7 scaphocephaly
10# H p.Q70X / Q70X M 0 0 4.6 normal
11 H c.1893del, p.F632fs/ c.1893del, p.F632fs F 1.2 1.2 scaphocephaly
12 H/S p.W402X/p.W402X M 1 0.4 pachycephaly
13 S p.W402X/n.i. M 5 7.9 14.5 normal
14 S p.R383H/c.474-2A>G F 2.3 2.6 normal
MPS II Neuropatic 
(N) / Nonneuropatic 
(NN)
IDS 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age 
first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
1 N p.S349R M 3 10.3 15.3 normal
2 N p.E521K M 3 11.2 pachycephaly
3 N p.P86L M 6 9.7 pachycephaly
4 N p.E459* M 2 8.7 13.7 normal
5 N p.S333L M 3 3.1 normal
6 N p.S117del M 0 0.2 normal
7 N c.1511del, p.G504fs M 4.7 5.5 8.6 normal
8 N c.544del, p.L182fs M 2 2.4 normal
9 N Total IDS del^ M 4 7.1 7.7 normal
10 N p.S333L M 2 0.2 1.7 (CT scan) plagiocephaly anterior right
11 N p.L522P M 1 1.1 normal
12 Unknown p.H229R M 5 6.7 normal
13$ NN p.F137S M 3.3 3.5 6.9 scaphocephaly
14$ NN p.F137S M 3.3 3.5 7.2 scaphocephaly
15 NN p.Y225D M 4.1 4.2 5.7 pachycephaly
MPS VI Rapidly 
progressive (R) /
Slowly progressive (S)
ARSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age
first X skull
(years)
Age
 last X skull
(years)
Scull shape
last 
radiograph
1 R c.1142+2T>C, p?/ c.1142+2T>C, p? F 2.9 5.7 14.8 Normal
2 R p.P313S/p.P313S M 12 12 13 scaphocephaly
3 R p.V332G/p.V332G M 2.7 2.9 pachycephaly
4 R p.P313S/p.P313S F 6.5 8.6 scaphocephaly
5 R p.N301K/p.N301K F 1.9 2.5 8.6 normal
6 R p.G324V/p.G324V M 1.4 2.2 8.2 scaphocephaly
7£ R p.P313A/p.P313A F 4.6 4.6 6.6 normal
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Table 1 Patients characteristics
MPS I
Pt nr.
Hurler (H) / 
Hurler/Scheie (HS) / 
Scheie (S)
IDUA gene
Protein
Gender
Male (M) /
Female (F)
Age
at diagnosis
(years)
Age
first X skull
(years)
Age
last X skull
(years)
Scull shape
last
radiograph
1 H p.Q70X/p.L218P M 2.4 11.8 normal
2 H p.Q70X/p.W402X F 2 6.1 scaphocephaly, pachycephaly
3 H p.Q70X/p.L218P M 1.7 6.2 8.1 pachycephaly
4 H p.Q70X/p.L218P M 0.9 1 scaphocephaly
5 H p.Q70X/p.A327P M 1 0.8 pachycephaly
6# H p.Q70X/p.Q70X F 1 1.2 2.2 scaphocephaly
7 H p.Q70X/p.L218P M 0.9 1.0 3.2 pachycephaly
8 H p.A327P/p.A327P F 1.3 1 scaphocephaly
9 H c.1273dup, p.H425fs/ c.1273dup, p.H425fs F 0.7 2.7 scaphocephaly
10# H p.Q70X / Q70X M 0 0 4.6 normal
11 H c.1893del, p.F632fs/ c.1893del, p.F632fs F 1.2 1.2 scaphocephaly
12 H/S p.W402X/p.W402X M 1 0.4 pachycephaly
13 S p.W402X/n.i. M 5 7.9 14.5 normal
14 S p.R383H/c.474-2A>G F 2.3 2.6 normal
MPS II Neuropatic 
(N) / Nonneuropatic 
(NN)
IDS 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age 
first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
1 N p.S349R M 3 10.3 15.3 normal
2 N p.E521K M 3 11.2 pachycephaly
3 N p.P86L M 6 9.7 pachycephaly
4 N p.E459* M 2 8.7 13.7 normal
5 N p.S333L M 3 3.1 normal
6 N p.S117del M 0 0.2 normal
7 N c.1511del, p.G504fs M 4.7 5.5 8.6 normal
8 N c.544del, p.L182fs M 2 2.4 normal
9 N Total IDS del^ M 4 7.1 7.7 normal
10 N p.S333L M 2 0.2 1.7 (CT scan) plagiocephaly anterior right
11 N p.L522P M 1 1.1 normal
12 Unknown p.H229R M 5 6.7 normal
13$ NN p.F137S M 3.3 3.5 6.9 scaphocephaly
14$ NN p.F137S M 3.3 3.5 7.2 scaphocephaly
15 NN p.Y225D M 4.1 4.2 5.7 pachycephaly
MPS VI Rapidly 
progressive (R) /
Slowly progressive (S)
ARSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age
first X skull
(years)
Age
 last X skull
(years)
Scull shape
last 
radiograph
1 R c.1142+2T>C, p?/ c.1142+2T>C, p? F 2.9 5.7 14.8 Normal
2 R p.P313S/p.P313S M 12 12 13 scaphocephaly
3 R p.V332G/p.V332G M 2.7 2.9 pachycephaly
4 R p.P313S/p.P313S F 6.5 8.6 scaphocephaly
5 R p.N301K/p.N301K F 1.9 2.5 8.6 normal
6 R p.G324V/p.G324V M 1.4 2.2 8.2 scaphocephaly
7£ R p.P313A/p.P313A F 4.6 4.6 6.6 normal
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Table 1 Continued
MPS VI Rapidly 
progressive (R) /
Slowly progressive (S)
ARSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age 
first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
8 R Unknown F 3.1 3.1 4.5 (CT scan) scaphocephaly
9£ R p.P313A/p.P313A M 2.2 2.4 4.4 normal
10 R p.H141P/p.L321P M 1.9 2.0 2.1 (CT scan) pachycephaly, brachycephaly
11 S p.R152W/p.R152W F 7.5 7.8 14 normal
12 S p.Y210C/p.P313A M 10.3 12.4 14.4 normal
13 S p.R152W/p.R152W M 0.7 7.7 15.1 normal
14& S p.Y210C/p.R327X F 6.4 7.3 15.3 normal
15& S p.Y210C/p.R327X M 5 5.3 14.3 normal
16 S p.Y210C/p.R327X M 5.9 5.8 13.1 normal
MPS 
VII
Mild / 
severe
GUSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age
 first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
1α Mild p.V99M/p.V99M M 8.4 8.4 normal
2α Mild p.V99M/p.V99M M 6.7 6.7 pachycephaly
#, $, £, & and α: siblings
Patient numbering is the same as in figure 2.
Table 2 Frequency of premature suture closure in MPS
Total MPS MPS I MPS II MPS VI MPS VII
≥ 1 Suture closed; n/total (%) 36/47 (77%) 10/14 (71%) 10/15 (67%) 15/16 (94%) 1/2 (50%)
≥ 1 Suture closed ≤6 year; n/total (%) 19/47 (40%) 6/14 (43%) 6/15 (40%) 7/16 (44%) 0/2 (0%)
1 Suture closed; n/total (%) 4/47 (9%) 2/14 (14%) 0/15 (0%) 1/16 (6%) 1/2 (50%)
> 2 Sutures closed; n/total (%) 31/47 (66%) 7/14 (50%) 10/15 (67%) 14/16 (88%) 0/2 (0%)
All sutures closed; n/total (%) 15/47 (32%) 2/14 (14%) 4/15 (27%) 9/16 (56%) 0/2 (0%)
All sutures closed ≤6  year; n/total (%) 6/47 (13%) 2/14 (13%) 1/15 (7%) 3/16 (19%) 0/2 (0%)
All sutures open; n/total (%) 11/47 (23%) 4/14 (29%) 5/15 (33%) 1/16 (6%) 1/2 (50%)
Skull shape; n/total (%)* N 24/47 (51%)
S 12/47 (26%)
P 11/47 (23%)
N 4/14 (29%)
S 6/14 (43%)#
P 5/14 (36%)#
N 9/15 (60%)^
S 2/15 (13%)^
P 3/15 (20%)^
N 10/16 (63%)
S 4/16 (25%)
P 2/16 (13%)
N 1/2 (50%)
S 0/2 (0%)
P 1/2 (50%)
*N; Normocephalic, S; Scaphocephalic, P; Pachycephalic. # one patient had both scaphocephalic and 
pachycephalic head shape. ^ one patient had only plagiocephaly at the right anterior side of the head 
and therefor data of one patient is missing
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Table 1 Continued
MPS VI Rapidly 
progressive (R) /
Slowly progressive (S)
ARSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age 
first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
8 R Unknown F 3.1 3.1 4.5 (CT scan) scaphocephaly
9£ R p.P313A/p.P313A M 2.2 2.4 4.4 normal
10 R p.H141P/p.L321P M 1.9 2.0 2.1 (CT scan) pachycephaly, brachycephaly
11 S p.R152W/p.R152W F 7.5 7.8 14 normal
12 S p.Y210C/p.P313A M 10.3 12.4 14.4 normal
13 S p.R152W/p.R152W M 0.7 7.7 15.1 normal
14& S p.Y210C/p.R327X F 6.4 7.3 15.3 normal
15& S p.Y210C/p.R327X M 5 5.3 14.3 normal
16 S p.Y210C/p.R327X M 5.9 5.8 13.1 normal
MPS 
VII
Mild / 
severe
GUSB 
gene
Protein
Gender
Male (M) /
Female (F)
Age 
at diagnosis
(years)
Age
 first X skull
(years)
Age 
last X skull
(years)
Scull shape
last 
radiograph
1α Mild p.V99M/p.V99M M 8.4 8.4 normal
2α Mild p.V99M/p.V99M M 6.7 6.7 pachycephaly
#, $, £, & and α: siblings
Patient numbering is the same as in figure 2.
Table 2 Frequency of premature suture closure in MPS
Total MPS MPS I MPS II MPS VI MPS VII
≥ 1 Suture closed; n/total (%) 36/47 (77%) 10/14 (71%) 10/15 (67%) 15/16 (94%) 1/2 (50%)
≥ 1 Suture closed ≤6 year; n/total (%) 19/47 (40%) 6/14 (43%) 6/15 (40%) 7/16 (44%) 0/2 (0%)
1 Suture closed; n/total (%) 4/47 (9%) 2/14 (14%) 0/15 (0%) 1/16 (6%) 1/2 (50%)
> 2 Sutures closed; n/total (%) 31/47 (66%) 7/14 (50%) 10/15 (67%) 14/16 (88%) 0/2 (0%)
All sutures closed; n/total (%) 15/47 (32%) 2/14 (14%) 4/15 (27%) 9/16 (56%) 0/2 (0%)
All sutures closed ≤6  year; n/total (%) 6/47 (13%) 2/14 (13%) 1/15 (7%) 3/16 (19%) 0/2 (0%)
All sutures open; n/total (%) 11/47 (23%) 4/14 (29%) 5/15 (33%) 1/16 (6%) 1/2 (50%)
Skull shape; n/total (%)* N 24/47 (51%)
S 12/47 (26%)
P 11/47 (23%)
N 4/14 (29%)
S 6/14 (43%)#
P 5/14 (36%)#
N 9/15 (60%)^
S 2/15 (13%)^
P 3/15 (20%)^
N 10/16 (63%)
S 4/16 (25%)
P 2/16 (13%)
N 1/2 (50%)
S 0/2 (0%)
P 1/2 (50%)
*N; Normocephalic, S; Scaphocephalic, P; Pachycephalic. # one patient had both scaphocephalic and 
pachycephalic head shape. ^ one patient had only plagiocephaly at the right anterior side of the head 
and therefor data of one patient is missing
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Figure 2 Craniosynostosis by MPS type in individual patients
Fig.2. For each MPS type, the suture closure over time is shown. Each suture is depicted by a symbol: 
coronal: square, lambdoid: circle, sagittal: diamond. Closure status is indicated by the filling of the 
symbol: transparent: open suture(s), shaded: partial closure, black: completely closed. For MPS I, II and VI, 
the most severe phenotypes are at the top and the  least severe phenotypes at the bottom of the graph.
Abbreviations in the graph: Pt.: patient, N: neuronopatic, NN: non-neuronopatic, R: rapidly progressive, 
S: slowly progressive
Right: skull shape, N: normocephaly, S: scaphocephaly, P: pachycephaly, B: brachycephaly, Pl*: plagioceph-
aly 
A black line is drawn at age 6 years. If suture closure occurs before the age of six, this is regarded as 
early onset craniosynostosis.
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Illustrative cases of craniosynostosis in MPS
Figure 3 shows photographs, skull X-rays, 3D CT scans and MRI cerebrum of a MPS II 
patient (patient 10) (fig. 3A) with bulging anterior fontanel due to craniosynostosis, a MPS 
VI patient (patient 8) (fig. 3B), with frontal bossing and scaphocephaly due to craniosyn-
ostosis and an adult MPS VI patient (brother of patient 4) (fig. 3C). This adult patient died 
unexpectedly at 25 years of age as a result of a respiratory tract infection in an already 
highly compromised respiratory setting. Figure 3C shows macroscopic pictures from the 
brain autopsy, with an impression of the sinus transversus in the skull (X-skull) and an 
impression of the brain gyri in the frontal bone, the result of raised ICP earlier in life. 
Head circumferences
Data from at least one head circumferences measurement was available for 94% of all MPS 
patients. Only two patients had a head circumference outside the normal reference range 
(-2SD). Both were MPS VI patients (patients 1 and 5) in whom all sutures closed before 
age 6, with stagnation (arrest) of skull growth. After age 6, their head circumferences 
started to increase again, in line with appositional growth of the skull. Supplemental 
figure 1 shows skull and height growth curves and photo- and radiographs of one of these 
patients (MPS VI patient 1). 
Ophthalmic examination 
Fundoscopy data was available for 85% of all MPS patients. Two patients had papilledema. 
In one of them, craniosynostosis was recognized at that time as the cause of increased 
ICP. Occipital cranial vault expansion with fronto-supraorbital remodulation surgery was 
performed at the age of 1 year and 9 months (MPS II, patient 10,  fig. 3A). In the second 
patient (MPS VI, patient 7), edema was mild, there were no clinical signs of increased 
ICP and skull growth was normal. Therefore, an intervention was deemed unnecessary. 
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Ventriculoperitoneal shunt (VPS) placement 
In six patients, a VPS was placed at a median age of 5.4 (range 2-7.5) years because of sus-
pected elevated ICP (table 3). Fundoscopy was performed or attempted in three patients 
before VPS placement. Two patients had no papilledema and in the other patient, fun-
doscopy was not possible due to corneal clouding or abnormal behavior. In five of the six 
patients, CT or MRI scan of the brain prior to VPS placement showed progressive hydro-
cephalus. They had clinical symptoms caused by the increased ICP such as neurological 
decline (faster than the expected decline due to GAG accumulation in the brain),  headache 
and epilepsy. In four patients, the SD value of the head circumferences increased before 
VPS placement. In one patient (MPS II, patient 6), this occurred in a relatively short time 
(increase from 1 to 4SD), with only slightly elevated CSF pressure measured at the time of 
VPS placement. In one patient (MPS VI, patient 3), head circumferences SD value declined 
prior to drain placement. This patient had partial closure of the lambdoid suture and com-
plete closure of the sagittal suture with elevated CSF pressure (30-45 cm H2O) at the time 
of VPS placement (fig. 2). We concluded that craniosynostosis, in combination with hydro-
cephalus, most likely contributed to the increased ICP in four out of the six patients with 
a VPS (table 3; MPS I, patients 2, 4 and 6; MPS VI, patient 3). In the fifth patient, craniosyn-
ostosis was not present (MPS II, patient 5) and in the sixth patient (MPS II, patient 6), no 
radiograph had been taken in the two years before shunt placement occurred. One year after 
VPS placement, all sutures were closed in this patient (fig. 2) suggesting this had already 
occurred, at least partially, before drain placement. 
Table 3 Characteristics of MPS patients with ventricular peritoneal shunt
MPS I
(Patient 2)
MPS I
(Patient 4)
MPS I
(Patient 6)
MPS II
(Patient 5)
MPS II
(Patient 6)
MPS VI
(Patient 3)
Age at VPS placement 7.5 2 5.3 7.5 2.5 5.5
Reason for VPS placement
- Clinical Neurological decline Neurological decline; 
headaches
Reduced concentration Neurological decline; epilepsy Neurological decline Headaches
- Brain imaging CT: mild progression 
triventricular 
hydrocephalus
CT: progression 
hydrocephalus,  bulging 
fontanel
MRI: progression hydrocephalus MRI: hydrocephalus MRI: mild progression 
quadriventricular 
hydrocephalus
MRI: no signs 
hydrocephalus
- CSF pressure* NP NP NP NP 20 mmHg 30-45 cm H2O
Head circumferences in SD values at the time of 
VPS placement
+1½SD +2½SD +2SD +2½SD +4SD -1SD
Head shape$ S/P S S N N S
Craniosynostosis
present before VPS placement
Yes Highly susceptible 
(bulging fontanel)
Yes No NP Yes
Papilledema (fundoscopy) No NP Not possible: corneal clouding NP NP No
MPS: mucopolysaccharidosis; VPS: Ventriculoperitoneal shunt; NP: Not Performed; SD: Standard Deviation; 
CSF: Cerebrospinal Fluid
*CSF pressure of >25 to 30 cm H2O (18-22 mmHg) an indication for VPS 
$ S: scaphocephaly; P: pachycephaly; N: normocephaly
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Figure 3 Three illustrative cases of craniosynostosis in MPS
A
B
Fig. 3A) Patient 10, MPS II, 1.5 years old. Photographs show the distinct facial features, MRI T2 flair and 
3D CT scan shows the bulging anterior fontanel (volcano sign) with plagiocephaly at the right anterior 
site of the head. 3D CT scan shows the premature closure of the left coronal suture, the sagittal suture 
and both lambdoid sutures.
Table 3 Characteristics of MPS patients with ventricular peritoneal shunt
MPS I
(Patient 2)
MPS I
(Patient 4)
MPS I
(Patient 6)
MPS II
(Patient 5)
MPS II
(Patient 6)
MPS VI
(Patient 3)
Age at VPS placement 7.5 2 5.3 7.5 2.5 5.5
Reason for VPS placement
- Clinical Neurological decline Neurological decline; 
headaches
Reduced concentration Neurological decline; epilepsy Neurological decline Headaches
- Brain imaging CT: mild progression 
triventricular 
hydrocephalus
CT: progression 
hydrocephalus,  bulging 
fontanel
MRI: progression hydrocephalus MRI: hydrocephalus MRI: mild progression 
quadriventricular 
hydrocephalus
MRI: no signs 
hydrocephalus
- CSF pressure* NP NP NP NP 20 mmHg 30-45 cm H2O
Head circumferences in SD values at the time of 
VPS placement
+1½SD +2½SD +2SD +2½SD +4SD -1SD
Head shape$ S/P S S N N S
Craniosynostosis
present before VPS placement
Yes Highly susceptible 
(bulging fontanel)
Yes No NP Yes
Papilledema (fundoscopy) No NP Not possible: corneal clouding NP NP No
MPS: mucopolysaccharidosis; VPS: Ventriculoperitoneal shunt; NP: Not Performed; SD: Standard Deviation; 
CSF: Cerebrospinal Fluid
*CSF pressure of >25 to 30 cm H2O (18-22 mmHg) an indication for VPS 
$ S: scaphocephaly; P: pachycephaly; N: normocephaly
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Figure 3 Continued
A
B
Fig. 3B) Patient 8, MPS VI 3.3 years old. Skull X ray shows frontal bossing and scaphocephaly. X-skull 
and 3D-CT scan show craniosynostosis of the metopic, both lambdoid and sagittal sutures. On MRI T2/
FLAIR cerebrum there are no signs of increased ICP.   
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Figure 3 Continued
C
Fig. 3C) MPS VI patient, 24 years old. Photographs and skull X rays show distinct facial features, scapho-
cephaly and sinus transversus impression in the skull.  
Macroscopic pictures from the autopsy at age 25 years show in red impressions of the brain gyri in the 
frontal bones and an abnormally thin bone layer. In blue (top to bottom), abnormally deep olfactory 
furrow, sella tursica and severe narrow foramen magnum. In green; thickened skull. The white arrow 
shows where there is an impression of the skull in the brain. 
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DISCUSSION
This is the first long-term prospective study assessing skull suture closure and its con-
sequences in patients with MPS I, II, VI and VII. Our results show that craniosynostosis 
occurs at a very high frequency in these different types of MPS. Premature closure of at 
least one suture was present in 77% of patients, with suture closure occurring before age 
6 in 40% of patients. In the general population, non-syndromic craniosynostosis occurs 
with a frequency between 0.4 and 1.0 per 1000 live births and syndromic craniosynostosis is 
even rarer [19-23]. The incidence found in the current study may even be an underestima-
tion, because only one skull radiograph was available for 43% of our patients. In addition, 
the median follow-up was relatively short (3.4 years). 
Consistent with syndromic craniosynostosis, the majority of MPS patients (66%) had 
early closure of more than one suture, with involvement of the lambdoid and coronal 
sutures [24].
An abnormal head shape resulting from early suture closure was seen in about half of all 
studied MPS patients with scaphocephaly and pachycephaly being the most frequently 
observed abnormalities. The trichonocephalic head shape resulting from early closure of 
the metopic suture was not present in our MPS population. 
Scaphocephaly due to premature closure of the sagittal suture was often (21%) seen in the 
severely affected MPS I (6 patients) and MPS VI (4 patients) patients. In 13% of all MPS 
patients, all sutures closed at an early age (pansynostosis), with normal head shape in 
two patients. Pansynostosis can easily be overlooked in these children, as their small head 
size can be interpreted as normal due to the fact that they are often small in stature. In 
MPS patients in whom growth stagnation of the head occurs (example in supplemental 
fig. 1), further investigation is warranted regardless of whether or not this is in line with 
their body length growth.
In MPS, evaluation of the consequences of craniosynostosis is complicated because 
increased ICP in this condition is often multifactorial. Hydrocephalus in MPS arises from 
accumulation of GAGs in cells of the brain (ventricles, arachnoid villi), in supporting 
structures (meninges or spinal column), or results from venous hypertension related to 
the flow limiting morphological changes in the skull base (fig. 3C) and craniocervical 
junction [2, 25].  Moreover, the detection of clinical symptoms of raised ICP, such as visual 
decline or headache and nausea, can be difficult to detect, especially in the cognitively 
impaired patients. 
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Supplemental figure 1 Example of early pansynostosis in a MPS VI patient
Supplemental fig.1. Patient 1, MPS VI, 9 years old. 
A) Photographs show the distinct facial features and the normal shape of the skull 
B) X-skull at age 6 years shows closure of all sutures. 
C) The growth curve shows the stagnation of the skull growth (from -1SD to -2SD at around the age of 
6 years). Decline in height (0SD to -8.8SD) from age of 1.5 till age 17 years old.
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Another pitfall in evaluation of the consequences of craniosynostosis in MPS is the 
assessment of increased ICP in these disorders. Papilledema is not always present in MPS 
patients with increased ICP (for example MPS VI patients pt. no. 3). While conversely, it 
can be present in patients with normal ICP as a result of GAG accumulation in the sclera 
or optic nerve [26, 27]. Expansion of the ventricles in response to increased ICP is often not 
present in MPS patients as the ventricles are stiff due to the GAG accumulation, while 
enlarged ventricles can be present without raised ICP in the neuronopatic MPS patients 
due to brain atrophy [25]. Therefore, in cases where clinical suspicion of increased ICP 
in MPS patients is high, thorough examination using different diagnostic modalities 
(including lumbar punction and/or 24 hours ICP monitoring) should be carried out before 
dismissing this diagnosis.
When hydrocephalus and craniosynostosis occur in the same MPS patient, this can result 
in severely elevated ICP since expansion of the skull in response to increase in pressure 
cannot take place. This is illustrated by the examples in our studied cohort. Patient 6 with 
MPS II did not have craniosynostosis and his skull could, therefore, expand to +4SD in 
response to the occurring hydrocephalus, resulting in near normal ICP. In contrast, high 
ICP was found in patient 3 with MPS VI. In this patient, all sutures closed at a young age 
leading to skull growth stagnation. The high ICP was potentially the result of a combi-
nation of a CSF drainage problem and craniosynostosis.  
In our patient cohort, craniosynostosis resulting in increased ICP also occurred in the 
non-neuronopathic MPS VI patients. This is demonstrated in the adult MPS VI patient in 
figure 3C, where the indentations of the brain in the skull, observed upon autopsy, indicate 
raised ICP earlier in life. In non-neuronopathic MPS patients, extensive GAG accumula-
tion in the brain is not observed and neurocognitive developmental is usually described 
as normal [1, 28]. Interestingly, we previously described mild cognitive impairment in three 
MPS VI patients [29]. In this study it is shown that two of these patients had pansynosto-
sis and one had closure of two sutures before the age of six (patients 1, 5 and 6). Whether 
craniosynostosis did indeed contribute to the cognitive disturbances in these patients 
remains to be determined by studying larger numbers of non-neuronopathic patients. 
In other craniosynostosis syndromes such as Apert and Pfeiffer syndrome, suture closure 
occurs in utero which results in increased ICP very early in life [30, 31]. In these cases, 
guidelines for treatment in the form of surgical cranial vault expansion are clear [32]. In 
MPS, suture closure seems to occur in early childhood, thus the clinical consequences are 
likely to be less severe. Increased ICP in MPS can be multifactorial therefore, treatment 
decisions should be made on a case-by-case basis with all aspects of the disorder being 
taken into account. In the non-neuronopatic MPS patients, surgical cranial vault expan-
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sion might be an option in early childhood. In the neuronopathic patients, placement of a 
VPS to decrease ICP may be the treatment of choice since ongoing neurocognitive decline 
due to intracerebral GAG accumulation is to be expected and surgery for craniosynostosis 
imposes a large burden on the child.
In order to prevent complications of craniosynostosis, we recommend monitoring skull 
growth by measuring head circumferences and performing radiographs of the skull yearly 
in both neuronopathic and non-neuronopathic MPS patients until at least the age of 6 
years. 
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CONCLUSION
Craniosynostosis occurs in the majority of the MPS patients. Since the clinical conse-
quences can be severe and surgical intervention is possible, skull growth and signs and 
symptoms of increased intracranial pressure should be monitored in both neuronopathic 
and non-neuronopathic patients with MPS. 
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SUMMARY
Mucopolysaccharidosis (MPS) and mucolipidosis (ML II and III) are lysosomal storage 
disorders with multisystem involvement. Several intra- and extracellular processes are 
activated and altered by intralysosomal glycosaminoglycan (GAG) accumulation. Skeletal 
abnormalities are common in MPS and ML patients and originate from GAG storage in 
cells of the cartilage, bones and ligaments. At present, only part of the processes involved 
in cartilage and bone disease in MPS and ML are well understood and there are still many 
uncertainties and unanswered questions regarding the mechanisms (chapter 2 and 7). 
Some of the most pressing of these questions and options for future studies to provide 
answers have been described in this thesis.
The pathophysiology of cartilage and bone disease in MPS and ML patients is immensely 
complex. Intracellularly, lysosomal GAG accumulation causes loss of cellular function 
by disturbed autophagy, polyubiquitination, mitochondrial dysfunction, inflammation, 
apoptosis and loss of lysosomal membrane integrity, followed by tissue damage and organ 
dysfunction (chapter 2). 
Altered cartilage and deformed bones are the result of dysfunctional chondrocytes, bone 
cells and extra cellular matrix (ECM). Then, pathological processes such as abnormal 
biomechanical forces on deformed bones, with inflammation, finally lead to early sec-
ondary osteoarthritis, often necessitating orthopedic surgical interventions early in life 
(chapter 2, 4, 5 and 7). Clinical aspects of skeletal pathology in MPS and ML III patients, 
such as hip disease and craniosynostosis, are described in chapters 4-6. 
Currently, available treatments for the MPS’s do not prevent and ameliorate the abnor-
malities in bones and cartilage as a result of these disorders (chapter 1 and 2). There are 
no therapeutic options for ML at this time. This disease is very complicated as no lyso-
somal enzymes are able to enter the lysosome. Development of new, targeted treatment, 
or improving existing therapies is vital for both diseases. 
In chapter 2 the histological and biochemical abnormalities in bones, joints, teeth and 
extracellular matrix (ECM) in MPS patients are reported against the background of 
normal tissue-specific processes. Cellular dysfunction by intralysosomal GAG storage in 
connective-tissue-forming cells directly affects the composition and metabolism of the 
ECM. These primary events create a cascade of pathological processes that have local 
effects on tissue and organ function, and distant effects on systemic functions. Clinically, 
these pathological processes lead to growth retardation, dysostosis multiplex, osteopenia/
osteoporosis, stiff joints and abnormal teeth.
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Chapter 3 describes the correlation between residual IDUA activity in cultured fibroblasts 
and the phenotype of MPS I patients. This may provide a tool for the early prediction 
of the phenotype of MPS I patients when the genotype is uninformative, for instance, 
after detection of a novel mutation with unknown effect. This would be very helpful for 
patients who will be picked up at an early age through newborn screening in the near 
future. 
The most frequently and most severely affected part of the skeleton in MPS and ML is 
the hip, often from early childhood onwards. Abnormal hip development in MPS VI and 
adult ML III patients is described in chapters 4 and 5. The hip problems in all MPS VI 
and in almost all ML III patients finally lead to pain and to severe limitations in mobility. 
In MPS VI patients, clinically significant hip abnormalities develop very early in life, 
starting with deformities of the os ilium and acetabulum. Femoral head abnormalities 
occur later, most likely due to altered mechanical forces in combination with epiphyseal 
abnormalities due to GAG storage. The final shape and angle of the femoral head differs 
between individual MPS VI patients and is difficult to predict; therefore, hip surgery, both 
in terms of timing and type of intervention, still remains a challenge with these patients. 
In adult ML III patients, abnormal bone development and severe progressive osteoar-
thritis lead to other severe skeletal abnormalities. These patients often undergo surgical 
orthopedic interventions early in life (chapter 5).
Future therapies for ML III should focus on improving cartilage and bone quality in these 
patients in order to prevent skeletal complications and improve mobility.
Another severe complication of bone and cartilage disease in MPS patients is early cranial 
suture closure (craniosynostosis) which is described in chapter 6. In our study, cranio-
synostosis occurred in the majority of the MPS I, II, VI and VII patients. Early recognition 
of craniosynostosis is important as closure of cranial sutures before the age of 6 may 
restrict skull growth, which can lead to elevated intracranial pressure (ICP), with visual 
and developmental impairment. Monitoring skull growth and the signs and symptoms 
of increased ICP in both neuronopathic and non-neuronopathic patients with MPS is 
necessary, as surgical interventions are possible.
Finally, Chapter 7 discusses and summarizes the findings of the studies, and provides 
new hypotheses and insights into the development of cartilage and bone disease in MPS 
and ML, which are relevant for future therapeutic strategies. 
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The pathological changes involved in cartilage and bone disease in MPS and ML starts 
very early in development. The fetal origin of the cartilage and bone pathology in MPS 
and ML patients presents a great hurdle for adequate treatment and explains the limited 
effects of existing therapies on skeletal complications. Besides development of innovative 
therapeutic strategies, future therapies should also focus on reducing pain and maintain-
ing patient independence. 
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Mucopolysaccharidose (MPS) en mucolipidose (ML II en ML III) zijn lysosomale 
stapelingsziekten, waarbij meerdere weefsels zijn aangedaan. Verschillende intra- en 
extracellulaire processen worden geactiveerd of verlopen anders door glycosaminoglycanen 
(GAGs) stapeling in het lysosoom. Skelet afwijkingen komen vaak voor in MPS en ML 
patiënten en ontstaan door GAG stapeling in kraakbeencellen, botcellen en in ligamenten. 
Op dit moment begrijpen we slechts een deel van de betrokken processen in kraakbeen en 
botziekte in MPS en ML en zijn er nog steeds veel lacunes in onze kennis met betrekking 
tot de pathofysiologie (hoofdstukken 2 en 7). 
Dit proefschrift beantwoord een aantal van de meest urgente van deze vragen en opties 
voor toekomstige studies. De pathofysiologie van kraakbeen en botziekte in MPS en ML 
patiënten is immens complex.
Lysosomale GAG stapeling veroorzaakt functieverlies van cellen, verstoorde autofagie, 
polyubiquitinatie, mitochondriële disfunctie, inflammatie, apoptose en verlies van 
lysosomale membraan integriteit, gevolgd door weefsel schade en orgaan dysfunctie 
(hoofdstuk 2).  
Veranderd kraakbeen en vervormde botten zijn het resultaat van dysfunctie van 
kraakbeen- en botcellen en van de extracellulaire matrix (ECM). Daarna leiden 
pathologische processen, zoals abnormale biomechanische krachten op vervormde botten, 
en inflammatie uiteindelijk tot vroege secundaire osteoartrose, waarvoor orthopedische 
chirurgische ingrepen vaak al op jonge leeftijd nodig zijn (hoofdstukken 2, 4, 5 en 7). 
Klinische aspecten van skeletpathologie, zoals heupziekte en craniosynostose, in de 
verschillende vormen van MPS en ML III, worden beschreven in de hoofdstukken 4 t/m 6. 
De op dit moment beschikbare therapieën voor MPS kunnen de afwijkingen in kraakbeen 
en botten bij deze ziekten niet voorkomen of genezen (hoofdstuk 1 en 2). Voor ML zijn 
er nog geen therapeutische opties. Deze ziekte is erg gecompliceerd, omdat vrijwel alle 
lysosomale enzymen niet in het lysosoom kunnen komen. De ontwikkeling van nieuwe 
doelgerichte therapieën of verbetering van bestaande therapieën is essentieel voor beide 
ziekten.   
In hoofdstuk 2  worden de histologische en biochemische afwijkingen in botten, gewrichten, 
tanden en ECM van MPS patiënten besproken, tegen de achtergrond van normale 
weefsel specifieke processen. Cellulaire dysfunctie door intra-lysosomale GAG stapeling 
in bindweefselvormende cellen, beïnvloedt direct de samenstelling en het metabolisme 
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van de ECM. Deze primaire gebeurtenissen veroorzaken een cascade van pathologische 
processen die lokale effecten hebben op weefsels en orgaan functie en effecten op afstand 
op systemische functies. Klinisch leiden deze processen tot groeiachterstand, dysostosis 
multiplex, osteopenie/osteoporose, stijve gewrichten en abnormale tanden. 
Hoofstuk 3 beschrijft de correlatie tussen restactiviteit van iduronidase in gekweekte 
fibroblasten en het fenotype van MPS I patiënten. Dit kan een hulpmiddel zijn voor de 
vroege voorspelling van het fenotype van MPS I patiënten, wanneer het genotype niet 
informatief is, bijvoorbeeld na detectie van een nieuwe mutatie met onbekend effect. Dit 
zou in de nabije toekomst heel erg kunnen helpen voor de patiënten die op een jonge 
leeftijd worden opgepikt door de neonatale screening. 
Het meest frequente en meest ernstig aangedane deel van het skelet in MPS en ML is 
de heup, vaak al vanaf vroege kinderleeftijd. Abnormale heupontwikkeling in MPS VI en 
volwassen ML III patiënten is beschreven in hoofdstuk 4 en 5. De heupproblemen in 
alle MPS VI en in bijna alle ML III patiënten leiden uiteindelijk tot pijn en tot ernstige 
beperkingen van de mobiliteit. In MPS VI patiënten ontwikkelen de klinisch significante 
heupafwijkingen zich zeer vroeg in het leven, beginnend met vervormingen van het 
os ileum en acetabulum. De heupkop afwijkingen volgen later, waarschijnlijk door de 
veranderde mechanische krachten in combinatie met epifysaire afwijkingen door GAG 
stapeling. De uiteindelijke vorm en hoek van de heup kop verschilt tussen de individuele 
MPS VI patiënten en is moeilijk te voorspellen. Daardoor blijven heupoperaties, zowel 
moment als type van interventie, nog steeds een uitdaging in deze patiënten.  
In de volwassen ML III patiënten abnormale botontwikkeling en ernstige progressieve 
osteoartrose geven andere ernstige skeletafwijkingen. Vaak ondergaan deze patiënten 
op jonge leeftijd orthopedische operaties (hoofdstuk 5). Toekomstige therapieën voor 
ML III zouden gericht moeten zijn op verbetering van kraakbeen en botkwaliteit in deze 
patiënten, om zo skelet complicaties te voorkomen en mobiliteit te verbeteren. 
Een andere ernstige complicatie van kraakbeen en botziekte in MPS patiënten is vroege 
sluiting van schedelnaden (craniosynostose) en wordt beschreven in hoofdstuk 6. In 
onze studie bleek  craniosynostose voor te komen in de meeste van de MPS I, II VI en VII 
patiënten. Vroege herkenning van craniosynostose is belangrijk, omdat sluiting van de 
schedelnaden vóór de leeftijd van 6 jaar de groei van de schedel kan remmen. Dit kan leiden 
tot verhoogde intracraniale druk, met als gevolg visuele- en ontwikkelingsbeperking. 
Het monitoren van de groei van de schedel en signalen en symptomen van verhoogde 
intracraniale druk in zowel niet-neuronopatische als neuronopatische patiënten met MPS 
is noodzakelijk, omdat chirurgische interventies mogelijk zijn. 
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Uiteindelijk worden in hoofdstuk 7 de resultaten van de studies bediscussieerd en 
samengevat en worden nieuwe hypothesen en inzichten gepresenteerd in de ontwikkeling 
van kraakbeen en botziekte in MPS en ML, die mogelijk van belang zijn voor toekomstige 
therapeutische strategieën. 
De pathologische veranderingen  in kraakbeen- en bot  in MPS en ML ontstaan al heel 
vroeg tijdens de embryonale ontwikkeling. De foetale oorsprong van de kraakbeen- 
en botpathologie in MPS en ML patiënten zorgt voor een grote belemmering  in de 
behandeling en verklaard de geringe effecten van de bestaande therapieën op de 
skeletcomplicaties. Toekomstige behandelingen zullen zich naast het ontwikkelen van 
vernieuwde therapeutische strategieën zich ook moeten focussen op het verminderen 
van pijn en het handhaven van zelfstandigheid van de patiënten.  
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PhD training
Year Workload
(ECTS)
Courses - general
Basis cursus regelgeving en management (BROK) 2017 0.9
Integrity in Medical Research 2016 2.0
Courses - other
Pompe disease expert day, Rotterdam 2010 0.5
11th Postgraduate Course on LSD’s Nierstein 2010 1.2
Orphan lysosomal storage disease 2e advanced level: European 2010 1.0
metabolic course 4Th inborn errors in neonatology
SSIEM academy 2011 0.5
Updates On Neurometabolic Disorders 2014 0.5
17th Postgraduate Course on LSD’s Nierstein 2018 0.3
Presentations and International conferences
MPS patient day Amersfoort (oral presentation) 2011 1.0
MPS patient day Amersfoort (oral presentation) 2012 1.0
12th international Symposium on Mucopolysaccharide and 
Related 
2012 0.5
Diseases, Noordwijkerhout (1e price poster presentation)
13th international Symposium on Mucopolysaccharide and 
Related 
2014 1.0
Diseases, Brazil (poster presentation)
Bot congress van de NVCB 2014 0.5
Grandround 2014 Erasmus MC-Sophia (oral presentation) 2014 1.0
14th international Symposium on Mucopolysaccharide and 
Related 
2016 1.0
Diseases, Bonn, Germany (poster presentation)
11th Scientific symposium on Niemann-Pick disease Type C 
(NP-C): 
2018 0.5
Continuing our 10-year voyage of discovery
17th Postgraduate Course on LSD’s (oral presentation) 2018 1.0
14th annual WORLD symposium, San Diego (poster presen-
tation)
2018 0.3
SSIEM annual meeting Athens 2018 0.5
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Teaching  tasks
Lysosomal storage disease education for nursing staff 
(yearly)
2011-2018 1.0
Lysosomal storage disease education for junior doctors 
throughout 
2009-2018 1.0
the year (roughly 1-2 hours a week)
Lecture on recognition of lysosomal storage diseases for 
child orthopedics
2013 0.5
Voordracht AMC ‘Craniosynostosis affects the majority of 2018 0.5
mucopolysaccharidosis patients and can contribute to 
increased 
intracranial pressure’
Onderwijs arts-assistenten over metabole ziekten 2018 0.5
Other tasks
The PhD project was combined with my duties as a meta-
bolic pediatrician
2012-2018
Involved in the palliative care team of the ErasmusMC-So-
phia weekly 3 hours
2017 2.0
Training kinderpalliatieve zorg 2017 0.5
Research skills
Certified Biologist, University of Amsterdam 1992–1997
Research at the Department of Neurogenetics 1998–1999
Academic Medical Centrum at Amsterdam
Fellowship Inborn Errors of Metabolism 2009–2012
Department Metabolic Diseases Erasmus MC-Sophia Rot-
terdam
Research meetings
Internal Research meetings, Department Clinical Genetics 2011-2018 2.0
De Vereniging tot bevordering onderzoek Erfelijke Stofwis-
selingsziekten (ESN)  
2010-2018 8.0
ECTS European Credit Transfer and Accumulation System
1 ECTS= 28 hours
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Esmee Oussoren is geboren op 7 mei 1973 in Zaandam. In Haarlem doorliep ze haar school-
carrière op het Eerste Christelijk Lyceum. Hier haalde zij in 1992 haar VWO diploma. 
Hierna ging zij Biologie studeren aan de Anna´s Hoeve aan de Universiteit van Amster-
dam. Na het derde studie jaar ging zij geneeskunde studeren aan de Universiteit van 
Amsterdam. In 1997 voltooide ze haar Biologie studie. Voor deze studie deed zij in 1995 
haar wetenschappelijke stage bij de vakgroep van de  Kindergastroenterologie in het 
Academisch Medisch Centrum (AMC) in Amsterdam. Tijdens haar geneeskunde studie 
deed ze wetenschappelijk onderzoek bij de Neurogenetica afdeling in het AMC. Meerdere 
publicaties volgden, waar zij ook medeauteur op was. In 2002 ronde zij haar geneeskunde 
studie af. Hierna werkte zij in het Spaarne ziekenhuis in Haarlem bij de afdeling Interne 
en als ANIOS kindergeneeskunde in het Bronovo ziekenhuis in de Haag. In 2003-2004 
was zij ANIOS kindergeneeskunde in het Erasmus MC-Sophia kinderziekenhuis. In dit 
ziekenhuis vervolgde zij haar opleiding tot kinderarts tot en met 2009 en werkte daarna 
1 jaar als supervisor op de kinderafdeling. Vanaf deze tijd startte zij met haar fellowship 
als kinderarts bij de afdeling metabole ziekten, bij het Centrum voor Metabole en Lyso-
somale ziekten, onder leiding van Prof. Dr. A.T. van der Ploeg. In 2012 beëindigde zij haar 
fellowship en kreeg zij een plek als stafarts op dezelfde afdeling. Vanaf 2012 is zij gestart 
met haar promotie traject bij dezelfde afdeling onder begeleiding van Prof. Dr. A.T. Van 
der Ploeg (promotor), dr. G.J.G. Ruijter (copromotor) klinisch chemicus bij de afdeling 
Klinische Genetica in het Erasmus MC en dr. M. Langeveld (copromotor) internist, bij 
de afdeling Endocrinologie en Metabolisme, Amsterdam Universiteit Medisch Centrum 
locatie AMC. Hiervan hebben jullie het resultaat in handen.
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